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Polycyclic polyprenylated acylphloroglucinols (PPAPs) are plant- (Guttiferae) derived 
natural products. They have fascinating bicyclo[3.3.1]nonane-2,4,9-trione or 
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PPAPs have been isolated, but only a few of them have been synthesized, although most 
of the synthesized PPAPs are of type A and have an exo substituent at C (7). Here, we are 
trying to make a type B 7-endo PPAP, 7-epi-clusianone. The synthetic plan involves an 
alkynylation–aldol strategy to construct the bicyclic core. Having established the bicyclic 
core, the synthesis presents a new challenge: the oxidation of a very hindered 2-alkenone 
to the β-hydroxy 2-alkenone.  
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1 Introduction to natural products 
1.1 Introduction 
According to Wikipedia, natural products (NPs) are defined as compounds or 
substances that are produced by any living organism.1, 2 Scientifically speaking, however, 
secondary metabolites are referred to as NPs. Their source may come from plants, marine 
organisms, or animals. From the beginning of time, NPs have been the main source of 
sustenance for civilization. Moreover, the NPs enriched with medicinal properties, in 
particular—obtained from various plants, marine organism, and animals—have been 
fighting diseases over several millennia.3-5 Mesopotamian inhabitants used to take clay 
tablets as medicines to cure several diseases 4000 years ago.4, 6 Ancient manuscripts found 
in India, China, and North Africa revealed that the inhabitants of those areas were aware 
of distinct medicinal properties of various plants. In early Egypt, scientists knew about the 
properties of different NPs that preserved mummies for ages without any decomposition. 
Those scientists most likely drew pictures of various usages of medicinal plants on the 
walls of pyramids.7 From folklore, there were traditional medicines, which are still 
common in modern households, used to fight minor illnesses all over the world. For 
example, mandrake helps ease pain, turmeric is used as a medicine for lowering blood 
pressure, and garlic is used to reduce the cholesterols in blood. Likewise, a Chinese herb, 
artemisinin, also known as qinghaosu, has been used to treat malaria for ages. Youyu Tu 
won the Nobel Prize for medicine in 2015 for her discovery of this herb’s usages. NPs not 
only aid in medicine but have also influenced civilizations across the globe. Because of 
them, some cities were built to cater the need of NPs for foreign traders. Romans and 
Greeks knew about one of the properties of red chilies in preserving meat from rotting. 
They sailed to Muziris port, now in Cochin, India, in search of red chilies. Indigo played a 
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significant role in the Peasant Movement in India back in 1870. Indigo, a plant that grows 
in mostly river deltas, was used for dying clothes and was in high demand by mills across 
England in the 1870s when the Industrial Revolution was at its peak. In other words, NPs 
have influenced human civilization in many ways, but most prominently, via medicinal 
benefits that are the primary source of their relevance today. 
In the 19th century, when experimental science was making advances, Friedrich 
Sertürner, a 20-years old German chemist, first isolated morphine (1) from opium and 
studied its effects on humans and dogs (Figure 1.1.1).8  
 
Figure 1.1.1. Some important natural products 
Then it followed that other NPs were discovered such as atropine (2),9 strychnine (3), a 
‘Bitter Nemesis’,10 and most recently, taxol (4).11 The most common anti-inflammatory 
drug, aspirin (5), was derived from salicin, a natural product extracted from the bark of the 
willow tree. Even in the present age of chemical biology, NPs are still the best source of 
life-saving drugs and inspiration for the new drug molecules. Many pharmaceutical 
companies, however, have reduced their research on NPs because of HAT screening and 
combinatorial drug research. Despite that, since 1940, out of 175 anticancer drugs, 141 
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small molecules were either directly taken from NPs or inspired by NPs. From 1981 until 
now, 75% of the small molecules and anti-cancer drugs were directly related to NPs.12 In 
2010; twenty new drug molecules came to the market, and half of them were from NPs.13 
According to WHO report, 80% of the world’s population still relies on plant-based 
materials for minor illnesses. Recently, Newman and Cragg published a review article in 
J. Nat. Prod, where they presented 34 years of data showing that one-third of the prescribed 
drugs are directly related to NPs, which reiterates the point: NPs are still a source of major 
drug discovery (Figure 1.1.2).13 
 
Figure 1.1.2. % Natural products/year (the figure has been taken from Newman and 
Cragg’s recent article).13  
1.2 Introduction to PPAPs  
Plants from Clusiacecae (Guttiferae) and related families, namely, Symphonia, 
Allanblackia, Ochrocarpos, and Moronobea, are known for their traditional medicinal uses 
across the globe.14-16 Since prehistoric times, people have been using these plants as a 
source of medicine for treatment of various diseases, like fever, diarrhea, and fungal 
infections. In general, Guttiferae plants are found all over the world, but in particular, in 
tropical regions. Fruits, flowers, and barks of the timber from this family of plants have 
been major sources in folklore medicine. Ancient Greeks used Saint John’s wort (SJW) as 
 21 
a remedy for depression. It was also effective in treating small burn and skin injuries.17 
SJW is a small- to medium-height herbaceous plant with yellow flowers. It is widespread 
in the northern part of Europe, and it is cultivated in North America. It is harvested and 
dried in late summer.  
 
Figure 1.2.1. Representative PPAP 
The dried herbs consist of a considerable number of phenolic derivatives of flavonoids, 
hypericin (about 0.1%) and pseudohypericin (about 0.2%). It is napthodiathone, however, 
that is responsible for the antidepressant activity. The famous Greek philosopher, Aristotle, 
advised Spartans to use propolis—a complex material produced by honeybees, containing 
primarily wax and resins collected from different buds or plant secretions—to heal wounds. 
Aristotle probably got inspiration from honeybees, which use resin and latex to construct 
hives. After killing intruders, honeybees keep the corpses of the intruders in the hives, 
which normally would cause bacterial infection in the bees. To avoid this, they use propolis 
to preserve the corpses. Studies have revealed that propolis contains nearly 200 
compounds.18, 19 The composition of propolis differs from region to region because of the 
biodiversity in Guttiferae plants. Propolis and hive extracts have shown a wide range of 
biological and medicinal attributes, such as anticancer,20 antioxidant, antiinflammatory,21 
and antimicrobial properties.22 Nemorosone was identified as one of the active ingredients 
in propolis. In the western part of India, especially the coastal region of Maharashtra, the 
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dried rind of the fruits from Garcinia, a plant from Clusiacecae family, is used to garnish 
the flavor and color of a curry. In turn, the famous kokum curry has been very effective in 
treating gastric ulcers.23  
1.3 Classification of PPAPs  
 
Figure 1.3.1. Core structures of PPAPs 
Recently, organic chemists have become more interested in secondary metabolites 
produced by these plants from the Guttiferae family. This is due in large part to the 
antidepressant activity of Hypericum perforatum, popularly known as St. John’s wort. 
Research data have shown that plants from these families contain a novel class of 
compounds, polycyclic polyprenylated acylphloroglucinols (PPAPs). Until now, more than 
200 PPAPs have been identified. After much rigorous analysis of these isolated PPAPs, 
researchers have found that they feature either bicyclo[3.3.1]nonane-2,4,9-trione or 
bicyclo[3.2.1]octane-2,4,8-trione core (Figure 1.3.1). These scaffolds are decorated with 
prenyl or geranyl group and sometimes also with lavandulyl or isolavandulyl side chains.  
Depending on unique structural patterns, PPAPs are broadly classified into two categories, 
namely, type A, type B (Figure 1.3.2). The classification is based on the spatial 
arrangement of prenyl and acyl groups on in the main scaffold. Type A has an acyl group 
at C1 and an alkyl group at C3. C1 is next to a quaternary center at C8, whereas, in the case 
of type B, the acyl group is at C3.7  
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Recently, some unusual structural patterns, which do not fall in the above 
classification, have been found in PPAPs.24, 25 Often, PPAPs can undergo further oxidation 
in prenyl or geranyl side chains to add more structural complexity, like in garsubellin A,26 
where the prenyl group undergoes further oxidative addition of C2 oxygen or C4 oxygen 
to form a tetrahydrofuran type ring in the molecule.27 Adamantane is also a common 
structural core, found in PPAPs, due to secondary cyclization.28  
 
Figure 1.3.2. Classification of PPAPs 
Type A and type B can be further classified into exo and endo. Therefore, type A 
can be both exo and endo; similarly, type B can be both exo and endo. However, most type 
A PPAPs are exo, while most type B PPAPs are endo. Exo and endo nomenclature are 
made by the orientation of C7 prenyl or geranyl group with respect to C9 keto group. If C7 
prenyl or geranyl appendage is cis to C9 keto group, it is termed as exo; in the case of trans, 
it is called endo (Figure 1.3.2).  
Recently, Xiao-Jiang Hao et al. isolated two unusual PPAPs from Garcinia 
multiflora.29 The detailed spectroscopic analysis revealed that these molecules contained 
an unusual caged type structure. The Hao group isolated two compounds, namely, 
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garcimulin A and B. The molecule contains tetracyclo [5.4.1.11,5,09,13] tridecane skeleton 
(Figure 1.3.3), which calls for an explanation in PPAPs biosynthesis. 
 
Figure 1.3.3. Unusual PPAPs 
1.4 History of PPAPs  
In modern PPAP history, a German scientist, W. Schmid, was probably the first to 
isolate a yellow crystalline compound from the plant Garcinia mangosta in 1855.30 Later, 
there were eight other scientists, after Schmid who isolated the same yellow crystalline 
substance from the Garcinia mangosta (Table 1.4.1).31 The structures proposed by the 
scientists were vividly different from each other. In 1932, a Japanese natural product 
scientist, J. Murakami, worked on the same yellow crystalline solid compound and 
proposed several structures. Five years later, in 1937, an Indian scientist, Sanjiva B. Rao, 
isolated a yellow crystalline product from the seeds from Garcinia morella. He termed it as 
morelline. The isolated compound was levorotatory, but 
8A 8B
 25 
Table 1.4.1. List of earlier works on Garcinia mangosta 
Scientists Formula Year of Publication 
W. Schmid C40H44O10 1855 
R. Hill C23H24O4 1915 
J. Dekker C16H22O5 1924 
S. Yamashiro C20H22O5 1930 
O. Dragendorff C18H18O4 1930 
 
Rao could not figure out the exact structure of morelline. He, however, proposed 
that morelline might have a chemical formula of C30H34O6 and might contain four phenolic 
OH groups.32 He also suggested that morelline might possess a structure very similar to the 
same compound that was extracted from Garcinia mangosta by Schmid and the other 
scientists.  
After World War ΙΙ, science and technology were leapfrogging because of 
numerous inventions, and chemistry benefited a lot, thanks to X-ray and NMR 
spectroscopy. At the beginning of the 1960s, almost 20 different PPAPs were isolated from 
various Guttiferae plants. Surprisingly, most of them were xanthones, and a few were 
phloroglucinols. 
 While working on morelline structure determination, in 1962, Kartha and his group 
proposed that morelline might contain a bicyclo[2.2.1]octane ring.33 Kartha’s group used 
NMR and crystallographic data to reach the conclusion that morelline contains prenyl 
appendages and a α,β-unsaturated aldehyde group with a chromone ring. Hyperforin was 
the first PPAP whose structure was determined after isolation by Koloso’s group in 1975. 
Later, his group also defined the absolute stereochemistry.  
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Figure 1.4.1. History of some PPAPs 
For type B PPAPs, xanthochymol and isoxanthochymol were isolated in 1970 by 
Karanjoakar et al. in a collaboration with Western Regional Research Laboratory, 
Berkeley.34 They proposed a bicyclic structure for isoxanthochymol based on the derivative 
of the naturally occurring crystals (Figure 1.4.1). Rao, however, could not figure out the 
xanthochymol structure. A year later in 1971, Dreyer predicted a very similar structure that 
was proposed by Rao et al.—a monocyclic structure of xanthochymol—after extracting it 
from an autograph tree (Clusia rosea).35 Dreyer, however, proved that there were three 
aromatic protons, three vinyl groups, and a disubstituted C=C bond in the molecule, but he 
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was not sure about vinyl C-methyl groups in the molecule. Moreover, overlapping integrals 
at δ 2.8 rendered him undecided on the structure of xanthochymol.  
In 1976, Blount and William revisited the structure of xanthochymol and iso-
xanthochymol.36 Relying on X-ray and 1H NMR data, the duo proposed the structures 
shown in Figure 1.4. To continue the research, they extracted xanthochymol and 
isoxanthochymol from Garcinia xanthochymus. The structure of isoxanthochymol was 
determined from a bromo derivative of 8.36 The lack of a sufficient number of H atoms in 
the bicyclic scaffold misled Dreyer to deduce the incorrect structure of xanthochymol. 
Blount and William assigned the correct structure of xanthochymol with the help of X-ray 
crystallography. 
Clusianone (9) and 7-epi-clusianone (10) remained enigmas for several years so far 
as their structures were concerned. Clusianone was first isolated from Clusia congestiflora, 
a plant from Guttiferae, which comprises of 40 genre and 1200 species,37 in 1976. X-ray 
analysis firmly established the structure of clusianone and showed that the C7 prenyl group 
is exo. In 1991, Dalle et al. reported clusianone—extracted from fruits of Clusia 
sandinesis—in the form of a white crystal.38 In 1996, De Oliveira isolated clusianone from 
the floral resin of Clusia spiritu-santensis after diazomethane treatment.39 The structures 
of clusianone and 7-epi-clusianone were markedly different from one another. Later, 
Santos et al. isolated 7-epi-clusianone from Raheedia gardneriana. NMR and X-ray 
analysis showed that the C7 prenyl group in 7-epi-clusianone is endo, thereby confirming 
the structure of 7-epi-clusianone (Figure 1.4.2).40  
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Figure 1.4.2. Clusianone and 7-epi-clusianone 
Lalibinone and its analogs, A–E (14-18), were isolated from Hypericum 
papuanum.41 It is a woody plant from the Guttiferae family and grows widely in mountains 
of Papua New Guinea. In folklore medicine, this tree’s leaves were used in treating sores. 
In 1999, Winlemann et al. isolated five different compounds from the aerial part of H. 
papuanum in the form of a hexane extract.42 Detailed structural analyzes—based on 1H 
NMR, 13C NMR, HMBS, and HSQC—of these isolated five compounds revealed that the 
molecules contain a tricyclic structure with a bicyclo[2.3.1] octane-2,4,8-trione core 
(Figure 1.4.3) 
Laxifloranone (19) is a unique PPAP. It was isolated from an organic extract of 
Marila laxiflora Rusby.43 The plant belongs to the Clusiaceae family. Bokesch et al. 
determined its structure in 1999.44 The molecule is rich with aromatic rings. Structural 
analysis showed that the molecule has a hydrocinnamic acid side chain, instead of a prenyl 
group. In that respect, the molecule is different than other PPAPs. It belongs to the type B 
endo PPAP family.  
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Figure 1.4.3. Lalibinones A-E and laxifloranone 
1.5 Revisiting some structures of type B endo PPAPs  
Along with medicinal properties and architectural diversity of NPs, the third reason 
for the total synthesis is to confirm whether existing structures in the literature are correct 
or not. This has been the case similarly with PPAPs. The correct structure determination 
of PPAPs has been a problem for years because of the relative stereochemistry at the C7 
appendage, which specifically categorizes a PPAP as endo or exo. In some cases, however, 
scientists were successful in isolating PPAPs from plants as crystalline solids. 
Consequently, X-ray analysis of those PPAPs unambiguously established their structures, 
including exo or endo stereochemistry of C7.40 In this section, I will revisit some of such 
stories related to the endo type B PPAPs, whose structures were corrected after they had 
been reported.  
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Figure 1.5.1. Structural diversity among PPAPs 
Although the overlapping peaks in 1H NMR spectra make the identification of 
PPAPs difficult, high-temperature NMR, nearly at 60 °C, resolves some of the issues, such 
as finding the 1,3-diketone framework in the molecule and the C3 substituent.41 The real 
problem, however, is the determination of exo or endo stereochemistry of the molecule 
concerned. Grossman and Jacob have demonstrated that 1H NMR and 13C NMR are very 
helpful in categorizing the PPAPs as exo or endo based on the chemical shifts of certain 
protons and carbons.45-47 They proposed that if the difference of chemical shifts between 
the two H atoms at C6 in the 1H NMR spectrum is 0.3 to 1.2 ppm, and the C7 chemical 
shift in the 13C NMR spectrum is 41 to 44 ppm, the PPAP is exo, whereas if the difference 
of chemical shifts between the two H atoms at C8 in the 1H NMR spectrum is 0.0 to 0.2 
ppm, and the C7 chemical shift in the 13C NMR spectrum is 45 to 49 ppm, the PPAP is 
endo. I shall utilize these observations to consider some endo PPAPs where the 
discrepancies were found in previous reports (Figure 1.5.2).  
Initially, there were doubts in assigning the stereochemistry of some endo type B 
PPAPs like garcinol (22) ([α]D –138 (0.1)) and isogarcinol (23)  ([α]D +224 (MeOH, 0.1)), 
and some endo PPAPs have different C(7)  or H(6) or H(8) chemical shifts, which were 
not consistent with endo PPAPs of the same configuration.5 The enantiomers of garcinol 
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and isogarcinol were named differently: (+)-garcinol (62) was given the name of 
guttiferone E (24) ([α]D –101 (0.1)), and (+)-isogarcinol (23) was given the name of 
isoxanthochymol (25) ([α]D +181 (EtOH, 0.6)) (Figure 1.5.2). Assigning the absolute 
configuration to these compounds becomes tough by various names and optical rotations. 
Moreover, the chemical shifts of C7 or hydrogens at C6 or C8 were not as per the general 
rule proposed by Grossman and Jacob.45 For isogarcinol and isoxanthochymol (Figure 
1.5.2), the values are within the range of exo compounds: C6 hydrogen in isogarcinol or 
C8 hydrogen in xanthochymol has a chemical shift of 0.75 or 0.70 ppm in HNMR 
respectively. Plietker and Socolsky noticed the discrepancies and attempted to resolve it 
via chemical synthesis. 
 
Figure 1.5.2. Structural conundrum: guttiferone E and isoxanthochymol 
The previously recorded X-ray crystallographic analyses of these compounds were 
confirmed with the crystals obtained from Plietker’s work. The crystal analysis of both 
compounds showed that the tetrahydropyran ring is at lowest energy conformation: in a 
twist boat form. Because of that, the isoprenyl substituent became equatorial. Socolsky and 
Plietker not only relied on chemical syntheses but also utilized TURBOMOLE6.5 in 
conjunction with the graphical interface Tmole 3.4. They also used TD-DFT (Time 
Dependent Density Functional Theory) to calculate the excitation energy and find out the 
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combinations of a possible number of allowed spins in excited states. They converted these 
data into simulated CD (circular dichroism) spectra that gave a theoretical graph. Then, 
they compared these simulated CD spectrum with the natural products (garcinol and 
isogarcinol) that Plietker’s group had synthesized. The theoretical CD spectrum of 
isogarcinol—where the relative configuration of C30 is S—showed both positive and 
negative Cotton effect at 220 and 265 nm respectively. That was agreeing with the 
experimental value obtained with chemically synthesized isogarcinol. This result proved 
that they synthesized the naturally occurring enantiomer of isogarcinol and garcinol. A 
similar result was observed with isoxanthochymol. Thereby, Socolsky and Plietker 
concluded that isoxanthochymol and isogarcinol are enantiomers. Previously, Grossman 
and Ciochina proposed the same observation in their review article.7 Socolsky and 
Plietker’s article reiterated the importance of chemical syntheses of NPs: to correct a 
structure of a natural product. 
There were also some discrepancies about the correct structures of guttiferone G 
(74) and guttiferone I (66) (Figure 1.5.3). These two compounds were isolated from the 
same source, G. hummulis, by Herath et al. NMR analysis, UV, and IR data showed that 
both molecules contain a dihydroxy phenol group. Nevertheless, there was confusion about 
the assignment of the C7 prenyl group. Initially it was thought that both compounds were 
endo type B.  The specific rotation, however, of both compounds were different; 
guttiferone I has a specific rotation of +8.7° in CHCl3, while guttiferone G showed a 
rotation of –25° in CHCl3 also. The J-coupling value for H atoms at C6-C8 in guttiferone 
I was 13.0 Hz, which is quite high among the all other type B endo PPAPs. 2D-NOE gave 
an indication that guttiferone I is a type B endo, but the experiment did not negate the 
possibility of type B exo either. Later, Nilar et al. attempted to assign the absolute 
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stereochemistry of guttiferone G–I, and because of conflicting data, they could not assign 
it.48  
 
Figure 1.5.3. Guttiferones I and G 
Another interesting revelation was determination of sampsonione P (26) and 
hyperibone I (28). Initially, scientists proposed that sampsonione P has an endo 
configuration and its isomer, hyperibone I, has an exo configuration. Grossman and 
Ciochina, however, predicted that hyperibone might be endo type B.7 Plietker and his group 
synthesized both the molecules and carried out 2D NOE to assign the absolute 
stereochemistry at C7. They observed a strong correlation between C7 H and C6 Hax. 
Moreover, there were two other strong correlations—firstly, between C6 axial hydrogen 
and an axial methyl group; secondly, C7 equatorial hydrogen and a C6 equatorial methyl 
group. In consideration of this evidence, the duo proposed the following structure (Figure 
1.5.4), proving Grossman’s hypothesis on hyperibone I correct. Similarly, they concluded 
the same relative configuration—type B endo PPAP predicted by Grossman and 
Ciochina—with sampsonione P. 
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Figure 1.5.4. hyperibone I and sampsonione P 
1.6 Biosynthesis of MPAPs  
The recent advances in labeling experiments have provided a deep insight into the 
biological pathways. Several research studies have shown enough evidence that PPAPs are 
products of two important biological pathways—shikimate and acetate-isoprenoid. The 
shikimate pathway contributes the phenol part to the overall molecule and the acetate-
malonate pathway provides side chains and carbocycle.49 Plants synthesize PPAPs from 
MPAPs, which are products from the acetate pathway. Three malonyl-CoA and an acetate 
unit combine in Claisen condensation to make a β-polyketoester. The poly ketoester can 
fold in two ways—one way goes to orselinic acid and the other to phloroglucinols (Scheme 
1.6.1), which are the starting unit of many MPAPs. An enzyme complex carries out the 
whole sequence of reactions without any detectable intermediates.50 From the organic 
chemist’s point of view, the formation of acylphloroglucinols from poly β-keto-esters is a 
result of Claisen condensation. 
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Figure 1.6.1. Diverse arrays of PPAPs from benzophenone 
The polyketide synthase and polyketide catalase are two enzymes responsible for 
Dieckman condensation in this case. The enzymes have structural resemblance with fatty 
acid synthase. The distinctive feature of this pathway is that the oxygenation pattern is 
meta, and even after the formation of the final product, the meta-oxygenation pattern is 
retained. The MPAPs can undergo various transformations further, and one of the 
transformations is prenylation with DMAPP (dimethyl allyl pyrophosphate) or GMAPP 
(geranyl pyrophosphate). The prenyl transferase catalyzes these reactions, leading to other 
MPAPs. The labeling experiments have shown that the prenylation goes via a non-
concerted way. Out of different MPAPs, cohulolones and colupulones are noteworthy since 
they have some commercial values.  
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Scheme 1.6.1. Biosynthesis of MPAPs 
The polyketide synthase and polyketide catalase are two enzymes responsible for 
Dieckman condensation in this case. The enzymes have structural resemblance with fatty 
acid synthase. The distinctive feature of this pathway is that the oxygenation pattern is 
meta, and even after the formation of the final product, the meta-oxygenation pattern is 
retained (Scheme 1.6.1). The MPAPs can undergo various transformations further, and one 
of the transformations is prenylation with DMAPP (dimethyl allyl pyrophosphate) or 
GMAPP (geranyl pyrophosphate). The prenyl transferase catalyzes these reactions, leading 
to other MPAPs (Scheme 1.6.2). The labeling experiments have shown that the prenylation 
goes via a non-concerted way. Out of different MPAPs, cohulolones and colupulones are 
noteworthy since they have some commercial values. MPAPs have shown anti-fungal, anti-
bacterial, and antifeedant properties. Hops—scientifically known as Humulus lupulus—
have been in use in folklore medicine as an anti-bacterial agent, tranquilizer, and healing 
the symptoms of menopause.51 The most significant hops are female inflorescences, which 
are used in beer production. Interestingly, MPAPs have shown anti-fungal, anti-bacterial, 
and antifeedant properties. Interestingly, it is the α-acid, which adds flavor and bitter taste 
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to the beer. The β- acids act as a radical scavenger and have shown anti-bacterial properties. 
it is the α-acid, which adds flavor and bitter taste to the beer (Figure 1.6.2). The β- acids 
act as a radical scavenger and have shown antibacterial properties (Table 1.6.1).  
 
Scheme 1.6.2. Synthesis of α and β-acids from MPAP 
 
Figure 1.6.2. α and β-acids  
 
Table 1.6.1. Different α-acids and β-acids  
R α-acids β-acids 
i-Pr Cohumulone Colupulone 
i-Bu Humulone Lupulone 
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1.7 Biosynthesis of PPAPs 
PPAPs are synthesized from MPAPs that could undergo further modifications in 
the presence of prenyl transferase to construct the bicyclo[3.3.1]nonane. Type A, B and C 
PPAPs originate from acylphloroglucinols through a series of carbocationic 
rearrangements (Scheme 1.7.1). The chemoselective bond formation in the enzymatic 
pathway leads either type A, B or C. According to Cuesta-Rubio, MAPPs cyclize in the 
presence of prenyl transferase to type A and type B from the same precursor 52. The 
mechanism needs an SN2 type attack on DMAPP by one of the enantiotopic prenyl groups, 
giving rise to a carbocation intermediate that could make a bond either to C1 or C5 in the 
aromatic ring. Attack from C1 end leads to a type A; while the C5 attack leads to a type B. 
Type C PPAPs are rare, and it can be explained by a mechanism mentioned in 
Scheme 1.7.2. To make a type C PPAP, C1 must have a quaternary center and to synthesize 
it naturally is not simple, possibly because of the steric factor. 
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Scheme 1.7.1. Precursors to type A, B, and C PPAPs 
In the previous section, we have said that MAPPs are synthesized from acetyl or 
malonyl-CoA via a series of Dieckman condensations.52 If we consider the detail of the 
mechanism, we find that benzoyl-CoA is derived from the shikimate pathway. L-
Phenylalanine undergoes a series of reactions, namely, deamination and decarboxylation 
to produce benzoyl-CoA (Scheme 1.7.1). Then benzoyl-CoA again undergoes a series of 
reactions, namely, Dieckman condensation, and alkylation, to produce type A, B, and C 
PPAPs. PPAPs can undergo further cyclization that adds more complexity to the overall 
structure of the PPAP. For example, the type A PPAPs may react with another molecule of 
DMAPP, and consequently, PPAP with an adamantane is formed. Plukenetione A 32 is an 
example of such a PPAP. 
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Scheme 1.7.2. Mechanistic pathway for type A, B and C 
In section 1.1.2, I mentioned two unusual PPAPs (17, 18) that contained a 
tetracyclotridecane skeleton. The formation of such an unusual skeleton can be explained 
based on [4+2] cycloaddition followed by a keto-enol tautomerism (Scheme 1.7.3).  
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Scheme 1.7.3. Mechanistic rationale for two unusual PPAPs 
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1.8 Sources and structures of type B endo PPAPs  
Until now, we know many things about PPAPs, including type A, B, and C, namely, 
their structure and biological activities. My predecessors, Roxana Ciochina and M. P. 
Suresh Jayasekara, have given a detailed account of biological importance and the sources 
of PPAPs in their dissertations.5, 53 Therefore, there is no point in going over the same 
PPAPs again, here. In past several years, however, natural product scientists have isolated 
many new PPAPs that were not talked about neither in Ciochina nor in Jayasekara’s 
dissertation. In this section, I will focus on endo type B PPAPs whose structures have been 
known or discovered recently. Nearly 23 new PPAPs have been identified between 2006 
to 2013.  There will be a separate section where I will place some new type B and some 
unusual type A PPAPs, which cannot be avoided because of structure and medicinal 
properties associated with them. However, focus of my research remains on type B endo 
PPAPs. 
Table 1.8.1. Type B endo PPAPs 
No. 
R group or 
structure. 
Name Source []D1 (°) 
 
59  
R1, R2= prenyl, R3= 
OH, 
guttiferone A 
S. globulifera2 
G. livingstonei3 
G.humils 
+34 (c4 
1.7) 
 
                                                 
 
1 OMe or OAc indicates the specific rotation was measured for that derivative 
2 S= Symphonia 
3 G = Garcinia 
4 not all of the stereocenters’ configuration have been assigned 
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60 
R2= prenyl; R3= 
OH, R1= ω-
lavandulyl 
guttiferone C S. globulifera 
mixed 
with 61 
+92 (c 
0.9) 
61 
R1= lavandulyl 
R2 = prenyl, R3= 
OH 
guttiferone D S. globulifera 
mixed 
with 60 
+92 (c 
0.9) 
 
62 
R1= (S) lavandulyl; 
R2= prenyl, R3= OH 
guttiferone E 
Cuban propolis 
C.rosea 
G.ovafolia 
 
+101 (c 
0.5) 
63 
R1= (S)-lavandulyl; 
R2=H (enantiomer), 
R3= OH 
garcinol 
(camboginol) 
G.cambogia 
G.indica 
–138 (c 
0.1) 
64 
R1= 3,4-(OH)2C6H3 
R2= prenyl; R3= 
(R)-isogeranyl, R4 = 
H 
guttiferone F 
Allanblackia  
stulhlmannii 
293 (c 
0.4) 
 
65 
R1= prenyl, 
R2= H; R3= OH 
aristophenone G.xanthochymus 
+58 (c 
0.1) 
OAc: +53 
(c 0.1) 
+54 (c 
0.1) 
66 
R1= geranyl; 
R2= H, R3= OH 
guttiferone I 
G. griffithii 
Cuban propolis, 
G.xanthochymus 
‒68 (c 
1.2) 
67 
R1 = (S)-ω-
lavandulyl; R2 = H, 
R3 = OH 
xanthochymol 
G.mannii 
G.staudtti 
G.subelliptica 
R. madrunno 
+138 (c 
0.1) 
68 
R1= (S)-lavandulyl, 
R2 = H, R3= H 
 
14-
deoxygarcinol 
M. coccinea 
+41 (c 
0.3) 
69 
32-hydroxy-ent-
guttiferone 
guttiferone M Rheedia edulis 
[α]D
25 = 
+9.6 
(c 0.1, 
MeOH) 
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70 
 
6-epi-guttiferone 
J 
Rheedia edulis 
[α]D
25 = 
+10.8 
(c 0.1, 
MeOH) 
 
 
71 
R1= Me; R2= Ph hyperibone L H. scabrum 
+69.5 (c 
0.2) 
72 R1= prenyl; R2= Ph 7-epi-clusianone 
Rheedia 
gardeneriana 
+62 (c 
1.1) 
73 R1=Me; R2=i-Pr hyperpapuanone H. papuanum 
+15 (c 
0.1, 
MeOH 
 
 
74 R1 = R2= prenyl guttiferone G 
G. humilis 
G. macrophylla 
‒25 (c 
0.04) 
75 R1 = prenyl; R2 = H oblongifolin C G. oblongifolia 
+23 (c 
0.35) 
 
76 R1= geranyl; R2 = H oblongifolin D54 G. olongifolia 
+44.6 (c 
0.21) 
 
 
 
O
R1
O OH
O
OH
R2
HO
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77 R2 = H, R1= prenyl isogarcinol55, 56 
G. indica 
G. pedunculata 
G. cambogia 
G. pyrifera 
G. subelliptica 
+224 (c 
0.1, 
MeOH) 
78 R2 = H; R1= prenyl 
isoxanthochymo
l55, 56 
(enantiomer) 
G. xanthochymus 
G.ovafolin 
+181 (c 
0.6, 
EtOH) 
79 
R2 = H, R1= 
isoprenyl 
(‒) 
cycloxanthochy
mol57 
G.subelline 
+80.5 (c 
2.20, 
MeOH) 
 
 
 
80 
R= (E)-CH= 
CHCMe2OH 
hyperibone H H. scabrum 
+12.4 (c 
0.4) 
81 R = prenyl hyperibone I H. scabrum 
+13.3 (c 
0.3) 
 
82 
 
sampsonione P H. samsonii 
+18.6 (c 
0.022) 
 
83 
 
hyperibone I 
Hypericum 
scabrum 
N/A 
84 
 
1,16-
oxyguttiferone 
A58 
 
or 
oxyguttiferone 
K1 
S. globulifera 
[α]D20 = 
+53 (c 1, 
MeOH) 
 46 
85 
 
 
hyperattenin J59 
 
H. attenuatum 
[α]D
25 = 
+23.8 (c 
0.3, 
MeOH) 
86 
 
attenuatumione 
E60 
 
H. attenuatumn 
[α]D
25 = 
+39.7 
(c 0.13, 
CHCl3) 
 
87 
 
 
attenuatumione 
F60 
 
H. attenuatum 
[α]D
25 = 
+19.6 
(c 0.18, 
CHCl3) 
88 
 
 
spiranthenones 
B61 
 
Spiranthera 
odoratissim 
[α]D
30 = 
+13 
(c 0.17, 
CHCl3) 
89 
 
 
guttiferone O62 
Garcinia afzelli N/A 
90 
 
 
guttiferone P62 
Garcinia afzelli N/A 
91 
 
7-epi-coccinone 
B63 
Symphonia 
globulifera 
N/A 
OOHO
O
O
geranyl
OH
OH
OH
O
O
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92 
 
symphononeE15 
Symphonia 
globulifera 
+50 (c 
0.4, 
CHCl3 
93 
 
symphonone B15 
Symphonia 
globulifera 
–50 (c 0.9, 
CHCl3) 
 
94 
 
symphonone I15 
Symphonia 
globulifera 
‒22 (c 0.4, 
CHCl3) 
95 
 
symphonone C15 
Symphonia 
globulifera 
‒67 (c 1.0, 
CHCl3) 
96 
 
guttiferone H64, 
65 
G. xanthochymus 
 
N/A 
97 
 
gambogeneone64 
G. xanthochymus 
 
N/A 
98 
 
7-epi-
isogarcinol 
G. multiflora 
 
N/A 
O
OH
OH
OH
O
O
HO
HO
O
OH
OH
OH
O
O
HO
O
O
OH
OH
O
O
O
H
OHO
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99 
 
guttiferone H64, 
65 
G. xanthochymus N/A 
100 
 
gambogenone64 G. xanthochymus N/A 
101 
 
coccinone A63 
Moronobea  
coccinea 
+28 (c 
1.0, 
CHCl3) 
102 
 
coccinone B66 
Moronobea 
coccinea 
‒55 (c 0.3, 
CHCl3) 
103 
 
coccinone C15 
Moronobea 
coccinea 
‒55 (c 0.2, 
CHCl3) 
104 
 
 
coccinone F63 
 
Moronobea 
coccinea 
‒32 (c 0.7, 
CHCl3) 
105 
 
coccinone G63 
 
Moronobea 
coccinea 
‒16 (c 1.0, 
CHCl3) 
106 
 
coccinone H63 
Moronobea 
coccinea 
+2 (c 1.0, 
CHCl3) 
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107 
 
R = prenyl 
garcicowin B56 Garcinia cowa N/A 
108 
 
R = prenyl 
garcicowin C56 Garcinia cowa N/A 
109 
  
R = prenyl 
garcicowin D56 Garcinia cowa N/A 
110 
 
 
R= prenyl 
garcimultifloron
e H67 
G. multiflora 
[α]D
20 = 
+29.8 
(c 0.62, 
MeOH) 
 
 
111 
R = prenyl; R2 = 
lavandulyl 
 
multiflorone J67 G. multiflora 
[α]D
20 = 
+11.1 
(c 0.44, 
MeOH) 
 
112 
 
oblongifolin J G. oblongifolia 
[α]D
25 = 
+8.6 
(c 0.03, 
MeOH) 
 
113 
 
oblongifolin K G. oblongifolia 
[α]D
25 = 
+55.4 
(c 0.07, 
MeOH) 
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114 
 
oblongifolin T G. oblongifolia 
[α]D
20 = 
+10.8 
(c 0.05, 
MeOH) 
 
115 
 
eugeniaphenon68 G. eugeniaefolia 
[α]D
27 = 
+41.6 
(c 0.11, 
MeOH) 
116 
 
paucinone D69 G. paucinervis 
[α]D
27 = 
+41.6 
(c 0.11, 
MeOH) 
117 
 
18-hydroxy-7-
epi-clusianone70 
H. hypericodies N/A 
118 
 
18-hydroxy-
clusianone70 
H. hypericodies N/A 
119 
 
sampsonione P H. sampsonii 
[α]D
20 = 
+18.6 
(c 0.022, 
CHCl3) 
1.9 Medicinal properties of type B endo PPAPs 
Until today, many type B PPAPs have been isolated from nature, and most of them 
have shown potential biological activities. Diseases such as leishmaniasis and 
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trypanosomiasis caused by parasites are on the rise. In the case of malaria alone, this 
tropical disease affects more than 300 million people all over the world and this has led to 
the death of a population of more than 429,000 people in the world in 2015. These diseases 
are becoming more lethal because of inefficient therapies, the toxicity of drugs, and 
growing resistance to current therapeutic drugs. For last few years, World Health 
Organization, WHO, has resorted to combinatorial therapy to deal with malaria because of 
increasing drug resistance. Artemisinin has been a champion drug for several years to treat 
malaria.71 Despite this, there are some evidence that mosquitos are moving toward 
resistance to artemisinin.52, 72 Therefore, new drugs are sought in order to win over these 
diseases, and type B PPAPs could be the ideal candidates. Here, we are giving of account 
some of them that have drawn the attention of the both biologists and organic chemists. 
1.9.1 Garcinol and its derivatives 
Garcinol and its epimer, isogarcinol, also known as camboginol and isocamboginol, 
are typical representatives of type B PPAPs (Figure 1.9.1) They are obtained from Garcinia 
indica, a tropical, medium- or small-sized tree with shiny dark green leaves and ovoid 
fruits, which are red or yellow in color with six to eight seeds embedded in a juicy rind. 
The plant is abundant on the west coast of India.73 The dried fruit’s rind is used as a gourmet 
item, kokum curry. Garcinols and its related members like isogarcinol (70), 
cycloxanthochymol, 30-epi-cambogin A, and 7-epi-garcinols (98) have shown very wide 
rgane of biological activity. Isogarcinol is very interrsting compound because of its wide 
range of therapeautic index, ranging from colon cancer, leukemia,74 HIV,75 
medullablastoma,76 antioxidant,77 antimicrobial,75, 78 transplant rejection, autoimmunine 
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diaseases like collagen-induced rheumatoid arthiritis79, 80 to breast cancer and Parkinson’s 
disease.80 Both garcinol and isogarcinol have shown promising biological activities. 
  
Figure 1.9.1. Garcinol and derivatives 
Traditionally, fruit rinds of garcinol have been in use for years to treat bowel 
problems and rheumatism and also available for human consumption in the form of 
mangosteen drink. Garcinol and isogarcinol are very effective against the methicillin-
resistant bacteria S. aureus with a comparison to vancomycin. It inhibits the topoisomerase 
I and II in a concentration comparable to etoposide.81 It has been known to suppress colonic 
aberrant crypt foci formation by acting as HATs inhibitors, inducing apoptosis through 
cytochrome c release, and activating caspases in the human leukemia HL-60 cell. Its 
antioxidant property is noteworthy. Several experiments have shown that garcinol 
suppresses superoxide anion, hydroxyl radical, and a methyl radical in H2O2-NaOH-
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DMSO. In spite of an unknown mechanism of the antioxidant property, garcinol is three 
times more potent than the 2,2-diphenyl-1-picrylhydrazyl (DPPH) and DL-α-tochopherol 
scavenging activity by weight. Garcinol and its epimer have been shown to inhibit NF-κB 
activation and a COX-2 expression. In addition, it decreases the iNOS expression and NO 
release from the LPS-stimulated macrophase by inhibition of the signal transducer and 
activator of transcription-I. Garcinol and isogarcinol have interesting antiulcer and 
antibiotic activities against methicillin-resistant staphylococcus aureus (MRSA). Garcinol 
has been shown to inhibit histone acetyltransferase and p300/PCB, a well-known gene 
regulator6. 
1.9.2 Guttiferone A-F, K, O, P 
Guttiferone and its analogs (Figure 1.9.2) are derived from Garcinia aristata in the 
form of a hexane extract from fruit rinds. They show very promising medicinal properties. 
For example, it has shown anti-HIV, cytotoxic, trypanocidal, antiplasmodial, 
leishmanicidal,82 and antibacterial activity.83, 84 Most recent studies have revealed its 
substantial neuronal quality and the permeability of the mitochondrial membrane. 
Guttiferone has shown moderate activity against gram-positive bacterium S.areus but has 
not demonstrated any discernable activity against E. coli, fungi T. rubrum, and C. albicans 
in vivo studies as manifested by IC50 ± SD values in μM (Table 1.8.1).82 
Table 1.9.1. Bioactivity of guttiferone A against different virus 
 S. aureus E. coli T. rubrum C. albicans 
Guttiferone A 7.5±0.8 >64 19.6±17.5 64.0 
 
But more interesting results are found in the fight against protozoa, P. 
falciparum—the prime reason for malaria—with IC50 values lower than 1 μM. The 
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cytotoxicity on the MRC-5 cell showed IC50 value in the range of 1.2 μM where the SI 
value is 24. Although the in vivo mechanism of this action has not been discovered for 
guttiferone A, in vitro studies have revealed that it can inhibit cysteine proteases B, papin, 
serine peptidase cathepsins G, and trypsin because these are present in plasmodium 
parasites for the development of the host cell. This explains why guttiferone A is lethal in 
fighting against malaria.  
 
Figure 1.9.2. Guttiferones A, E, C, D 
In a different study, guttiferone A revealed its role as antineurodegenerative agent 
by scavenging ROS and thereby protecting the cell against oxidative stress .85 
Recently, Xin Li’s study84 has demonstrated that guttiferone F (GF) can inhibit the 
growth of prostate cancer cell lines under serum starvation by inducing the increase in a 
sub-G1 fraction and DNA fragmentation. By controlling the Bcl-2 protein family, GF 
promotes the apoptosis targeting mitochondria. It also reduces the expression of an 
androgen receptor and the phosphorylation of ERK½ protein, and increases JNK protein 
phosphorylation and Ca2+ influx. Therefore, controlling the caloric restriction, GF could be 
lethal against prostate cancer without much toxicity although the viability of in vivo caloric 
restriction has been a subject of debate. In a different study, guttiferone K (0.1-25 μg⁄mL), 
like guttiferone A, has revealed its power in protecting protein and lipid degradation by 
reducing the formation of the carbonyl group and TBARS.86 
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Table 1.9.2.  IC50 values on different cell lines of guttiferone F 
Cell line Cell type IC50 (μM) 
Ln Cap Prostate cancer 5.17±0.20 
Hep G2 Hepatocellular carcinoma 32.92±1.56 
HeLa Cervical cancer 13.13±1,32 
CNE Nasopharyngeal carcinoma 17.97±1.30 
PC 3 Prostate cancer 12.64±3.01 
Ligand-controlled transcriptional factors are members of a nuclear receptor family 
that controls embryogenesis, calcium homeostasis, and lipid and glucose metabolism. 
Guttiferone I has inhibited the binding activity selectively to the LXR  receptor with an 
IC50 at 3.4-nM in a binding assay.87 Guttiferone O and P have shown inhibitory effects on 
phosphorylation of the synthetic biotinylated peptide substrate KKLNRTLSVA. These two 
PPAPs stop this process by the serine/threonine protein kinase MAPKAPK-2 (Figure 
1.9.3). The IC50 value is 22 mM. As a result, these two PPAPs could be potential drugs for 
inflammatory diseases and cancer.62 
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Figure 1.9.3. Mechanism of transcription regulation by LXR triggered by guttiferone I88 
 
Figure 1.9.4. Diagram for cell death mechanism induced by guttiferone A 
1.9.3 Clusianone and 7-epi-clusianone 
Clusianone (9) is a member of the PPAP family with a wide biologically active 
profile. It is extracted from the roots of Clusia congestiflora. Clusianone, a type B exo 
LDL
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LXA-SPA
binding assay
guttiferone I
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PPAP, and its 7-endo epimer have drawn the attention of scientists because of their 
extensive medicinal properties, namely, anti-HIV, anti-Epstein-Barr virus, being cytotoxic 
against HD-MY-Z, K-562, KE-37 tumor cell lines, antimicrobial, antinociceptive, and anti-
inflammatories.89-95  
 
Figure 1.9.5. Clusianone and 7-epi-clusianone 
In the past several years, chemotherapeutic drugs have been in use for treating 
cancer, and one of the problems of these drugs is that competent cancer cells develop 
resistance to them, leading to an increase in dose and, ultimately, failure of the treatment. 
Therefore, scientists are in urgent need to find new types of drugs. Clusianone (9) and 7-
epi-clusianone (10) could be alternatives to current therapeutics.  
Biologists have shown that 7-epi-clusianone could be used to cure lung cancer, 
which is one of the largest causes of death worldwide. Despite its antiproliferative effects 
against several tumor cells, 7-epi-clusinone’s activity against lung cancer cell lines is very 
promising. Cell lines A549 derived from lung cancer tumors are under investigation in 
several studies against the activity of 7-epi-clusianone. In in vitro studies, these results have 
demonstrated a new understanding of how 7-epi-clusianone acts as a potent 
antiproliferative agent.  
Studies done by Marisa Ionta et al.96 showed that 7-epi-clusianone has been very 
effective in arresting the cell cycle in the G1/S transition and promotes apoptosis. 
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Generally, healthy cells that have wild type P53 arrest the cell cycle in the G1 phase 
because of the G1 phase check point activation. Conversely, the cells that have mutated or 
impaired P53 arrest the cell cycle in the G2 phase.  
The research conducted by Marisa Inota et al. has shown that 7-epi-clusianone can 
activate the G1 check point to arrest the cell cycle of the cancer cells. The results showed 
that the cell viability was reduced drastically, in a concentration-dependent manner, after 
48-hour incubation, indicating an IC50 value of 16.13 ± 1.12 μM. 7-epi-clusianone has 
shown better potency than cisplatin (IC50 value of 21.71 ± 1.17 µM), the most commonly 
used chemotherapeutic drug. In a similar study, cytotoxicity of 7-epi-clusianone was tested 
against several cancer cell lines like KE-37 (T-cell-leukaemia), K-652 (chronic myeloid 
leukaemia) and HD-MY-Z (Hodgkin’s lymphoma) and daunorubicin was taken as a 
reference. The result was promising and 7-epi-clusianone has shown cytotoxicity against 
these cancer cell lines (Table 1.9.3). 
Table 1.9.3. Cytotoxicity against cancer cell lines 
IC50 (µmol) 
Compound KE-37 K-652 HD-MY-Z 
7-epi-clusianone 13.6 ± 1.5 11.8 ± 1.3 9.8 ± 1.4 
Daunorubicin 0.6 ± 0.01 1.5 ± 0.1 2.1 ± 0.11 
Like guttiferone A, 7-epi-clusianone has shown promising activity against 
trypomastigotes of T. cruzi in vitro with a dose of IC50 at 518 mM. The result was not very 
encouraging in the mouse model study because of the ineffectiveness of the drug in vivo. 
7-epi-clusianone has indicated an activity against Leishmania amazonensis with an IC50 
value of 19.13 M. The drug, however, has been toxic to mammalian cells.97 The role of 7-
epi-clusianone as a vasodilator has been known since 1998. The effect of the molecule was 
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studied on rat model by Cortes and his colleagues. The research group observed an 
endothelium-dependent vasodilating response at a lower concentration but induced a 
vasocontractile effect at higher concentrations.98 
Obesity is a growing concern in the modern world. A current estimation has shown 
that 30% or more world population are either obese or overweight.99 7-epi-clusianone has 
revealed its promise to be an alternative to Rosiglitazone, an antidiabetic drug, because of 
its high hydrophobicity, electrostatic, π-stacking interaction, and hydrogen bonding 
capacity because of keto functionality. The conclusion was drawn from SAR studies with 
Rosiglitazone which possesses akin structure to 7-epi-clusianone, although the latter has 
fewer OH groups than are essential to potency, as revealed by the docking studies.100 
Piccinelli et al. have shown that clusianone is active at very low concentration (EC50 
= 0.02 µM) with a reduced therapeutic index, whereas its 7-epimer has better anti-HIV 
(EC50 = 2.0 M) properties, with an enhanced therapeutic index of 10.37 The difference 
between these values is contingent upon the orientation of the C7 prenyl group.  
The exact mechanism of action of these two molecule are debated, but Reis et al. 
demonstrated how the cytotoxicity of clusianone against Hep2 cells ultimately led to 
apoptosis by specifically targeting the mitochondrial membrane potential (Figure 1.9.6).101 
Their studies indicated that the free enolic OH played an instrumental part in targeting the 
mitochondrial potential. 89When the enolic OH was protected as a methyl enol ether, it lost 
potency.7 Therefore, it was concluded that the free enolic OH was important to target the 
mitochondria. The study also showed that the apoptosis was related to the depletion of 
ATP, which ultimately triggered the cell death (Figure 1.9.6). The similar argument could 
be put forward in the context of 7-epi-clusianone, which is a known topoisomerase II 
inhibitor. 
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Figure 1.9.6. Possible mechanism of action of clusianone 
1.9.4 Coccinones A-H 
Coccinones A-H were extracted from the latex of Moronobea coccinea. Extracts 
from the trunk bark and fruit of this tree have revealed encouraging antiplasmodial activity. 
Coccinone A through H have shown effective activity against chloroquine-resistant P. 
falciparum and have been proven to be cytotoxic to human MRC-5. However, all the 
coccinones were not equally effective; coccinones A through E were proved to be effective 
with an IC50 value in the range of 3.3 to 9 µM. The value surprisingly indicated a typical 
pattern in the structure of coccinones A-E; all five PPAPs contain a tetrahydropyran ring 
fused to the bicyclo [3.3.1] nonane. However, coccinones F through H showed a reduced 
antiplasmodial activity toward P. falciparum, having an IC50 value of more than 10 µM, 
and these three PPAPs have a free enolic hydroxyl group. On the other hand, in case of 
cytotoxicity, coccinones that have a free enolic hydroxyl group were noteworthy.63 
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Table 1.9.4. Biological activity of coccinones A-H 
Coccinone IC50 p.f.FcB1 (µM)± 
SD3 
IC50 MRC 5(µM) 
A 4.3±1.3 3.3±0.8 
B 5.5±0.4 11.7±0.6 
C 9.0±1.2 9.3±1.1 
D 7.0±0.9 10.9±0.3 
E 4.9±0.7 9.1±1.3 
F 17.0±9.4 21.3±2.8 
G 19.2±5.9 11.5±0.4 
H 16.6±6.1 10.5±0.6 
chloroquine 0.078±0.006 25±3.8 
 
1.9.5 Symphonones A-I 
Symphonones A-I were derived from Symphonia globulifera by Marti et al. in a 
continuing research aimed at finding a better PPAP for treating malaria, a leading cause of 
death in the developing world. They observed a very similar trend mentioned in the 
previous section, during their study towards the activity of coccinones against P. 
falciparum. The research group carried out a similar study as they performed with 
coccinones. Symphonones A through E, and G— which contain either a fused 
tetrahydropyran or a tetrahydrofuran ring—gave better anti-plasmodium activity than 
symphonones F, H, and I—have a free enolic hydroxyl group—with IC50 values ranging 
from 2.1 to 10.1 µM. The trend was reversed in the case of cytotoxicity; the PPAPs with a 
free enolic hydroxyl group gave better cytotoxic responses than those PPAPs containing a 
fused ring attached to the bicyclo[3.3.1]nonane framework.15 
1.10 SAR (structure-activity relationship) studies in type B PPAPs 
The wide range of biological activities of PPAPs has inspired several scientists to 
study SAR on these molecules (Figure 1.10.1). The results from these experiments are 
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interesting and can lead to new drug discoveries in the future. Several research studies have 
debated over the importance of a phenyl ring or a phenol moiety in PPAPs for the potency. 
It is no doubt that presence of the phenyl ring affects the cytotoxicity of PPAP to cancer 
cell lines. In 2010, Kuo published an article on the cytotoxicity of different PPAPs, namely, 
garcinialiptone A (a type A), garcinialiptone B, cycloxanthochymol (a type B), and 
garcinialiptone C (a type C), xanthochymol (a type B), and isoxanthochymol (a type B), 
having a 2,3-dihydroxy-phenol moiety common in all of them. These compounds were 
tested against HeLa and WiDr cells. Paclitaxel (Taxol) was used as a positive control in 
the experiment. The cytotoxic study revealed that all the compounds have a moderate to a 
borderline activity (IC50 4-5 µg/mL range); interestingly, garsubellin A—which does not 
have an aromatic ring—has no cytotoxic effect on the cancer cell lines. Although these 
molecules were less active than paclitaxel but were active against the MDR subline, it was 
concluded that these six molecules could be potential anticancer agents.102  
Phenolic compounds are known for their antioxidant activity. The research carried 
out by Saputri et al. demonstrated that the number of OH groups at the benzene ring 
influences the antioxidant activity because the phenolic OH groups stabilize the radicals, 
which are essential for antioxidant activity.103 
Keto-enol tautomerism is an important phenomenon in PPAPs, which influences 
cytotoxicity activity of the NPs. The comparative studies repeatedly demonstrated that 
etherification or cyclization of enolic oxygen diminishes the antioxidant activity.81 
However, the etherification of the phenolic oxygen also reduces the antioxidant activity. If 
there is more than one phenolic OH, etherification of one the phenolic OH has less impact 
on the antioxidant activity.104 
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Figure 1.10.1. Structure activity relationship of PPAPs 
Prenyl groups also play a significant role in SAR.65 Some research data show that 
the presence of more prenyl groups increases the potency of the PPAPs against 
leishmanicidal activity.105 Pereira’s study demonstrated a direct correlation between 
lipophilic character and leishmanicidal activity of some PPAPs.97  
The importance of the enolic hydroxyl group in PPAPs has been debated over last 
decade.106 In an interesting study, Iinuma established that the presence of an enolic 
hydroxyl group was necessary for the cytotoxicity against the methicillin-resistant 
Staphylococcus aureus.107 In that research, the scientists studied five different PPAPs, 
namely, garcinol, isogarcinol, xanthochymol, isoxanthochymol, and cycloxanthochymol 
that were obtained from the pericarps of G. subellipta. Out of the five PPAPs, only garcinol, 
and xanthochymol showed strong anti-MRSA activity. The minimum inhibitory 
concentration or MIC for xanthochymol showed a range of 3.13 to 12.5 µg/mL against 
MRSA, which was equal to vancomycin, 6.25 µg/mL. Isogarcinol, isoxanthochymol and 
cycloxanthochymol were found to be less reactive compared to xanthochymol and 
garcinol. This result suggested that the chelation of the hydroxyl group is necessary for 
inhibitory activity.107 
 64 
The side chains, like geranyl or lavandulyl or isolavandulyl, and fused rings, like 
tetrahydropyran and tetrahydrofuran, in PPAPs, also play a significant role in 
antiplasmodial activities (Fig. 1.10.1).66 Marti et al. have proposed that the presence of 
nonpolar side chains contributes to antiplasmodial activity against falciparum FcB1 and 
cytotoxicity on the human fibroblast cell line MRC5. The studies on symphonones A-I and 
coccinones A-H have demonstrated a strong correlation in activities with the presence of 
fused side rings.  
Surprisingly, the free enolic hydroxyl group reduced the antispasmodic activity. 
For symphonones A-H, the IC50 values ranged from 2.11 to 10.1 µM, which were close to 
the result obtained on a similar study on M. coccinea by the same research group, Marti et 
al.71 The result concluded that the presence of a fused ring with the bicyclo[3.3.1]nonane 
slightly increases the antiplasmodial activity, whereas 7-epi-garcinol (98), with no fused 
ring to bicyclo[3.3.1]nonane, showed a reduced potency. These studies show that the 
presence of an enolic hydroxyl group plays a significant role in the cytotoxicity of the 
cancer cells, whereas a fused ring attached to bicyclo[3.3.1]nonane is required for 
antiplasmodial activity.88  
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2 Synthetic endeavors towards type B endo-PPAPs 
2.1 Introduction  
Organic chemists have always been impelled by the total synthesis of natural 
products. This is not only because of the fascinating architectural design of many natural 
products but also the fact that they provide numerous medicinal benefits. Almost 70% of 
drugs in the market, for example, have been derived from natural products.108 Total 
synthesis also prods synthetic organic chemists, particularly regarding structural 
revision.37, 109 For the last six decades, synthetic organic chemists have been learning from 
and utilizing quintessential works of Woodward, Overman, Corey, Nicolaou, Baran, Stoltz, 
Sarpong, and numerous others. PPAPs meet the criteria noted above. In some parts of the 
world, they are used as food garnishing material, while in others they are found in folklore 
medicine. PPAPs have shown very potent biological activities:  
Nemorosone - antibacterial;  
Clusianone - antimicrobial and antiproliferative;  
Garsubellin A - antineurodegenerative;  
Hyperforin - antidepressant (signature member of all PPAPs, popularly known as Saint 
John’s wort). 
It is highly encouraging that hyperforin is on the market and sold as Saint John’s 
wort. However, hyperforin has developed some problem because of drug-drug interaction. 
It has manifested itself by the total number of syntheses reported. Less than 20 of the nearly 
200 PPAPs have been synthesized to date. Many research groups were investigating the 
process of developing a method to construct PPAPs synthetically. In 1999, Nicolaou and 
his group at Scripps first published a methodology to construct bicyclo[3.3.1]nonane core 
for garsubellin.110 Seven years later, Danishefsky’s group published the total synthesis of 
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garsubellin A,111 and subsequently, a classic divergent synthesis of nemorosone and 
clusianone.112 Then came Shibasaki’s ent-hyperforin synthesis in 2010,113 which consisted 
of nearly 55 steps.114 That was the first enantioselective synthesis of any known PPAP. 
Since then, numerous research groups have focused on synthesizing different PPAPs or 
trying to find new, shorter routes to construct these molecules. A few years ago, Maimone’s 
and Shair’s groups synthesized hyperforin independently.115, 116 Recently, Barriault’s 
group also synthesized hyperforin, papuaforin, and nemorosone using gold catalysis. These 
remarkable syntheses reiterate the importance of total synthesis of PPAPs even today. In 
all of these cases, the number of steps continued to decrease to less than twelve. There is a 
commonality in the previously mentioned syntheses: all the molecules are exo type A 
PPAP, expect Porco’s seminal work on 7-epi-nemorosone, which was the only endo type 
A PPAP synthetically reported until today. 
Much progress towards the total synthesis of PPAPs was made for type A exo 
PPAPs, but syntheses of type B endo PPAPs were elusive until 2011. In that year, Plietker’s 
synthesis of an endo type B PPAP117 was the first of this kind and, since then, his group 
has published the synthesis of several type B endo PPAPs.  
My research centers on finding a viable route for the total synthesis of 7-epi-
clusianone (10), a type B endo PPAP. Therefore, syntheses of some type B endo PPAPs 
will be summarized in this section. Although my research focuses on type B endo PPAPs, 
some of the notable syntheses of type A PPAPs, published between 2012–2015, will also 
be discussed.  
My predecessors, Jayasekara and Ciochina, who had worked on the PPAP project 
before me, wrote elaborately about the syntheses of type A compounds before 2009 in their 
dissertations.5, 118 There is no point in rehearsing these details here. At the same time, it is 
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very tough to resist talking about some of the recently published (post 2010) total 
syntheses, because these are state-of-the-art. As far as our knowledge of this topic goes, no 
group has yet reported the synthesis of any type C PPAP. Finally, each of the syntheses is 
unique, and it will also be interesting to see how these syntheses have resolved the issue of 
C4 oxidation to install a 1,3-funtionality in the respective molecules. 
Organic chemists approach a total synthesis in two ways: one is strategy derived 
where an organic chemist prudently disconnects a molecule so that they could use the 
chemistry available to them; the other think of developing a new methodology of a key 
reaction in the scheme, which could lead to the final target. In the recent years, mostly after 
2010, we came across some new interesting methodology developments to synthesize 
PPAPs. I have summarized some of them here. 
2.2  Some newer synthetic strategies for constructing bicyclo [3.3.1] nonane  
In this section, I discuss some new synthetic methodologies that were published in 
recent years for synthesizing the bicyclo nonane functionality in PPAPs.  
2.2.1 Annulation approach of allenyl sulphonate esters to make bicyclo nonane by 
Bhat et al. 
To synthesize bicyclo[3.3.1]nonane, Bhat et al. proposed an annulation of allenyl 
sulphonate esters (Scheme 2.2.1).119 Synthetically speaking, the reaction is nothing but an 
addition to an sp carbon atom of an allenyl ester 131, followed by a reductive aldol 
condensation. The reaction looks apparently straightforward; however, it proceeds via an 
enol-lactone intermediate 132, instead of a bicyclic diketone, which Bhat et al. did not 
expect. Fortunately, they realized the enol-lactone could be transformed into a 
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bicyclo[3.3.1]nonane in two-step process via the reductive-aldol reaction. Finally, the aldol 
product could be oxidized to the bicyclic diketone with an excellent yield.119 
 
Scheme 2.2.1. Synthesis of bicyclo[3.n.1]nonane by Bhat et al. 
The research group attempted the methodology over several substrates and found 
out that the viability of the synthetic route was acceptable. The diastereomeric ratios, 
however, in some cases, were not excellent, merely an average of 5:3 (Table 2.2.1). 
Table 2.2.1. Substrate Scope for annulation 
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The reaction Scheme 2.2.1 might look promising in constructing a bridged bicyclic 
compound, the main motif in PPAPs; however, one of the shortcomings is that the 
construction of a 1,3-diketone functionality that was not addressed in the article. The 
synthesis of 1,3-diketone functionality could be achieved by oxidizing the vinyl methyl 
group to carboxylic acid, followed by converting the resulting acid to acid azide which 
would lead to diketone functionality, thanks to Curtius rearrangement. This strategy can 
only be applied in the substrate with β-vinyl methyl group, and not the substrates with both 
α and β vinyl dimethyl groups. Another problem with the synthesis is that diastereomeric 
ratio in annulation step is not very high, which might prove to be the Achilles’ heel of the 
scheme. 
The reaction mechanism for the formation of the bridge bicycle was absorbing and 
shown below (Scheme 2.2.2). It started off with the nucleophilic attack of sp carbon of 
allenyl ester 131 by the enolate from 135 via a reductive aldol fashion. The reaction 
ultimately furnished enolate 137 that kicked off the sulphonate group, and then reduction 
to generate the diol 138. The final oxidation of 138 brought forth the bridge bicycle 139.  
 
Scheme 2.2.2. Mechanism of annulation strategy 
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2.2.2 Metathesis-acylation approach to construct bicyclo [3.3.1] nonane  
In 2014, S. Schmitt et al. proposed a new synthetic methodology for constructing a 
bicyclic core of PPAPs using a ring-closing metathesis and a transannular cyclization of 
the acid chloride.120 According to Schmitt et al. plan (Scheme 2.2.3) that compound 140  
 
Scheme 2.2.3. Retrosynthetic analysis of bicyclo[3.3.1]nonane by Schmitt et al. 
envisioned, retrosynthetically, by a disconnection from cycloocteneacidchloride 141, 
which could be synthesized by Grubbs’ metathesis of the ester compound 145, furnished 
by a TiCl4-catalyzed Sakurai reaction between pent-4-enal 143 and 4-methyl-2-oxo-3-
pentenitrile 144. Sakurai reaction yielded an ester 142 with an 89% yield. The resulting 
alcohol was protected as methyl ether 145 with an excellent yield of 93%. The protected 
methyl ether set the stage for Grubbs’ metathesis, which underwent with an impressive, 
thanks to the gem-dimethyl effect. For a transannular ring closer of an acid chloride, 
cyclooctenemethyl ester 146 was required to be hydrolyzed to acid 147, and this reaction 
was proved to be tough to accomplish because of the gem-dimethyl group next to the 
tetrahedral carbon.  
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Scheme 2.2.4. Synthesis of bicyclo [3.3.1] nonane by Schmitt et al. 
However, the research group found a harsh condition: refluxing ester 146 in DME, 
in the presence of LiOH and water, for four days yielded the acid, which was converted 
into acid chloride 148. This acid chloride then set the transannular ring closer that furnished 
149 with a poor yield in the presence of AlCl3; however, the corresponding acid chloride 
in DME at 21 hours of reflux yielded the required bridge bicycle. The reaction yielded both 
exo and endo diastereomers in an 18:1 ratio (Scheme 2.2.4). The current plan 
unambiguously showed that the reaction had some problem, and Schmitt et al. realized that 
instead of acid chloride, the acid anhydride would better serve the purpose for the 
transannular ring closer. Moreover, it turned out as per expectation; the mixed anhydride 
of the TFA salt of the acid, in situ, furnished the exo diastereomer exclusively at 0 °C, and 
the yield of the reaction increased to a 98% (Scheme 2.2.5). The next task was to complete 
the synthesis of the model compound and therefore, the TFA compound was cleaved into 
two diastereomeric alcohols that were treated with NaHCO3 to remove TFA, and then 
oxidation of the resulting alcohol yielded 152. The next challenge was to install 1,3-
diketone functionality in the molecule to finish the synthesis. Schmitt et al. have not offered 
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such a route in their present scheme. This might be a major problem for the applicability 
of the route. 
 
Scheme 2.2.5. Modified approach to bicyclononane by Schmitt 
2.3 Domino Michael-aldol approach by Alexakis 
We have seen many PPAPs with a bicyclo[3.2.1]octane core. Lalibinone A, enaimeone A, 
and liliflodione are few examples of such PPAPs that contain a bicyclo[3.2.1]octane 
scaffold (Figure 2.3.1). This was the inspiration for Alexakis et al. to propose a domino 
Michael–aldol reaction strategy to construct a bicyclooctane motif. 
 
Figure 2.3.1. PPAPs family having bicyclo [3.2.1] octane cores 
Alexakis et al. planned to accomplish a bicyclo[3.2.1]octane core in a step using tandem 
Michael/aldol reaction (Scheme 2.3.1). They chose a bifunctional catalyst 160 after 
screening cinchona alkaloid and urea derivatives. However, to make an octane scaffold, 
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they needed a five-carbon unit, which came from a cyclopentanone derivative, and a three-
carbon unit, which came from ethyl (3E)-2-oxo-4-phenyl-3-butenoate 159.  
 
Scheme 2.3.1. Synthetic scheme for domino Michael–aldol reaction by Alexakis et al. 
With this plan in mind, they applied the condition of domino Michael–aldol reaction to 
ethyl (3E)-2-oxo-4-phenyl-3-butenoate 159 and methyl 2-oxocyclopentane-1-carboxylate 
160 catalyzed by urea-based bifunctional catalyst (Figure 2.3.2). The reaction yielded the 
bicyclo[3.2.1]octane with four stereocenters with an excellent diastereoselectivity; 
however, the enantioselectivity was not impressive (Scheme 2.3.2). Using other 
bifunctional catalysts, namely, 163, 164, and 165, the improvement in enantioselectivity 
did not increase, even using a 20 mol% catalyst in the reaction. 
 
Scheme 2.3.2. Probable mechanism for domino Michael–aldol reaction 
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Figure 2.3.2. Bifunctional catalysts  
With this plan in mind, they applied the condition of domino Michael–aldol reaction to 
ethyl (3E)-2-oxo-4-phenyl-3-butenoate 159 and methyl 2-oxocyclopentane-1-carboxylate 
160. The catalyst used in the reaction was a urea-based bifunctional catalyst (Figure 2.3.2). 
The reaction yielded the bicyclo[3.2.1]octane with four stereocenters with an excellent 
diastereoselectivity; however, the enantioselectivity was not impressive. Using other 
bifunctional catalysts, namely, 163, 164, and 165, the enantioselectivity did not increase, 
even using a 20 mol% catalyst in the reaction. 
2.4 Syntheses of (+)-30-epi, (–)-6-epi, and ()-6,30-diepi-13,14-didehydroxy-
isogarcinol by Porco et al. 
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Figure 2.4.1. Several target didehydroxyisogarcinols 
Impressed by the therapeutic index of 13,14-didehydroxyisogarcinol, namely, 
potent against leukemia, colon cancer, HIV, medulloblastoma, autoimmune disease, Porco 
and his research team devised a scheme to synthesize different series of nonnatural 
diastereomers of 13,14-didehydroxyisogarcinols.121 His group is famous for dearomatizing 
annulation, a thoughtfully crafted strategy that had already delivered some remarkable 
syntheses.122-124 However, he wanted to synthesize three different molecules, (+) 30-epi-, 
(‒)-6-epi-, and (+)-6,30-diepi-13,14-didehydroxyisogarcinols, from a common 
intermediate, either 170 or 169, and to achieve that he needed another strategy—that could 
fulfill his goal—which is called diastereoselective, Lewis-acid-controlled cyclization. In 
many ways, the approach is partly reminiscent of Nature’s strategy to synthesize PPAP 
molecules from a common intermediate; that is, we see Nature manufactures type A and 
type B PPAPs from a common cationic intermediate via a diastereoselective carbocationic 
cyclization (Scheme 2.4.1). 
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Scheme 2.4.1. Retrosynthetic analysis of (‒)-6-epi and (+)-30-epi-13,14-
didehydroxyisogarcinols 
2.4.1 Retrosynthetic analysis of epi-didehydroxyisogarcinols  
The retrosynthetic analysis (Scheme 2.4.1) of 166 and 168 started from a 
diastereoselective cationic cyclization and metathesis from chiral intermediates 170 and 
174 respectively.125 Compounds 170 and 174 could be synthesized from 171 and 175 
respectively via vinylic alkylation using higher order cuprate chemistry. 171 and 175 could 
be accessed from a common intermediate 169 via a diastereoselective cationic O-
cyclization, which is the crucial step in the whole total synthesis, because (+)-30-epi- and 
O
O Ph
O
O
O Ph
O
(+)-30-epi-13,14-didehydroxyisogarcinol
(+)-6-epi-13,14-
didehydroxyisogarcinol
168
O
OH
Ph O
O
Me
chiral
166
OH
O
HO
O
H
OH
Ph O
O
Me
169
OH
O
HO
Ph O
OH
+
O
OMe
H
O
PhO
O
OMe
H
O
PhO
O
OMe
O
PhO
170
171
175174
172173
O
O
commercially availble
 77 
(‒)-6-epi-13,14-didehydroxyisogarcinol diverged from this intermediate, 169. 
Regioselective dearomative cyclization of 172 with alcohol 173 would provide 169, and 
on the other hand, alcohol 173 could be synthesized from a commercially available starting 
material, ethyl 3-methyl-2-butenoate, whereas 172 could be prepared from commercially 
available phloroglucinol 174 via Friedel-Crafts acylation. 
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Scheme 2.4.2. Syntheses of bisalkylated didehydrobenzopyrans 
2.5 Synthesis of (+)-6-epi, (+)-30-epi-13, 14-didehydroxyisogarcinols 
The synthesis started with the regioselective alkylation of 172 with the triflate 
derivative of racemic alcohol 173 in the presence of LiHMDS (Scheme 2.4.2). The reaction 
produced three dearomatized enols, namely, 178A, 178B and 178C in a diastereomeric 
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ratio of 1.9:1.4:1. Out of these three enols, 178A is a racemic enol, whereas 178B and C 
are meso/ achiral, and their structures were confirmed by X-ray crystallography. From pure 
enantiopure alcohol of 173, after regioselective alkylation, the reaction brought forth 
enantiopure 169. Intermediate 169 then set the stage for diastereoselective Brønsted/Lewis 
acid-base carbocyalization. Porco and his group found the right conditions to get the 
desired diastereomers from the same intermediate. Use of SnCl4/phosphoric acid 
combination produced a single enantiomer, 171, with a 10:1 dr, whereas BF3-OEt3 
furnished 175 with a 5:1 dr. To get two different enantiomerically pure single 
diastereomers from an enantiomerically pure single diastereomer, Porco needed a reagent 
that could differentiate between two diastereomeric alkenyl appendages in 169, based on 
the rate of protonation. In one case, he found that 169 reacted with SbCl5/ phosphoric acid 
and produced 171 that would lead to (+)-6-epi-13,14-dehydroisogarcinols, whereas BF3-
OEt3 combination reacted with 169 to produce 175, which would lead to (+)-30-epi-13,14-
dehydroisogarcinol.  
The acidity of a Brønsted acid increases upon the addition of a Lewis acid, and this 
increased acidity also restricts the release of H+, depending on the accessibility of a 
protonating center. This property was exploited in this cyclization reaction for the 
construction of the pyran ring. Authors gave a detailed account of computational studies to 
explain this result with the help of several reaction trials, using different Bronsted/ Lewis 
acid combination. Deprotonation of the pyranodienones -H in 171, 175 and 181 with Li 
(2-Th)2Cu(CN)Li and then, reacting with allyl bromide furnished 170, 174 and 182 in a 
good yield. The next critical step was to convert pyradienones, 170, 174, and 182, into 
bicyclo[3.3.1]nonane trione cores 185, 184 and 183 repectively. The formation of (–)-6-
epi-13,14-didehydroxyisogarcinol from 185, and similarly, (±)-6,30-epi-13,14-
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didehydroxyisogarcinol from 183 did not pose as much of a challenge as for (+)-30-epi-
13,14-didehydroxyisogarcinol from 184. In the previous two cases, TFA/H2O in a 1:1 ratio 
at 60°C smoothly converted the pyradinones to bicyclo[3.3.1]nonane, giving rise to 166 
and 168 in impressive yields (Scheme 2.5.1). 
 
Scheme 2.5.1. Finishing the total synthesis of (+)-6-epi- and 30-epi-13,14-
didehydroxyisogarcinol  
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The axially oriented allyl group at C6, generated from 174, increases the energy of 
the transition state as shown in (Figure 2.5.1) by clashing with benzoyl group in T1A. There 
is no such unfavorable interaction in T2A, leading to product 183. In neat TFA, compound 
174 produced O-alkylated product 184A as a major product in addition to the required C-
alkylated product. However, in the presence of water, the diastereomeric cationic carbo-
cyclization favored C-alkylation product with a low yield. The amount of water was very 
critical for this transformation, which could favor the reaction toward either 184A or 184 
(Figure 2.5.1). Fortunately, 1% water in TFA proved to be the ideal condition for the 
reaction, which gave the correct diastereomer 184, with a low yield of 14%. Surprisingly, 
the reaction took 5 days to complete, and the prolong reaction time could be another reason 
to the increased amount of O-alkylated product 184A (Scheme 2.5.2). 
 
Figure 2.5.1. Transition state model for cyclization 
The axially oriented allyl group at C6 in T1A (Fig. 2.5.1), generated from 174, increases 
the energy of the transition state by clashing with benzoyl group. There is no such 
unfavorable interaction in T2A, leading to product 183. In neat TFA, compound 174 
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produced O-alkylated product 184A as a major product in addition to the required C-
alkylated product. However, in the presence of water, the diastereomeric cationic carbo-
cyclization favored the C-alkylation product with a low yield (Scheme 2.5.2).  
 
Scheme 2.5.2. By-product formation 
Finally, global Grubbs’ metathesis of 185, 184 and 183 produced 166, 168 and 166 with 
an excellent yield of 98%, 70% and 91% respectively. 
2.6 Total synthesis of natural analogs of (+)-clusianone by Coltart et al.  
Coltart and his research group at Duke University were intrigued by PPAPs because 
of its synthetic challenges and medicinal properties. Subsequently, his group came up with 
α-alkylation of chiral N-aminocarbamate derived hydrazones 191 strategy to synthesize 
enantiomerically pure α-alkyl cyclohexanones 187 to synthesize some of the PPAPs.126 
The idea behind the route was that chiral auxiliary would react rapidly with ketones to 
furnish corresponding hydrazones, which later would undergo deprotonation by the strong 
base to an aza enolate to install prenyl group at α to the ketone and this -ketone would, 
then cyclize with malonyl dichloride to construct bicyclo[3.3.1]nonane. With this idea in 
mind, the group disconnected the -prenyl group at C3 from 9 to produce 187 (Scheme 
2.6.1). The reason behind this disconnection was that Danishefsky showed that the late 
stage bridgehead alkylation was possible. 187 could be obtained from 189 by a base-
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mediated ring closer with malonyl dichloride. 189 could be synthesized from 188 by 1,4-
Michael addition to the , - unsaturated double bond followed by a methyl enol formation. 
The conjugated ketone 188 could be furnished from 189 with a LDA mediated prenylation 
of hydrazone of 190 in good yield. 
 
Scheme 2.6.1. Retrosynthesis of (+)-clusianone by Coltart 
 
Scheme 2.6.2. Synthesis using enantioselective alkylation 
Synthesis commenced with a mono-alkylation of 1,3-cyclohexanedione with prenyl 
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2.6.2). Oxalyl chloride converted to vinyl chloride 192. 192 was dechlorinated with Zn in 
AcOH in the presence of AgOAc to 190. The ketone, 190, formed a hydrazone 193 with 
191 and alkylated with prenyl bromide by LDA to yield 194 with a high chiral induction 
of 98:2 dr. The removal of the chiral auxiliary with P-TsOH produced 195 with a high er 
of 99:1. 
 
Scheme 2.6.3. Finishing the total synthesis of (+)-clusianone 
The next two steps were the nucleophilic addition of MeMgBr to the product from 
194 to produce alcohol 195 and subsequent allylic rearrangement of that alcohol catalyzed 
by PCC to furnish 188 (Scheme 2.6.3). Methylmagnesium bromide added a methyl group 
to 188 in the presence of CuBr·Me2S to provide 196 with an impressive yield of 85%. The 
base mediated methylation of 196 resulted in isomeric enol ethers, 197 and 198, and 
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subsequently the ring closing by Effenberger cyclization, with malonyl dichloride PTC, 
and benzyl triethyl ammonium chloride, afforded the desired bicyclo[3.3.1]nonane 199 
plus 196. Compound 199 was converted into its methyl enol ether in two steps. A 
bridgehead allylation with LDA and allyl bromide produced 200. Finally, acylation at C3 
with benzoyl chloride, LiTMP, and hydrolysis of the methyl enol ether with LiOH in 
dioxane built a natural analog of (+)-clusianone 9, in 79% yield in the final step (Scheme 
2.6.3). 
2.7 Total synthesis of ()-hyperforin by Shair 
Two years after Shibasaki’s hyperforin synthesis, in the year of 2012, Matt Shair’s group 
proposed a biomimetic approach towards hyperforin116 and a successful synthetic route 
comprised of 18 steps, bringing it down 33 steps from Shibasaki’s synthesis, which 
required 51 steps.  
 
Scheme 2.7.1. Retrosynthetic analysis of hyperforin by Shair’s group 
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Retrosynthetically, hyperforin 6 (Scheme 2.7.1) could be obtained by assembling 
six chemicals. Therefore, he envisaged that hyperforin could be obtained by bridgehead 
alkylation of alcohol 201, and alcohol 201 could be made from stereoselective and 
chemoselective Lewis acid mediated epoxide ring opening of 202. This cyclohexene 
containing epoxide could be synthesized regioselectively from the reaction of 1,5-
dimethoxy-1,4-cyclohexadiene 203 with prenyl chloride 204 and epoxy geranyl bromide 
205. Although the route was inspired by nature’s robust mechanistic artillery, known as an 
enzyme, Shair’s group had no such luxury (Scheme 2.7.2); as a result, they thought that 
epoxide moiety might be placed in such a way that stereochemical information could be 
passed on to construct 201, and the selective choice of Lewis acid would do the job. 
However, the issue was concerned with diastereoselectivity, the stereochemistry of C7 in 
201, and whether OH would occupy axial or equatorial position based on the transition 
state (TS). Thus, the boat TS was disfavored over the chair TS (Scheme 2.7.4). The boat-
like TS, however, led to 5-(enol-endo)-tet cyclization to form a bicyclo[3.3.1]nonane, and 
this cyclization is unfavorable; therefore, the reaction follows the 6-(enol endo)-tet 
cyclization. This watershed reaction ultimately took care of three major issues: formed the 
bicyclo[3.3.1]nonane scaffold, established the C5 stereochemistry, and also defined the 
stereochemistry at C8.   
 
Scheme 2.7.2. Matt Shair’s biomimetic approach 
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Based on these findings, Shair’s group set out to synthesize the target molecule, 
hyperforin. The synthesis (Scheme 2.7.3) began with enantioselective epoxidation of 
geraniol and bromination, which yielded 205 (91% ee). Oxymercuration–hydration of 205, 
and then protection of the concomitant alcohol with TESCl gave 206 in 88% yield. 1,3-
Dimethoxycyclohexadiene—obtained from 1,3-dimethoxybenzene by Birch reduction—
was subjected to prenylation with the help of ortho-lithiation and mediated by freshly 
synthesized BaI2, giving 207 in 85% yield.  
 
Scheme 2.7.3. Hyperforin synthesis by Shair 
The next goal was to install a geranyl moiety into the molecule for building the 
bicyclic motif. Again, with the help of ortholithiation mediated by s-BuLi, the allyl anion 
generated from 207 reacted in SN2 fashion with 206. Then, 208 underwent cyclization in 
the presence of TMSOTf to produce ketal 209 in a decent yield. This step accomplished 
three tasks: establishing the stereochemistry at C5 and C8 and construction of the bicyclic 
motif. The next step was the allylic oxidation of C2, which was accomplished by the 
treatment of TBHP, PhI(O2CCF3), and O2. The reaction yielded 210 in 55% yield. This 
Br
O
205
Br
O
TESO
1. Hg(OAc)2, H2O
2.TESCl
206
OMe
OMe
1. Li in Liq NH3
2. t-BuLi; BaI2; 204
85%
OMe
OMe
207
s-BuLi; 206
85%
OMe
MeO
O
TESO
208
O
OMe
OMe
TESO 5
7
8
209
TMSOTf
79%
overall 88%
 88 
oxidation was challenging and has been a bottleneck for many PPAP syntheses, given the 
stereoelectronic environment around carbon.  
 
Scheme 2.7.4. The origin of diastereoselectivity 
The Lewis acid, BrBMe2, opened the epoxide ring of 210 via a chair TS, leading to 
alcohol, which was converted to thiocarbonate 211 in 72% yield in three steps. BEt3 /air 
worked to initiate a free radical prenylation reaction with allyl tributyltin in 62% yield. The 
reaction was famously known as Keck allylation. This reaction was followed by metathesis 
with 2-methyl-2-butene in the presence of Grubbs II catalyst (Scheme 2.7.5).  
Bridgehead acylation with isopropyl cyanoformate, using LiTMP as a hindered base, 
installed the isopropyl ketone moiety at C1, and microwave-assisted desilylation went 
smoothly. Then deprotonation of C3 by LDA, transmetallation with Li(2-Th)CuCN, and 
trapping the resulting vinyl anion with prenyl bromide installed the last prenyl group on 
C3. Finally, heating 213 in DMSO-LiCl mixture unmasked the hydroxyl group and brought 
forth hyperforin. Thereby, after 18 steps, the total synthetic scheme yielded 40 mg of 
hyperforin (Scheme 2.7.5).  
 89 
 
Scheme 2.7.5. Finishing synthesis of hyperforin by Shair et al. 
The key features of the synthesis were: 1) desymmetrization of the hidden 
symmetry of the molecule; 2) the attaching of a geranyl epoxide appendage to 1,4-
cyclohexadiene; and, 3) an enantiotopic double bond was made diastereotopic for the 
preferential attack of pro-R-enol to the epoxide via chair TS. It is also interesting to notice 
that Shair and his group resorted to late stage oxidation of C2 in hyperforin in their 
approach (Scheme 2.7.4). 
2.8 Biomimetic approach to hyperforin by Maimone 
In 2015, Maimone published an enantioselective synthesis of hyperforin,115 reducing the 
number of steps in the synthesis to 10. To the best of our knowledge, it has the least number 
of steps involved in any PPAP synthesis to date. The key feature of the synthesis was the 
oxidative rearrangement that constructed the bicyclo[3.3.1]nonane motif with the correct 
stereochemistry at C8. 
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Scheme 2.8.1. Retrosynthesis of hyperforin by Maimone 
Nature’s synthetic approach toward hyperforin relies on the attack of an enol to a 
carbocationic intermediate 214A, which is involved in the crucial bond formation reaction 
to construct the bicyclic scaffold (Scheme 2.8.1). Drawing his inspiration from nature, 
Maimone resorted to a polarity-reversed approach to decipher the molecule of his interest: 
hyperforin. He thought of creating an intermediate 214C, which might rearrange to bicyclic 
motif via the [1,2] alkyl shift. The idea of proposing the reversal of polarity in intermediate 
214C stems from 214B, where the polarities of C1 and C8 were opposite in 214A, which 
was connected to the biosynthetic pathway. Now, the strategic disconnection of 214C 
showed that the intermediated 214C could be achieved from 214D and 214E via a series 
of reactions. 
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Scheme 2.8.2. Synthesis of hyperforin by Maimone 
Based on the retrosynthetic principle mentioned above, Maimone’s synthesis 
started off from the conjugated addition to 214, mediated by CuI, of (3-methyl-3-buten-1-
yl)magnesium bromide and trapping the concomitant enolate by homoprenyl bromide 
(Scheme 2.8.2). The product from this reaction underwent isomerization, catalyzed by 
TsOH and heat, to generate to convert the terminal, disubstituted alkene to an internal, 
trisubstituted one. The reaction gave a 40% yield of 215 with 3:1 dr. LDA-promoted 
prenylation of 215 gave an excellent yield of 216 and set the stage for the annulation 
reaction. Using a highly hindered and strong base like LiTMP, the enolate anion, generated 
from 216, underwent acylation and annulation with diketene to furnish 5,6-cis-fused 
bicycle 217 as a single diastereomer. In spite of this spectacular transformation, the yield 
of the reaction was not impressive, merely 45%, and calculated based on the recovered 
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starting material. This step might prove to be an Achilles’ heel for the overall synthetic 
scheme. They, however, did not consider this low yielding step and proceeded with the 
scheme. Compound 217 was converted into regioisomeric vinylogous esters, 218 and 219, 
in 1:1 ratio by the action of TMS-diazomethane. These esters were separable, and later, 
after a rigorous analysis, compound 219 was found to be the requisite intermediary for the 
synthesis of hyperforin.  Compound 219 was a milestone in the hyperforin synthesis and 
set the stage for an oxidative rearrangement, which is the unique selling point of this total 
synthesis (Scheme 2.8.3). 
 
Scheme 2.8.3. Proposed mechanism of oxidative rearrangement 
After a lot of screening of stoichiometric oxidants, they found PhI(OAc)2 was the 
ultimate choice. The mechanism of the reaction is interesting (Scheme 2.8.3). It showed 
that hypervalent iodine oxidizes the resulting enolate to 220, which then began to expel the 
iodobenzene, leading to a 1,2- alkyl shift: reminiscent of Favoriski-like rearrangement. 
This step added a new dimension to the synthesis by locking the stereochemistry at C8 with 
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an excellent yield of 92%. LiTMP-mediated deprotonation of the C3 proton, followed by 
chlorination with TMSCl, gave a good yield of 221. The halogen-metal exchange has not 
been effective for vinyl chloride. Using Li(2-Th)CuCN, however, they performed a 
halogen metal exchange with vinyl chloride 222 and which underwent a reaction with 
prenyl chloride resulting in 200. Finally, LiCl in DMSO removed the methoxy group and 
installed the OH group leading to 1,3-diketone functionality in the molecule. 
In a nutshell, the focus on the synthesis was an Umpolung-derived oxidative 
rearrangement of an intermediate 217 to construct the bicyclic motif in 221. This approach, 
regarding synthesis, resembles the biosynthetic pathway. It is also interesting to note that 
C4 in the molecule (in the case of a type A PPAP) is already in a right oxidation state from 
the beginning of the synthesis. Thus, chemists need not think about the intricacies of a late 
stage oxidation.  
2.9 Hyperforin and papuaforin A-C, and formal synthesis of nemorosone by 
Barriault et al. 
In 2014, Louis Barriault and his group developed a gold-catalyzed carbocyalization 
approach to construct PPAPs (Figure 2.9.1) and published the synthesis of hyperforin, 
papuaforin A-C, and nemorosone from a common intermediate (Figure 2.9.1).127 In many 
ways, this synthesis reminds researchers of Danishefesky’s seminal work on the total 
synthesis of clusianone and nemorosone,111 where the latter resorted to a common 
precursor, which was en route to two different PPAPs via a series of riveting chemical 
transformations.  
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Figure 2.9.1. Target molecules for Barriault’s group 
2.9.1 Retrosynthetic approach of Barriault  
Chemoselectivity of gold (Ι) phosphine carbene complexes have been well 
addressed in synthetic chemistry for decades.128-131 Inspired by the fascinating gold (Ι) 
carbene chemistry, Barriault’s group proposed a gold-catalyzed carbo-cyclization of an 
alkyne to set up a bicyclo [3.3.1] motif via the 6-endo-dig mechanism. They hypothesized 
that the carbocyclization of an enolether catalyzed by the gold carbene complex would lead 
to the required bicyclic motif via the 6-endo-dig instead of the 5-exo-dig pathway. 
Moreover, to achieve the carbo- cyclization, the group used a special gold catalyst with 
suitable ancillary ligands.  They published a detailed study of ancillary ligands used for 
this type of transformation in 2009 and, based on their findings, C4 carbon was not in the 
proper oxidation state.132, 133 They struggled over the years to figure out the solution of 
oxidation at C4. Eventually, they choose bromo alkyne 225 so that bromine could be 
replaced to oxidize C4.  
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Scheme 2.9.1. Synthesis of PPAP core by gold catalysis 
Retrosynthetically speaking, all allyl groups replaced the prenyl groups in 200 
(Scheme 2.9.2). Compound 226 could be obtained from the alkylation of C3 by a sterically 
hindered base, and 227 could be converted to 226 by bridgehead acylation following 
Danishefsky’s method, which he adopted in synthesizing clusianone and nemorosone.111 
Compound 228 could be obtained by the 6-endo-dig cyclization of silyl enol ether 227, 
thanks to  [(JohnPhos)Au(NCMe)][SbF6]. Compound 227 could be easily traced back to a 
commercially available 3-methoxycyclohex-2-en-1-one, 230. 
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Scheme 2.9.2. Retrosynthesis of type A PPAPs by Barriault 
2.9.2 Synthesis of hyperforin, nemorosone, and papuaforin A-C by Barriault et al. 
With the retrosynthetic scheme in mind, Barriault’s group started by alkylating 230 
with allyl bromide and LDA (Scheme 2.9.3). The resulting compound from the previous 
reaction underwent a Grignard reaction that depended upon the final target compound 
(Figure 2.9.1). For example, for hyperforin, the group used (but-3-en-1-yl) magnesium as 
a Grignard reagent. Yet, for nemorosone, they chose MeLi. Subsequently, hydrolysis with 
1 M HCl, depending on target compound, furnished 229 in a decent yield (>80%, 
depending on the Scheme). LiHMDS-mediated alkylation of 229 gave a decent yield. 
Deprotonation of the C5 hydrogen from 229A, 229B, or 229C and then, treating the 
resulting enolate with the 3-(TMSCl)-2-propynal. The reaction yielded 232 in alkynol with 
a variety of diastereomeric ratios, which was dependent on the synthesis of the target PPAP 
(Figure 2.9.1) 
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The next step was very interesting regarding setting up the stereochemistry at C8. 
The conjugate addition to 232 was tricky since substrate 232—a δ substituted 
cyclohexenone—was prone to an anti-addition but, fortunately, Barriault’s group observed 
a syn-addition (Scheme 2.9.3). Magnesium makes a chelate on the top face of the double 
bond and, thereby, facilitates the nucleophile to approach to the double bond by syn 
fashion; this was a steric approach control that determined the outcome of the 
stereochemistry.  
 
Scheme 2.9.3. Syntheses of the silyl ketones 
Next, oxidizing the propargyl alcohol to the ketone and deprotecting the silane 
group, followed by bromination with AgNO3 and NBS, furnished 232. The ketone was 
protected with TBSOTf to produce enol ether, 228. This step set the stage for the most 
important reaction of the entire synthetic scheme: a gold(Ι)-catalyzed carbocyclization for 
the construction of a [3.3.1] bicyclo nonane motif, 227A-C. The bromo-bicyclic enone was 
converted to methoxy enone, 226A-C with a good yield.  
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The step was critical for finishing the synthesis of the PPAPs because of the steric 
and electronic encumbrance around the C4 carbon, which has been a red herring in 
numerous trials for successful PPAP synthesis. Compounds 226 A-C were important 
stopping points in the syntheses. Hyperforin and papuaforin A-C, along with the synthesis 
of nemorosone, took different routes.  
 
Scheme 2.9.4. Synthesis of bromoalkyne for cyclization 
In other words, compounds 226A-C proved to be an important junction in the whole 
synthetic endeavor. Nemorosone was synthesized from 226A within five steps (Scheme 
2.9.5) by following Simpkin’s method.134, 135 The Barriault-group needed to take 
precautions for the synthesis of hyperforin and papuaforin because of bridgehead acylation. 
It was surprising from the synthetic point of view because there was literary precedent for 
such acylation.136 Danishefsky’s solution of bridgehead acylation saved their day.  
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Scheme 2.9.5. Finishing the total synthesis of nemorosone 
The LDA-mediated iodination of the bridgehead carbon (C1), not touching the other double 
bonds, as well as an I/Li exchange using t-BuLi, installed the isopropyl ketone in all the 
final molecules; namely, nemorosone, hyperforin, and papuaforin A-B. Although 
bridgehead acylation helped the group reach their targets, the yields were not satisfactory, 
ranging between 18% to 29%. 
Once the bridgehead acylation was done in 226A-C, depending on the end 
molecule, they set out to finish the synthesis, and the next few steps—alkylation of C3 with 
hindered Li-Cu salt, Grubbs’ metathesis, and demethylation with LiCl in DMSO—were 
uneventful (Scheme 2.9.6). Papuaforin A-C, however, contains an extra dihydropyran ring, 
which is a further modification because the C3 prenyl group underwent an acid-catalyzed 
carbocyclization. Using PdCl2 and molecular O2, the dihydropyran ring was installed 
diastereoselectively leading to papuaforin A and B.  
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The mechanism for the formation of the ring is very simple: Wacker type oxidation. 
Since the 1,3-diketone functionality is in equilibrium with two different mesomeric forms, 
both the keto oxygen at C2 and C4 act as nucleophilic centers, resulting in papuaforin A 
and B (Scheme 2.9.6). 
 
Scheme 2.9.6. Finishing the syntheses of papuaforins A–C 
Key points from this synthetic research are the formation of a bicyclo[3.3.1]nonane motif 
by gold catalysis from bromoalkyne (228), and the subsequent replacement of the Br-group 
in 227 with an OMe group to circumvent the problem of oxidation at C4. 
2.10 Total synthesis of 7-epi-nemorosone by Porco 
John A. Porco was the first to devise a synthetic scheme for a type A endo PPAP, 
7-epi-nemorosone, after successful synthesis of some type B endo PPAPs by Plietker.117 
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Porco’s approach to these types of compounds is known as dearomatization-annulation. 
Using this method, his group synthesized (±)-clusianone.123 
 
Scheme 2.10.1. Retrosynthetic scheme of 7-epi-nemorosone by Porco 
With the help of metathesis, all the prenyl groups could be introduced easily; this 
thought led retrosynthetically to 235, which could be obtained from 236 by a retro-aldol 
reaction (Scheme 2.10.1). Interestingly, this adamantane core was not necessarily needed 
to synthesize these kinds of molecules; in other words, he could have avoided this scheme, 
which proceeds via an adamantane motif. He and his group, however, prudently devised 
such a scheme so they could access the PPAPs that contain an adamantane core. 
Adamantane alcohol 236 could be accessed in one step from aldehyde, 237, and phenol, 
238, via a Michael–aldol reaction. 
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Scheme 2.10.2. Synthesis of 7-epi-nemorosone by Porco et al. 
The synthesis (Scheme 2.10.2) started off with deprotonation of phenolic hydrogen 
of 238 by one equivalent of LiHMDS; the resulting phenoxide underwent 1,4-addition to 
237, at which point the nascent enolate anion expelled acetate. The second equivalent of 
LiHMDS generated phenoxide again, and this resulting phenoxide anion underwent 
Michael addition followed by aldol condensation to generate adamantane alcohol 236 
(Scheme 2.10.3). 
 
Scheme 2.10.3. The mechanism of formation of adamantane alcohol 
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Using steric congestion around the adamantane core in 236, a CeCl3 / vinyl 
magnesium-mediated tandem retro-aldol condensation was followed by a Grignard 
reaction. It furnished two alcohols esterified by Ac2O and pyridine. The deacylation of 239 
catalyzed by Pd(PPh3)4, however, proved problematic because of an unusual rearrangement 
to adamantane core 241 as a major product.  
 
Scheme 2.10.4. Mechanistic rationale for unusual rearrangement 
Detailed mechanistic analysis (Scheme 2.10.4) showed that there were two 
competitive mechanisms in place: one was a nucleophilic attack on the C4 acyl group 
followed by deacylation, resulting in 241; the other was expected, namely, a deacylation 
reaction that led to 235. Porco and his team quickly figured out the issue: using a larger 
protecting group for the 1,3-diketone. Thus, they replaced acetate with pivalate (Scheme 
2.10.5), and the issue was resolved. Once adamantane alcohol 236 was esterified with 
Piv2O in pyridine and carried out the same reaction sequence like in Scheme 2.9.5, they 
secured an exclusive pivalate derivative of 236 with a 61% yield. The remaining steps went 
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smoothly; 242 was reductively de-acylated with ammonium formate with the help of 
Pd(PPh3)4, and Grubbs (ΙΙ) catalyst replaced all the allyl groups with prenyl groups. Finally, 
Bu4NOH, in a 1,4-dioxane-H2O mixture, deprotected the pivalate ester 243, resulting in 7-
epi-nemorosone in an impressive 78% yield. 
 
Scheme 2.10.5. Finishing the synthesis of 7-epi-nemorosone 
Key points from this synthesis are dearomative/cyclization and a CeCl3-catalyzed 
vinyl magnesium-mediated ring opening to bicyclo [3.3.1] nonane (Scheme 2.10.5). 
Although the synthesis is unique in the sense that it was the first synthesis of type A endo, 
the final purification step was cumbersome, leading to purification via prep HPLC. Finally, 
the construction of a 1,3-diketone functionality was clearly not a problem here since Porco 
and his group started with 2-benzoyl-5-methoxy-4, 6-bis(prop-2-en-1-yl)benzene-1, 3-diol, 
which has the 1,3 diketone already built in; thus, there was no oxidation problem. 
2.11  Plietker’s divergent approach for the total syntheses of type B endo PPAPs  
2.11.1 Synthesis of 7-epi-clusianone, oblongifolin, hyperibone L, hyperpapuanone, 
and regio-hyperpapuanone 
Until 2011, most of the successful total syntheses of PPAPs had been exo type A, except 
clusianone, which is a type B exo. There were multiple research groups trying to synthesize 
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type B endo PPAPs because of their unique structure and a wide range of medicinal 
properties, but success was elusive. From my perspective, the geometry of type B endo 
compounds was the main reason behind the long list of unsuccessful synthetic attempts by 
organic chemists. The type B endo PPAPs exist in a boat conformation rather than a chair, 
which is common to type an exo PPAPs. Things changed in 2011—when Bernd Plietker 
and his group developed a unique approach to addressing these challenges for the type B 
endo synthesis.117 This led to the total synthesis of 7-epi-Clusinone, oblongifolin, 
hyperibone L, hyperpapuanone, and regio-hyperpapuanone. As far as our knowledge goes 
in this field, his group is the only one that has been synthesizing type B endo compounds 
successfully. Here, I will provide an account of his method and decipher the philosophy of 
these state-of-the-art syntheses. Since his approach to this synthetic challenge is the same 
for all five compounds, I shall only discuss 7-epi-Clusinone, which is also the molecule of 
my interest, in more detail. The remaining four compounds will be discussed briefly. 
2.11.2 Retrosynthetic analysis of type B endo PPAPs  
Plietker’s group decided to approach the synthetic challenge using simple 
chemistry without a protecting group strategy (Scheme 2.11.1). Plietker envisioned 
developing a common module that would deliver a diverse array of type B endo PPAPs. 
Accordingly, he proposed that target 245 could be achieved from 248 via Dieckman 
condensation, which would be applied here for the first time to synthesize type B endo 
PPAPs. Compound 248 could be obtained from 247 by tandem conjugate addition and -
alkylation. Compound 247 could be made from 3-methyl-3-buten-2-one derivative 246 via 
a tandem Michael–Knoevenagel reaction. Finally, compound 246 could be synthesized by 
alkylation of acetyl acetone followed by aldol condensation with formaldehyde.  
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Scheme 2.11.1. Retrosynthetic analysis of Plietker’s synthesis of type B endo PPAP 
2.11.3 Total synthesis of 7-epi-clusianone  
Keeping in mind the diversification of the synthetic route, acetyl acetone was the 
starting point and suitable alkylating reagent. For 7-epi-clusianone, prenyl bromide was 
used. NaH-mediated alkylation was followed by an aldol-type methylation and an 
extrusion of acetate anion, giving the desired enone, 246 epi_c (since we are discussing 7-
epi-clusianone) (Scheme 2.10.1). MeMgCl-promoted conjugate addition of dimethyl-1,3- 
acetonedicarboxylate to 247 epi_c, followed by a tandem Michael-Knoevenegal reaction, 
furnished cyclohexenone 247epi_c (Scheme 2.35). Once the cyclohexenone ring was 
constructed, the aim was to install the prenyl group at C1 with the correct stereochemistry. 
Deprotonation of 247 epi_c with NaH, followed by addition of MeLi, 18-crown-6, and 
prenyl bromide converted the C5 ester group to a methyl ketone and successfully installed 
the second prenyl group at C1 with the correct stereochemistry, trans to the C7 prenyl 
group. Interestingly, only one of the two ester groups in 247epi_c was converted into a 
methyl ketone by the action of MeLi (Scheme 2.11.2).  
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The question that arose here, inevitably, was: which reaction should go first, 
alkylation at C1 or MeLi addition at C5 ester carbonyl carbon? The molecule, being a β-
keto ester, has the option to distinguish between two esters. Thus, NaH first deprotonates 
the C1 proton because of its low pKa. Subsequently, the ester group at C1 becomes poorly 
electrophilic since the negative charge on C1 can now be delocalized between C1 ester and 
C9 carbonyl. MeLi could now be added easily to C5 ester carbonyl, converting it into a 
methyl ketone. Once the conversion of the ester into ketone was successful, the addition of 
prenyl bromide added the second prenyl group at C1 with the correct stereochemistry. The 
yield was 62% in this step. This step also fixed the oxidation state of C4.  
 
Scheme 2.11.2. Synthesis of 7-epi-clusianone 
The next goal was to construct a gem-dimethyl group at C6 in 248 epi_c (Scheme 
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MeMgBr at 78 °C. The reaction yielded the desired product, 246 epi_c. Having 
established a gem dimethyl group at C6, there were three more steps to accomplish the 
total synthesis of 7-epi-clusianone: (Ι) installing the last prenyl group at C5 with a correct 
stereochemistry; (ΙΙ) making bicyclo[3.3.1]nonane; and the last, (ΙΙΙ) putting the phenacyl 
group at C3. When the group tried to install the prenyl group at C5 by alkylation using 
NaH, they faced steric congestion at C6 because of the gem-dimethyl group. This led to 
failure in seeding the prenyl appendage at C5. After deliberations, they decided to rely on 
the allylic alkylation method,137 which they had developed in their lab, using a 
Bu4N[Fe(CO)3(NO)] catalyst. The reaction demanded putting the prenyl group at C5 trans 
to C7 prenyl with an acceptable dr. Fortunately, they succeeded in installing the prenyl 
group at C5 with an acceptable dr with a high yield of 90%. This allylic alkylation deserves 
some deliberation regarding diastereocontrol. Two equivalents of KO-t-amylate were used. 
One was used to deprotonate C5 in 246 epi_c, the pKa of which is very low, near 10, and 
the second equivalent was used to prevent acetate anion from picking up an α-proton. The 
enolate anion from the deprotonation created flattened chair conformation, where the 
bottom face was covered by carboethoxy and Me group, because of the chelation by the 
iron between C9 carbonyl oxygen and C5 methyl ketone oxygen. Now, the incoming 
electrophile, π-allyl complex, had no option but to approach the reactive center other than 
from the top face (Figure 2.11.1). 
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Figure 2.11.1. Rationale for diastereoselection of allylic substitution 
The next step was to construct a bicyclo [3.3.1] nonane in 249 epi_c. They envisioned 
making a C2–C3 bond by Dieckman condensation and, to do that, compound 249 epi_c 
needed to switch from a chair conformation to a boat one, which is energetically 
unfavorable (Figure 2.11.1). However, the formation of a C–C σ bond and deprotonation 
of the product 1,3-diketone provide sufficient driving force in this reaction; this led to the 
construction of a bicyclo [3.3.1] nonane.  
 
Figure 2.11.2. Dieckman condensation to construct the bicyclo [3.3.1] nonane 
The resulting enolate from the Dieckman reaction, which was trapped by benzoyl chloride 
for C-acylation at C3, resulted in a mixture of tautomers in a 72% yield. Finally, after the 
base treatment, the reaction furnished 7-epi-clusianone (10) with an overall yield of 22%. 
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2.12 Total synthesis of oblongifolin 
Oblongifolin is another type B endo PPAP.117 It has the same structure as 7-epi-
clusianone, but includes the C7 appendage, which is a geranyl rather than a prenyl group. 
So, the overall scheme remains the same. 
 
Scheme 2.12.1. Synthesis of oblongifolin 
Since the retrosynthetic approach towards the molecule was the same as 7-epi-
clusianone (Scheme 2.11.2), Plietker’s group accomplished the total synthesis of 
oblongifolin with the same methodology (Scheme 2.11.2). In the first step, acetyl acetone 
underwent alkylation with geranyl bromide, followed by aldol type methylenation, to set 
the stage for the Michael–aldol reaction. The last step, the acylation at C3 with 3,4-
dihydroxybenzoyl cyanide, resulted in oblongifolin in 33% yield (Scheme 2.12.1). The 
yields in each step were very much on par with 7-epi-clusianone 10.  
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2.13 Total synthesis of hyperpapuanone  
Hyperpapuanone (73) is a type B endo PPAP and structurally very similar to 7-epi-
clusianone (10), but with two minor differences: first, there is is a methyl group at C1 
instead of a prenyl group; and second, there is an isobutyryl substituent at C3 instead of a 
benzoyl group (Figure 2.13.1).117  
 
Figure 2.13.1. Hyperpapuanone, regio-hyperpapuanone, and 7-epi-clusianone 
Since the retrosynthetic approach towards the hyperpapuanone was the same as 7-
epi-clusianone (Scheme 2.13.1), Plietker’s group approached the total synthesis of 
hyperpapuanone with the same methodology. In the process, the second alkylation step 
where a NaH/MeI combination methylated C1, the transformation of 247 hyp_c into 248 
hyp_c, as well as acylation at C3 with 2-methylpropanoyl cyanide, were the only two 
different reactions in the entire total synthetic scheme (Scheme 2.13.1). The yields in each 
step were very much at par with 7-epi-clusianone, along with the overall 21% yield. 
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Scheme 2.13.1. Synthesis of hyperpapuanone 
2.14  Total synthesis of hyperibone L and regio-hyperpapuanone 
Structurally, hyperibone L and regio-hyperpapuanone are very much like one 
another. The C3 substituent in hyperibone L contains a benzoyl; by contrast, regio-
hyperpapuanone has an isobutyryl group at C3. Plietker’s group approached the total 
synthesis of hyperibone L and regio-hyperpapuanone with the same methodology as they 
used to prepare 7-epi-clusianone.117 The approach to hyperibone L and regio-
hyperpapuanone (Scheme 2.14.1) differed from the approach to 7-epi-clusianone only 
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when the last alkylation step was reached, where a KH/MeI combination methylated C5, 
which resulted in the transformation of 246 epi-c into 249 hyp-c. The last step, acylation 
at C3 with isobutyryl cyanide and benzoyl cyanide respectively, was the only step that 
differentiated the syntheses of hyperibone L and regio-hyperpapuanone. The overall yields 
were quite on par with 7-epi-clusianone at 22% and 14%, respectively.  
 
Scheme 2.14.1. Synthesis of regio-hyperpapuanone and hyperibone L 
There are many noteworthy aspects of these total syntheses. This strategy was 
effectively executed to make five compounds from a common precursor with moderate to 
good yields in less than seven steps. Last, but not least, Plietker et al. realized the 
importance of C4 oxidation for the success of their synthetic plan. Thus, they did not rely 
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upon late stage oxidation; rather, they devised a strategy where the C4 was at the desired 
oxidation state from the very beginning, and they took care of this step in the Michael–
aldol tandem reaction. Perhaps the structure of the final molecules, which exist in a boat 
conformation rather than a chair—a common feature among endo PPAPs, led to this kind 
of approach. They envisioned constructing the bicyclo[3.3.1]nonane via Dieckman 
condensation from the precursor, which was in a chair conformation but was required to 
transform into a boat form. The explanation was the same what I have proposed in the case 
of clusianone (Scheme 2.11.1).   
2.15 Total syntheses of sampsonione P and hyperibone I by Plietker et al. 
After his seminal work in 2011, Plietker and his group did not stop there; they 
continued exploring additional type B endo PPAPs employing their established 
methodology. In this process of exploration, the group published a total synthesis of 
sampsonione P (81) and hyperibone I (82) in 2013 (Figure 2.15.1).109 These are two unique 
type B endo PPAPs with tetrahydrofuran side chains. Plietker and his group were not only 
fascinated by the unique structures of these PPAPs, but also intrigued with determining 
them correctly and differentiating their useful biological properties. Sampsonione P was 
isolated from Hypericum sampsonii, a family of Hypericaceae, in 2007, and hyperibone I 
was obtained from Hypericum scabrum in 2002.138 There was confusion about the correct 
structure of both PPAPs; initially, it was thought that hyperibone I and sampsonione P were 
isomers, differing only at the C7 appendage orientation; that is, hyperibone I was thought 
to be an exo type B PPAP, while sampsonione P was assigned to be an endo type B PPAP. 
Dr. Grossman et al. had proposed a type B endo structure for hyperibone I in 2006 based 
on the available data.7  
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Figure 2.15.1. Sampsonione P and hyperibone I  
To confirm Grossman’s proposal, Plietker and his group set out to synthesize these 
two molecules. They relied on the same strategy that was published in 2011,117 which was 
discussed in detail in previous sections. Retrosynthetically speaking, 81 and 82 are the 
same as 7-epi-clusinanone, hyperpapuanone, and hyperibone L, but there is an extra 
tetrahydrofuran ring present in hyperibone I (82) and sampsonione P (81) (Scheme 2.15.1). 
This tetrahydrofuran ring is the result of further oxidation and cyclization of one of the 
prenyl side chains. The strategy was to install prenyl and allyl groups regiospecifically in 
254 to give regioisomers 252 and 253, and then to execute a chemoselective epoxidation 
of the prenyl group to construct the tetrahydrofuran rings in 81 and 82 (Figure 2.15.1).  
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Scheme 2.15.1. Retrosynthetic analysis of sampsonione P and hyperibone I 
The synthesis began with acetylacetone (Scheme 2.15.2) and was the same as 7-
epi-clusianone in both cases. Therefore, only noteworthy steps will be discussed here.  
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Scheme 2.15.2. Synthesis of sampsonione P and hyperibone I 
2.15.1 End of synthesis of sampsonione P 
Sampsonione P necessitated an installation of a prenyl group at the C5. To install a 
prenyl group required an allyl group in 256 sam at C5, but NaH-mediated C5-allylation 
was tough because of the C6 quaternary center. Therefore, 256 sam was converted to an 
O-allyl carbonate, 257 sam, with allyl chloroformate and NaH, and 257 sam then 
underwent a Pd-catalyzed intramolecular allylation to furnish two diastereomers in a 5:1 
ratio, 258 sam being a non-required diastereomer, and required being 259 sam. The 
required diastereomer, 259 sam, where the C1 and C7 allyl groups were trans to each other, 
was directly utilized for Dieckman condensation catalyzed by potassium t-butoxide. The 
intramolecular Dieckman condensation generated an enolate, 260 sam, which was trapped 
by PhCOCN in situ to furnish 261 sam. The C1 prenyl group was converted into an epoxide 
regioselectively over the less electron-rich allyl group but with low diastereoselectivity, 
and this step was followed by epoxide ring opening via a nucleophilic attack of OH at the 
O O
O O
O
O
254
NaH 
allyl bromide
NaH, prenyl  bromide
THF
THF
O O
O
O
O O
O
O
LiCl, MeMgBr, 
Me3SiCl
LiCl, MeMgBr,
 Me3SiCl O O
O
O
83%
89%
255 hyp
255 sam
256 hyp
256 sam
d.r = 3.:1
d.r = 3.5.:1
d.r= 95.:5250
O O
O
O
 118 
C2. This reaction installed the tetrahydrofuran ring in 262 sam. Finally, the stage was set 
for Grubbs metathesis to convert the two allyl groups into prenyl groups; this was 
accomplished to give sampsonione P (81) in 65% yield (Scheme 2.15.3). 
 
Scheme 2.15.3. Syntheses of sampsonione P 
2.15.2 End of the synthesis of hyperibone I  
The total synthesis of hyperibone I (Scheme 2.15.4) was problematic since the 
installation of the prenyl group at C5 proved to be difficult. Therefore, they decided to 
implement the same idea, which was used in 7-epi-clusianone, namely, an iron-catalyzed 
allylic substitution. The yield was not satisfactory; they also recovered O-prenyl 257’ hyp, 
which yielded 17%. The remaining steps were the same as in the synthesis of sampsonione 
P; repeating them led to hyperibone I, 82.  
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Scheme 2.15.4. Finishing the synthesis of hyperibone I 
2.16 Total syntheses of guttiferone A and 6-epi-guttiferone A by Plietker et al. 
In 2014, Plietker’s group published another article on the total synthesis of 
guttiferone A and 6-epi-guttiferone A. 139  
 
Figure 2.16.1. Substrate similarity comparison 
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Structurally, guttiferone A is an endo type B PPAP (Figure 2.16.1) and contains geranyl 
appendage at C6. If we compare hyperforin and guttiferone A, it is quite clear that they 
both possess the same structure, differing in C3 substituents, where guttiferone A has a 
phenacyl group at C3 and hyperforin has an isopropyl ketone at C5. Guttiferone and epi-
guttiferone are epimers. The stereochemistry only differs at C6. 
2.16.1 Retrosynthetic approach of guttiferone A and 6-epi-guttiferone A 
Based on the retrosynthetic strategy (vide supra), they delivered a couple of successful 
endo type B PPAPs beforehand. Therefore, they envisaged that dimethyl cuprate type 
addition to an enone Scheme 2.16.1 (Scheme 2.16.1) would establish the quaternary center 
at C6 with the correct stereochemistry. The geranyl appendage must be cis to the allyl 
group in 264 in guttiferone A, while trans in epi-guttiferone A. This was the prime 
challenge in the total synthesis. The remaining steps in the syntheses were the same as the 
other type B endo PPAP syntheses, which were discussed in depth in the previous sections, 
beginning with the alkylation of acetyl acetone with allyl bromide. 
 
Scheme 2.16.1. Retrosynthetic analysis of guttiferone A and 6-epi-guttiferone A 
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2.16.2 Synthesis of 6-epi-guttiferone A  
The Plietker began their synthesis of guttiferone A by alkylating acetylacetone with 
allyl bromide, followed by aldol-type demethylation to generate 267 in 47% yield. Then, 
267 was allowed to react with dimethyl-1,3-acetonedicarboxyate in the presence of 
MeMgCl at low temperature to furnish cyclohexenone 266 in an 84% yield. This reaction 
was a tandem Michael-Knoevenegal reaction, which brought two ester groups in a 
molecule, separated by a ketone. Compound 266 was first treated with MeLi to convert C5 
ester to methyl ketone and was then prenylated in the same pot at C1 using NaH 
stereoselectively. After this, the most interesting step of the sequence was performed: the 
installation of a 3-buten-1-yl group at C6 to construct the quaternary center. Following 
Yamamoto protocol, compound 268 was added to a cuprate, generated from the action of 
CuI and 3-buten-1-ylmagnesium bromide, gave 265A as a single diastereomer at C6 (but 
an inconsequential 1:1 mixture of stereoisomers at C5, between the two ketones). This 
result was unexpected, and it caused the group to change the target of their synthesis from 
guttiferone A to 6-epi-guttiferone A.  
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Scheme 2.16.2. Synthesis of 6-epi-guttiferone A 
The next challenge was to install an allyl group at C5, which would be trans to the 
butenyl group at C6. Bu4N[Fe(CO)3(NO)] was the initial catalyst of choice for C-allylation, 
but it did not bring forth the desired result. Thus, they resorted to a palladium-catalyzed 
decarboxylative allylation, which was quite an effective method for Plietker’s group in 
previous schemes. To execute the plan, they allowed 266 to react with allyl carbonate and 
NaH. The reaction yielded two regioisomers in a 1:2 ratio. Heating induced a Claisen 
rearrangement of the allyl vinyl carbonates. The diastereocontrol of the Claisen 
rearrangement was excellent, 95:5.  
Once the construction of the quaternary center at C5 was accomplished, the next 
aim was to generate the bicyclo[3.3.1]nonane that was furnished by Dieckman 
condensation using potassium tert-butoxide. Global Grubbs metathesis replaced all the 
allyl groups with the prenyl groups and, finally, K2CO3 deprotonated a C3 proton, and the 
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resulting enolate reacted with 3.4-bis-acetoxybenzoyl to accomplish the total synthesis of 
6-epi-guttiferone (59) (Scheme 2.16.3). 
 
Scheme 2.16.3. Synthesis of 6-epi-guttiferone A 
2.16.3 Synthesis of guttiferone A 
After completing the total synthesis of 6-epi-guttiferone A, Plietker et al. decided 
to revisit the challenge of the synthesis of guttiferone A. They realized that C6 
stereochemistry would hold the key for the success of the synthesis. Remember that the 
1,4-addition reaction, following modified Yamamoto’s condition, gave an unexpected 
product, 265A, when they envisioned getting 265 (Scheme 2.16.3). Therefore, they needed 
to devise a plan in such a way that it could establish a geranyl substituent on C6 and make 
the Dieckman condensation route feasible. The research group planned to introduce the 3-
buten-1-yl moiety at the very beginning of the synthesis so they could induce the 
diastereoselection later via suitable reagents. 
Based on this idea, they set out to synthesize guttiferone A (Scheme 2.16.4). The 
synthetic scheme began by acylation of 1,8-nonadien-5-one by LiHMDS and was followed 
by the methylenation with formaldehyde. Then, as usual, a tandem Michael–aldol 
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condensation of 271 with dimethyl acetonedicarboxylate constructed cyclohexene 272. 
Prenylation of 272 gave enedione 273. Then, conjugate addition of a methyl cuprate to 273 
went exclusively cis to the allyl group at C7 to give 274, as desired and expected from the 
6-epi-guttiferone synthesis.  
 
Scheme 2.16.4. Beginning of the synthesis of guttiferone A 
Fe-catalyzed allylic substitution at C5 of 274 was not possible in this case because 
of the steric demand, and this led them to consider palladium-catalyzed decarboxylative 
allylation. The action of NaH and allyl chloroformate on 274 yielded both 275 and 275A 
(Scheme 2.16.5). The decarboxylative allylation of either compound by Pd(ΙΙ), however, 
gave 276 as a major product, which had the undesired stereochemistry. The ester groups 
on C1 and the keto methyl group on C5 were trans to each other, which was not a correct 
geometric requirement for Dieckman condensation to construct the bicyclo[3.3.1]nonane 
motif.  
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Scheme 2.16.5. New diastereoselectivity problem in the synthesis of guttiferone A 
Therefore, they thought of an alternative plan: the introduction of a cyclic group 
from the two unsaturated appendages in 274 would enhance the formation of the required 
diastereomer. Thus, they converted 274 into 277 using Grubbs-ΙΙ in 94% yield (Scheme 
2.16.6). After that, they tried NaH-mediated allylation of 277 with allyl chloroformate and 
the reaction produced 278 and 278B, which was followed by Pd-catalyzed decarboxylative 
allylation to furnish 280 and 280B. The yield of the reaction was impressive, nearly 94%, 
and the diastereomeric excess ratio was 95:5 with respect to the desired isomer, 280B. 
Compound 280B was treated with potassium t-butoxide to construct the 
bicyclo[3.3.1]nonane 281. Finally, global Grubbs’ metathesis of 281 and acylation with 
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3,4-bis-acetoxybenzoyl cyanide yielded guttiferone A in 58% yield in 13 steps (Scheme 
2.16.6). The most important points from this synthetic plan are: I) developing a route to 
install the correct geometry at C1 and C5 so that Dieckman condensation could take place; 
and, II) starting from a precursor with the correct oxidation state at C4 so that late stage 
oxidation would not pose any threat to the new route. 
 
Scheme 2.16.6. Synthesis of guttiferone A 
2.17 Total synthesis of garcinol and isogarcinol 
Socolsky and Plietker published an article in 2015 showing the total synthesis of 
garcinol and isogarcinol. The purpose of this paper was not only to devise a route to endo 
PPAPs but also to ascertain the relative configuration of the molecules correctly. There 
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were discrepancies in secondary literature concerning the relative configuration of garcinol 
and isogarcinol (Figure 2.17.1. Garcinol and isogarcinol).140  
 
Figure 2.17.1. Garcinol and isogarcinol 
In 2011, Plietker and his group published a seminal work on the total synthesis of 
endo type B molecules.  The 2015 article is a continuation of their earlier work. The 
retrosynthesis started from the removal of all the prenyl groups from the molecule and 
replacing them with allyl groups (Scheme 2.17.1). They relied as usual upon an internal 
Dieckman condensation to set up a bicyclo[3.3.1]nonane trione core. The key challenge, 
however, in the whole synthetic scheme was to affix a lavandulyl side chain on the carbon 
C5.  That step involved a lot of fascinating chemistry, which I explain later. 
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Scheme 2.17.1. Retrosynthetic analysis of garcinol and isogarcinol 
The synthesis started from acetyl acetone (Scheme 2.17.2), which underwent 
alkylation with prenyl bromide followed by extrusion of acetate via aldol reaction, to 
furnish the prenylated ketone. The prenylated ketone underwent tandem 
Michael/Knoevenegal reaction to construct the cyclohexenone, 255. Next, 255, a keto-
diester, was made a keto-monoester 254 by using NaH and MeLi under standard 
conditions, which the group employed several times. The C-5 allylation with (2E)-4-
chloro-3-methylbut-2-en-1-yl acetate went smoothly without complication. The reaction 
produced 282 with a decent yield. Allylation at C1 proved to be a roadblock for the 
synthesis since Trost-Tsuji allylation did not work, presumably because of the gem 
dimethyl group.  Therefore, they resorted to formation of the allyl carbonates. Two O-allyl 
carbonates formed, 284 and 285, but both yielded the required diastereomer of 286 after 
Claisen rearrangement.  
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Scheme 2.17.2. Syntheses of garcinol and isogarcinol 
The conversion of the acetoxyprenyl group at C5 of compound 286 to a lavandulyl group 
was challenging, since a palladium catalyzed allyl–allyl exchange reaction could result in 
a simple SN2 substitution with hydrogen and β-elimination (Scheme 2.17.2). Alter 
screening many ligands and bases, they found that [Pd2(dba)3], dppe, allyl(pinacol)borane, 
and CsF gave the best result of the exchange reaction, although they recovered some β-
elimination product (Scheme 2.17.2). The stereochemical outcome could be explained by 
the TS model (Scheme 2.17.3), where Pd coordinated to the carbonyl group in cyclohexane 
ring by forming a palladacycle that prevented the allyl transfer from the other direction, 
leading to the stereoselective fixation of the allyl group on the prenyl moiety.  
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Scheme 2.17.3. Stereochemistry of the exchange reaction 
After installing the lavandulyl moiety at C5, Dieckmann condensation of 287 
promoted by KO-t-Bu was followed by Grubbs metathesis (Scheme 2.17.4). The 1,3-
diketone was again deprotonated and trapped by 3,4-dihydroxybenzoyl cyanide. Garcinol, 
69, was produced in 43% yield over the two steps. Isogarcinol, 77, was made from garcinol 
by the action of concentrated HCl. The reaction yielded isogarcinol in 87% yield. Overall, 
there were 13 steps in the garcinol synthesis and 14 in the isogarcinol one. Plietker’s group 
separated the two compounds by chiral HPLC along with possible four enantiomers, and 
each of them was identified by an arduous characterization process, namely 1H NMR, 13C 
NMR, and 2D correlation spectroscopy. After data analysis, they reached the conclusion 
that guttiferone E and garcinol were enantiomers, as were isogarcinol and 
isoxanthochymol. How they reached such a conclusion was discussed in detail in Chapter 
1.  
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Scheme 2.17.4. Synthesis of isogarcinol 
Plietker’s group separated two compounds by chiral HPLC along with possible four 
enantiomers, and each of them was identified by arduous characterization process, namely 
1HNMR, 13CNMR, 2D-correlation spectroscopy. After data analysis, they reached the 
conclusion that guttiferone E and garcinol are enantiomers, as are isogarcinol and 
isoxanthochymol. How they reached such conclusion was discussed in detail in chapter 1. 
2.18  Grossman’s approach to the synthesis of PPAPs  
Dr. Grossman’s group has a longstanding interest in this field. They have 
contributed by devising a synthetic route to construct a bicyclo[3.3.1]nonane,7, 141 which is 
known as the ‘alkynylation–aldol approach.’ They envisioned developing a scheme that 
would work as a model for the synthesis of any PPAPs irrespective of their classification. 
The scheme was initially designed for nemorosone, a type A PPAP, but later, they realized 
that the newly devised scheme would also be effective for type B endo PPAPs with some 
minor modifications. They envisioned replacing the prenyl groups with robust allyl groups 
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(Scheme 2.18.1), which would make the reactions simpler. When decoration around the 
bicyclic core was needed, prenyl groups would be introduced by global metathesis in 290. 
Compound 290, on the other hand, could be constructed from 291 by an aldol followed by 
oxidation. The most interesting point about 291 is that it is a Z-alkenal and, to construct 
291, it was necessary for the aldol condensation. Here, they thought about making a model 
system to synthesize 291 without the gem-dimethyl next to the benzoyl group in 291. 
Therefore, they redrew their retrosynthetic scheme without the gem-dimethyl group and 
291 could be deconstructed to 292, which did not contain a gem-dimethyl group. 
 Grossman et al. thought to reduce the alkynal chemoselectively using cobalt 
catalyst. They decided on a model study to examine if the route proposed could be realistic. 
Therefore, 292 was replaced by 293, which could be synthesized via a double alkylation 
from ethyl acetoacetate, 294.  
 
Scheme 2.18.1. Retrosynthetic analysis of nemorosone by Grossman et. al. 
They began with ethyl acetoacetate 294, which was first alkylated with allyl 
bromide (Scheme 2.18.2) to 295. The addition of prenyl bromide to the dianion of methyl 
3-oxo-6-heptanoate furnished 296 with an overall yield of 67%. SnCl4-promoted 6–endo-
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dig cyclization of 296 converted it into 298 via a radical mechanism. The cyclic β-keto 
ester 296 was then converted to dimethoxy compound 297 by Pb(OAc)4 and subsequent 
hydrolysis yielded 298.  
 
Scheme 2.18.2. Model study by Grossman et al. 
Alkynal 298 was hydrosilylated to alkenal 299 by Co2(CO)8 and Et3SiH. One of the 
interesting aspects of this chemistry is that the triple bond was reduced to a cis double bond. 
The Z-geometry of the double bond is essential for closing the ring by aldol condensation. 
An HCl-mediated aldol reaction led to bicyclic compound 300. The real challenge was to 
install a 1,3-diketone functionality in 300 by oxidizing the C4 carbon. It appeared from 
their model study that C4 carbon was too reluctant to undergo sp2 to sp3 hybridization. All 
the methods to put any oxygen-containing group at C4 failed, presumably because of the 
gem-dimethyl groups at C8. Although the route did not deliver the result, and the synthesis 
of nemorosone was not accomplished, the route would be exploited with some 
modifications in the synthesis of 7-epi-clusianone 10. 
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3 Our strategy for 7-epi-clusianone 
3.1 Introduction 
In chapter 1, I have discussed the medicinal properties of PPAPs in detail.27, 142 
Frankly speaking, they are one of the prime reasons for chemists to synthesize these 
molecules. My reasons for synthesizing these molecules are not different. These molecules 
are fascinating, partly because of the wide range of therapeutic properties in their initial 
trials. Initial studies of these molecules hint towards this direction—garsubellin A shows 
antineurodegenerative activity,26 hyperforin shows antidepressant activity,101, 142, 143 and 
clusianone shows antibacterial activity.88, 101 There is another aspect of PPAPs— endo and 
exo epimers differ quite substantially,98 as far as their medicinal properties are concerned. 
However, these results are not conclusive enough that these molecules could be marketed 
for fighting diseases. For these reasons, we need to have enough of these molecules on 
hand to carry out conclusive research.  
On the other hand, we are synthetic organic chemists, and therapeutic details of a 
compound cannot be the only goal of our research; there must be another dimension to it. 
The architectural design acts as an added flavor to our research. In particular,7-endo type 
B PPAPs exist in a boat conformation, and this makes their synthesis more challenging. 
Furthermore, many total syntheses of 7-exo type A PPAPs have been reported, but the 
syntheses of type A endo, except 7-epi-nemorosone, and type B endo, with the exception 
of Plietker’s seminal works, have not been well addressed.117, 144 Therefore, we have striven 
to find a viable method to synthesize type B 7-endo PPAPs so that we could develop a 
model that would work for many PPAPs.  
We chose 7-epi-clusianone as our target compound. There are two reasons for this 
selection: one, its wide range of biological activity—anticancer,89 antiplasmodic,71 
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vasorelaxant,145 and antibacterial91, 96, 146—and the second, its unique structure, which 
exists in the boat conformation.37 When we started this project back in 2011, no one had 
published a total synthesis of a type B 7-endo PPAP. However, in 2011, a research group 
in Germany led by Bernd Plietker published the first total synthesis of 7-epi-clusianone.117 
Since then, to the best of our knowledge, no group has reported any total synthesis of the 
molecule using a different route. Herein, we have sought to devise a path for the total 
synthesis of 7-epi-clusianone 10 following the alkynylation-aldol method. 
3.2 Initial retrosynthetic strategy 
The first approach to synthesize 7-epi-clusianone 10 came from a joint venture led 
by my predecessor, M. P. Suresh Jayasekara, and Dr. Grossman. They approached the 
retrosynthesis of the molecule differently; initially, they realized that compound 10 might 
be synthesized from 1,3-diketone 310a by an acylation of C3, followed by a global Grubbs’ 
metathesis (Scheme 3.2.1). They believed that they could prepare 1,3-diketone 310a by 
oxidation of the enone in 310b. They envisaged constructing the bicyclic system by making 
a bond between the C4 and the C5 carbon (dark bond) in 310b. Therefore, diketone 310b 
might be accessed from 310c, in equilibrium with 310d, by an intramolecular aldol 
condensation followed by oxidation of the diastereomeric alcohols. They believed that the 
equilibrium between 310c and 310d would favor 310d, but they postulated that enough 
310c would be produced at equilibrium to allow the aldol reaction. Cis enal 310d, they 
thought, could be synthesized from 310e by Still-Gennari reaction. The trans relationship 
of the C2 and C4 allyl appendages in 310e was crucial for the synthesis of the desired 7-
epi-clusianone 10. They assumed that 310e could effectively be obtained from by Trost-
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Tsuji allylation of -keto ester 310f, which could ultimately be synthesized from 
cyclohexanone 310g and thence 1,3-cyclohexanedione in six steps.  
 
Scheme 3.2.1. First retrosynthetic strategy 
3.3 Synthesis of 7-epi-clusianone 
The details on the synthesis based on this first retrosynthetic strategy can be found 
in Jayasekara’s dissertation, therefore, I am not discussing every aspect of it. However, I 
will comment on why the route (Scheme 3.3.1) did not succeed, because it was a pertinent 
question so far as my approach towards the molecule was concerned. He commenced from 
1,3-cyclohexanedione, and, after that, successfully synthesized 310d. There, he faced a 
roadblock to constructing the bicyclic molecule 310b: the aldol reaction of 310d did not 
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proceed. He reasoned that A1,2-strain in 310c1 prevented the enol or enolate from forming, 
preventing the intramolecular aldol reaction from occurring. 
 
Scheme 3.3.1. A1,2-strain 
3.4 Revised retrosynthetic strategy  
Realizing that the A1,2-strain made the intramolecular aldol of 310d impossible in 
the first trial, they pondered over redesigning the retrosynthetic strategy, keeping the 
overall approach the same. Hence, they decided to disconnect the C1–C2 bond of 10 
instead of the C4–C5 bond (Scheme 3.4.1); in that case, there would not be any issue of 
A1,2-strain in the enol or enolate undergoing the key intramolecular aldol reaction. They 
envisaged that the C4 OH group of 310a might be introduced into simple alkenone 310, 
which, in turn, could be synthesized by an intramolecular aldol reaction of compound 312. 
The strategy requires that 312 assume its higher energy conformation, 312a, before 
undergoing the reaction. The essential Z-alkenal 312 might be obtained by a stereoselective 
reduction of alkynoate 313, which could be prepared by two-carbon homologation from β-
keto ester 314. They planned to make ester 314 from alkenone 315, which could be 
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accessed from commercially available 1,3-cyclohexanedione in three steps with good 
yields. I inherited the scheme, and my research goal was to oxidize the C4 carbon of 310 
and then complete the total synthesis, which was three steps away from the target.53  
 
Scheme 3.4.1. Revised retrosynthetic strategy for 7-epi-clusianone 
3.5 Enol ether formation and allylation followed by methylation 
We commenced from commercially available 1,3-cyclohexanedione, and converted 
it into an isopropyl enol ether 316 in a high yielding reaction (Scheme 3.5.1).147 
Subsequently, compound 316 underwent LDA-mediated allylation and furnished 315 
without any purification (93% yield).148 We were happy to be able to avoid any rigorous 
column purification in the two initial steps.  
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Scheme 3.5.1. Synthesis of allyl enone 315 
3.6 Methylation and hydrolysis 
 
Scheme 3.6.1. Methylation and hydrolysis 
Following the Stoltz protocol for Stork-Danheiser reaction, a nucleophilic addition 
of MeLi or MeMgBr to the carbonyl carbon of 317 gave allyl alcohol 317B, and addition 
of 1 M HCl to 317B induced a transposition of an allylic double bond to compound 315 in 
87% yield after column purification (Scheme 3.6.1).  
3.7 Synthesis of -keto ester 
Compound 315 was treated with lithium dimethylcuprate in the presence of HMPA 
to add a methyl group across the double bond to construct the C6 quaternary center. The 
resulting enolate was trapped by methyl or ethyl cyanoformate to furnish β-keto ester, 318B 
or 318 with a decent yield ranging from 79% to 76% (Scheme 3.7.1).149 The yield of the 
reaction was very sensitive to the amount of HMPA used. We screened several reactions 
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using 1 to 8 equivalents of HMPA to find the optimum conditions, and the best result was 
obtained using 7.2 equivalents of HMPA. Less than 6 equivalents of HMPA promoted O-
acylation rather than C-acylation. We tried to replace HMPA with DMPU because of 
HMPA’s carcinogenicity, but the yield was very low in that case.  
Both my predecessor and I encountered several challenges in maintaining a good 
yield while scaling up this reaction. I surmounted this impediment by using mechanical 
stirring and slow cooling of the reaction to –70 °C using a dry ice–isopropanol bath; the 
slow cooling helped the magnetic stirring. As we scaled up, cost motivated us to prepare 
our own ethyl or methyl cyanoformate. We prepared them by Webber and Childs’ 
protocol,150 but the yield was higher when we prepared ethyl cyanoformate in a large 
amount (59% yield vs. 30%), so thereafter we used ethyl cyanoformate and prepared 318.  
 
Scheme 3.7.1. Synthesis of β-ketoesters 318 and 318B 
3.8 Allylation and enol ether synthesis 
The keto ester 318 was converted into O-allyl vinyl ether 324 (Scheme 3.8.1) using 
NaH and allyl bromide with an excellent yield of 88%.151 The O-allyl ether 324 was 
dissolved in dry toluene and heated in a sealed tube for 12 h at 150 °C. A [3,3]-sigmatropic 
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rearrangement yielded two diastereomers, 314 and epi-314, in a 3:1 ratio and excellent 
yield.152  
By examining a transition state model (Figure 3.8.1), we thought that the reaction 
would more likely to proceed via TSa, which had fewer steric interactions than the 
alternative TSb, and we, therefore, believed that TSa would produce the major 
diastereomer; whereas TSb would produce the minor diastereomer epi-314, which was 
expected to be undesired one. We also expected the major diastereomer to be the desired 
one. But we did not know yet at this point. We purified the both diastereomers by column 
chromatography and attempted to confirm our hypothesis by 1H NMR, COSY, and 
NOSEY. Unfortunately, overlapping peaks in the 1H NMR spectra of both diastereomers 
made it difficult to assign their stereochemistry unambiguously. Therefore, we reserved 
our judgment on whether the major product was 314 or epi-314 until we could 
unambiguously assign the structures of downstream intermediates in the synthesis.  
 
Scheme 3.8.1. O-allylation and Claisen rearrangement and enol ether synthesis 
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Figure 3.8.1 Transition state model for the diastereoselectivity 
3.9  Determination of stereochemistry of major diastereomer 
It was necessary to reduce the ester carbonyl in C-allylated β-ketoester 314 to an 
aldehyde to allow us to carry out a two-carbon homologation. Before doing that, we 
protected the keto group so that we could selectively reduce only the ester group. The 
reason behind choosing methyl enol ether as a protecting group was not because of the easy 
synthetic preparative method, but the steric bulk around the quaternary carbon. We 
previously attempted different protecting groups, like TMS or TBDMS, but in those cases, 
the alkynylation turned out to be very low-yielding, as was also the case when we left the 
ketone unprotected. Therefore, we selected the methyl enol ether as the optimum protecting 
group for the ketone, even though the protecting group strategy necessitated an extra step. 
We converted the ketone in 314 to methyl enol ether with trimethyl orthoformate 
and H2SO4 (cat) in 94% yield. In past, we had trouble converting 314 fully into 325, 
especially upon scale-up (from 500 mg to 6 g scale) (Scheme 3.8.1). We tried several acids 
like PTSA, CSA, and PPTS. At last, we found that a few drops of concentrated H2SO4 
worked the best. We also attempted several equivalents of trimethyl orthoformate, but we 
found 25 equivalent of CH(OMe)3 was essential for the complete conversion, although 25 
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equivalents sounded like a lot of CH(OMe)3. Pleasingly, we did not observe any 
transesterification in this reaction, although there was a possibility of it because of the 
presence of an ethyl ester.  
 
 
Figure 3.9.1. 1H NMR spectrum of 325 in C6D6 
We had reserved our judgement on the identification of the major diastereomer in 
the Claisen rearrangement (314 or 314A) because of overlapping peaks in its 1H NMR 
spectra. Here, in the case of 325 (Figure 3.9.1), 1H NMR isochrony at 400 MHz did not 
impede the assignment of the diastereomers. Therefore, we could proceed with a COSY 
and NOESY analysis. Assignments of peaks in COSY experiment was essential for 
establishing the trans geometry of the two allyl groups in 325. Because we needed these 
correctly assigned protons in NOSEY which is the main experiment to assign the geometry. 
We, here, were using the process of elimination to find a proton which was the key for the 
whole process; it was H5. We had to assign it.  
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We assigned the resonance at  4.60 ppm as the enol ether double bond proton H3 
because it was quite distinct from the rest and it was vinylic proton, showing a doublet of 
double. However, we had two other vinylic protons but they were further downfield and 
multiplets. Therefore, neither of them could be H3. Therefore, we found that this resonance 
correlated with resonances at  2.12 ppm and 1.60 ppm in the COSY spectrum (Figure 
3.9.2), which we assigned as H4a and H4b. Due to their chemical shift and multiplicities, 
we could assign resonances at  2.68 ppm and 3.01 ppm to the two H8 atoms; these 
resonances showed a correlation in the COSY spectrum to the resonance at  6.00 ppm, 
which we assigned to H9. This assignment then allowed us to assign the resonance at  
5.85 ppm to H11, which in turn allowed us to identify the resonances at  2.20 ppm and 
1.86 ppm as H10a and H10b. So, only proton left to assign was H5; and we assigned it. 
However, identification of H8 and H9 were not important from COSY perspective, but 
identification of these two peaks led us to assign H5 which was a very important proton to 
establish the trans geometry of the two-allyl groups in 325. Finally, we were able to assign 
the resonance at  1.78 ppm as H5 due to its strong correlations with H10a, H10b, H4a, 
and H4b in the COSY spectrum.  
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Figure 3.9.2. COSY spectrum of 325 
In the NOESY spectrum of 325 (Figure 3.9.3), we observed a strong correlation 
between resonances due to H5 and one of the H8 atoms, unambiguously establishing the 
trans geometry of the two allyl groups (Figure 3.9.1, major product). We would not have 
observed this correlation if the two allyl groups had been cis (Figure 3.9.1, minor product). 
We also found a strong correlation between peak 12, which was a methyl group, with 4b, 
and therefore, they must be both axial. On the contrary, we did not observe any correlation 
of 12 with either of 8a or 8b. These observations unambiguously established the trans 
geometry of the two allyl groups in 325. Since 325 was synthesized from 314, so we 
concluded that 314 was the major and desired diastereomer. 
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By contrast, in the NOSEY spectrum, the minor constituent which we assigned epi-
325 correlated H8 and axial CH3 (identified by correlation to axial which had large JH4-
H5 (Figure 3.9.4). 
 
Figure 3.9.3. NOESY spectrum of 325 
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Figure 3.9.4 NOE interactions in 325 and epi-325  
3.10 Conversion of ester to aldehyde 
Ester 325 was reduced to alcohol 326 (Scheme 3.10.1) in 87% yield with LiAlH4.152 
We carried this alcohol 326 forward to the next step without any purification. Applying the 
Dess-Martin periodinane to 326, the reaction completed within 4 hours. After purification 
by a short column chromatography, the reaction gave aldehyde 327 in an overall yield of 
92% over two steps.153 
 
Scheme 3.10.1. Synthesis of aldehyde before alkynylation 
3.11 Alkynylation and allyl–methyl exchange 
With aldehyde 327 on hand, we concentrated on the most exciting part of the total 
synthesis, which started with the homologation of one carbon unit. There are several 
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precedents in the literature about converting an aldehyde into an alkyne.154 In our case, 
probably because of the steric bulk around the sp2 carbon of the aldehyde, we had a poor 
yield when we used the Corey–Fuchs reaction. However, we obtained an excellent yield 
when we used a Colvin rearrangement to convert 327 to 328 (Scheme 3.11.1).155  
 
Scheme 3.11.1. Synthesis of alkyne and O-allyl vinyl ether 
The mechanism of the Colvin rearrangement (Scheme 3.11.2)155 starts with the 
deprotonation of TMSCHN2 by n-BuLi, and the resulting carbanion reacts with aldehyde 
327. The nascent alkoxide undergoes a Peterson olefination-like reaction to generate a 
carbene intermediate, 327B, after the expulsion of N2 from 327A. Finally, a 1,2-shift 
furnishes 328. The Colvin rearrangement of 327 probably proceeds better than the Wittig 
reaction because of the reduced steric bulk and greater nucleophilicity of the organolithium 
regent used in the former reaction.  
 
Scheme 3.11.2. Mechanism of Colvin rearrangement 
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At this point in the synthesis, for introducing the third, and the last, allyl group in 
the molecule, we decided to exchange the O-methyl vinyl ether for an O-allyl vinyl ether 
(Scheme 3.11.1). Our idea was to later introduce an allyl group on the C1 carbon by Claisen 
rearrangement. We applied allyl–methyl exchange reaction to add the allyl group in the 
molecule 328, converting it into 329 with a decent yield of 78%. We screened several 
catalysts, but CSA·2H2O gave the best result. Hydrolysis of the enol vinyl ether to the 
ketone was not a problem under these conditions. Pleasingly, we isolated the product 329 
without need for column purification. 
3.12 Carboxymethylation and reduction 
After installation of an alkyne and the allyl group in 329, the next task was to 
introduce a CHO group at the terminal alkyne carbon in compound 329. Alkynes are 
readily converted into alkynoates,156 alkynals157 or propargyl alcohols158 by treating them 
with n-BuLi followed by an electrophile such as chloroformate, DMF, or 
paraformaldehyde. We attempted all of these conditions, but, to our surprise, we recovered 
only the starting material 329. Therefore, we searched for an alternate route. Thankfully, 
the alkynoate 313 was synthesized from 329 using CO, MeOH, NaOAc, and CuCl2 and a 
catalytic amount of PdCl2 (Scheme 3.12.1).159 After column purification, the reaction 
yielded the alkynoate 313 in 87% yield. The reaction was sensitive to scale-up: the reaction 
of more than 5 mmol scale failed several times.  
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Scheme 3.12.1. One-carbon homologation–methoxycarbonylation 
To our surprise, compound 329B was a solid. Pleasingly, X-ray crystallographic 
analysis revealed that both the allyl groups at the C5 and C7 were trans to each other 
(Figure 3.12.1), which confirmed our stereochemical assignment of 325 and its precursor, 
314.  
 
Figure 3.12.1. X-ray Structure of 329B 
Next, we reduced alkynoate 313 to a propargylic alcohol 330 in 87% yield using 
LiAlH4. The substrate could have been sensitive to further reduction of the triple bond to 
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the double bond, but we did not observe this overreaction. After column purification, the 
reaction gave O-allyl alkynol 330 in 86% yield. 
3.13 Claisen rearrangement and oxidation of alcohol 
We were now ready to install the last allyl group. Therefore, we subjected 
compound 330 to Claisen rearrangement (Scheme 3.13.1). After heating compound 330 in 
a sealed tube for two hours at 150 °C, the reaction yielded 331 as an inconsequential 
mixture of diastereomers at C1 in nearly 75% yield. We were not concerned with the 
diastereomers since C1 would shortly undergo deprotonation as part of the aldol 
condensation. We carried the crude mixture over to the next step, which involved a DMP 
oxidation, furnishing the alkynal 332 in 92% yield within 4 h.153 
 
Scheme 3.13.1. Synthesis of the alkynal 
3.14 Stereoselective reduction of alkynal to Z-alkenal, and intramolecular aldol 
reaction 
We envisaged reducing the C≡C triple bond chemoselectively to Z–alkenal 312 so 
that we could make the bicyclo[3.3.1]nonane ring via aldol condensation (Scheme 3.14.1). 
For years, our lab has been studying the regiospecific syn reduction of alkynals in the 
presence of isolated double bonds.5, 118 A catalytic amount of Pd(PPh3)4 and a 
stoichiometric amount of (n-Bu)3SnH reduced 332 to cis alkenal 312 in 52% yield.160 The 
reaction was clean and finished within 1 hour.  
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Scheme 3.14.1. Reduction of alkynal to cis alkenal 
This result was rather surprising to us, because alkynoates generally undergo 
hydrostannylation under such conditions,161 but we observed the only syn reduction of the 
triple bond. We hypothesized that the reaction might proceed via a Pd-stannylketene 
intermediate 312a, which could then be protonated on its less hindered face to give the cis 
double bond in alkenal 312. There could be another possibility; after the initial 1,4-addition 
of H– to the alkynal 332, reductive elimination of 312a could lead to the stannyloxyketene 
intermediate and then, the protonation led to the formation of the cis double bond in 312 
via the same mechanism. 
 
Figure 3.14.1. Possible intermediate in syn reduction  
Armed with alkenal 312, we were ready for aldol condensation, for which we used 
NaOEt in EtOH (Scheme 3.14.2). We envisaged enolate conformers 312-hc5 and 312-fhc6 
in equilibrium. We believed the equilibrium would favor 312-hc due to a reduced 1,3-
diaxial interactions, but we also believed that enough 312-fhc might be formed to allow 
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the aldol reaction to proceed. Our hope was that the formation of the C–C bond in the 
product 333 would compensate for the increased steric strain in the bicyclic compound 333 
as opposed to 312. In the event, the aldol reaction finished within 2 hours, giving us two 
diastereomeric alcohols 333. Without purification, we used DMP to oxidize the alcohols, 
and, after column purification, we obtained bicyclic diketone 310 in a solid crystalline form 
and in 92% yield over the two steps. The crystal structure (Figure 3.14.2) unambiguously 
established the endo geometry of the bicyclic core of 7-epi-clusianone. It was necessary to 
establish the endo geometry of the bicyclic structure in order to synthesize 7-epi-
clusianone. 
 
Scheme 3.14.2. Synthesis of bicyclo[3.3.1]nonane via aldol reaction 
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Figure 3.14.2. Bicyclic structure of 310 
3.15  Oxidation of C4 in bicyclo[3.3.1]nonane: a dilemma or enigma?  
With bicyclic compound 310 in hand, we set out to oxidize the C4 carbon in 310 to 
move closer to the finish line, only three steps away. To the best of our knowledge, no one 
had ever done a late stage C4 oxidation in a synthesis of a 7-endo type B PPAP, so it would 
be significant if we could develop a method for this oxidation. My predecessor tried 
unsuccessfully to oxidize the C4 to advance in the total synthesis.5 Here, we are not 
rehashing those results. However, we will be discussing some of his ideas.  
 
Scheme 3.15.1. Ultimate roadblock to the success! 
3.16 Plan for the oxidation of C4 in 310 
3.16.1 Desaturation followed by oxidation 
We envisaged that adding MeLi followed by an allylic oxidation would give us a 
3-methyl enone (Scheme 3.16.1). We would then oxidize the methyl group to a carboxylic 
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acid and subsequently form the acid azide 336X. The resulting acid azide could undergo a 
Curtius rearrangement to give a 3-isocyanato enone 336Y. Finally, the hydrolysis of the 
product from the Curtius rearrangement would give us the 1,3-diketone functionality. If 
the oxidation of the Me group to a CO2H group proved difficult, we could instead use 
BnOCH2Li, which would provide a handle for the oxidation.  
 
Scheme 3.16.1. Proposed synthetic scheme for the oxidation of C4 in 310 
With this idea, we allowed MeLi to react with 310 to furnish 335a (Scheme 3.16.2). 
The resulting diastereomeric alcohol 335a was directly subjected to oxidation. Because the 
alcohol in 335a was allylic and tertiary, we expected an oxidative allylic transposition to 
occur. There is a lot of literature precedent for such chemistry.162, 163 PCC, CrO3, and IBX 
are common oxidants for this type of reaction. However, my predecessor showed that in 
our case, neither PCC, CrO3 gave the desired product, leading to either unreacted starting 
material or the rearrangement into 310. I further attempted the allylic transposition reaction 
on 335a with IBX in DMSO at 60 °C, and disappointingly, we also recovered starting 
material.  
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Scheme 3.16.2. Failed allylic transposition  
The alkyllithium LiCH2OCH2OMe also reacted with 310 to furnish the 
corresponding tertiary alcohol, but my predecessor showed that treatment of this compound 
with PCC or CrO3 either gave back 310 or did not result in a reaction at all.118 The reason 
for the failure was attributed to steric hindrance around the C4 carbon, which made it very 
resistant to change its hybridization. 
3.16.2 Reduction and enol ether formation followed by oxidation 
Next, we thought of reducing the double bond of the enone in 310 chemoselectively 
to diketone 337 (Scheme 3.16.3). Our idea was that ketone 337 could be converted into 
TIPS-enol ether 338., which we then might be able to oxidize at C4 with the help of C–H 
activation. In 2003, Corey and Yu had shown that such an oxidation worked in a bicyclic 
system.164 This idea was successfully implemented by Nakata in his hyperforin 
synthesis.165 So, we are hopeful that we could try this method of oxidation.  
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Scheme 3.16.3. Strategy for C4 oxidation via Corey-Yu’s method 
We set off to reduce the conjugate double bond in 310. The reductions of 
conjugated double bonds are very common in organic chemistry.161, 166, 167 Because 310 
had three allyl groups, we had to find a chemoselective method of reducing the conjugated 
double bond. Transition metal hydrides have demonstrated the ability to reduce such 
conjugated double bonds. Stryker’s reagent, [(PPh3)CuH]6, is an example of one such metal 
hydrides. Therefore, we attempted to reduce 310 with Stryker’s reagent, but we found that 
the reagent did not touch the conjugated double bond at all, and we ended up recovering 
the starting material.167  
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Scheme 3.16.4. Attempts to reduce the α, β-unsaturated ketone in bicyclic enone 310 
Stryker’s reagent, however, is bulky, and because of that, we thought, the delivery 
of H to the double bond might have been difficult. Therefore, we envisioned generating 
CuH in situ, and then we could reduce the conjugated double bond. Accordingly, we 
attempted to reduce the conjugated double bond in 310 using CuH, generated in situ from 
the action of CuI and Bu3SnH, in the presence of LiCl and TMSCl. Unfortunately, this 
reaction furnished the allylic alcohol, leaving the conjugated double bond unreacted 
(Scheme 3.16.4).  
Not discouraged by the results, we turned our attention to other metal hydrides. 
TeH is also reported to reduce conjugated double bonds.168 Unfortunately, TeH, which we 
generated by the action of Te powder and NaBH4, in ethanol, reduced both ketones in 310, 
instead of the conjugated double bond, producing allylic alcohol 341.  
The dissolving metal reduction of α,β-unsaturated ketones has long been utilized in 
organic synthesis.169 We were hopeful that the lack of steric demand of the reducing agent 
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in this reaction would allow our desired reaction to proceed. When 310 was subjected to 
Li in liquid NH3 without any cosolvent, however, we obtained an intractable mixture of 
products, and the NMR spectrum of the crude product indicated that there had been no 
reduction of the conjugated double bond. The same reaction in the presence of the proton 
source t-BuOH did not reduce the conjugated double bond in 310, but caused the loss of 
an allyl group to give 342 (Scheme 3.16.5). Na2S2O4 failed to react completely.170  
 
Scheme 3.16.5. Trials for dissolved metal reduction 
We were aware that Hudlicky’s group had done a lot of research on chemoselective 
reduction of a conjugated double bond in α,β-unsaturated esters using Mg/MeOH.161, 171-
173 After allowing 310 to react with Mg in refluxing MeOH for 4 h, we obtained a strange 
result: the reagent not only reduced the double bond but also promoted the skeletal 
rearrangement of bicyclo[3.3.1]nonane, leading to the completely unexpected 
bicyclo[4.3.0]nonane 343 in 51% yield, along with some allylic alcohol (Scheme 3.16.6). 
X-ray crystallographic analysis established the stereochemistry of 343 without doubt 
(Figure 3.16.1).  
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Scheme 3.16.6. An unusual reaction of 310 with Mg in methanol 
 
Figure 3.16.1. Crystal structure of 343 
A possible mechanism for the rearrangement is shown here (Scheme 3.16.8). To 
the best of our knowledge, it was a new kind of reaction where bicyclo[3.3.1]nonane had 
rearranged to a bicyclo[4.3.0]nonane motif. Unfortunately, though, it did not contribute to 
a solution to our problem.  
The proposed mechanism suggested that the α, β-unsaturated ketone of 310 was 
indeed reduced to the saturated ketone before further reaction occurred. Therefore, we 
attempted to forestall the rearrangement by using less Mg powder (<10 equivalent), but to 
no avail. An alternative mechanism for the unusual transformation could be proposed 
(Scheme 3.16.7). We believed that mechanism in the Scheme 3.16.8 is less likely to 
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happen because of the formation of cyclopropane intermediate, which is a high in energy. 
 
Scheme 3.16.7. An alternate reaction mechanism for the bicyclo[4.3.0]nonane 
 
Scheme 3.16.8. Mechanistic rationale for an unexpected rearrangement 
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These failed trials hint us that the C4 carbon of 310 is very resistant to changing its 
hybridization from sp2 to sp3. Therefore, we need to rethink our strategy to overcome the 
challenge. A late-stage oxidation strategy may not work here; we need to think about an 
early stage oxidation. 
 
3.16.3 Epoxidation and nucleophilic ring opening  
Nucleophilic epoxidation of an enone has been an efficient route for the oxidation 
of β-carbon of an enone because the resulting epoxide is prone to nucleophilic ring opening 
(Scheme 3.16.9). Ciochina successfully implemented the strategy—a nucleophilic 
epoxidation followed by the ring opening—on a model compound in proposing a route for 
the total synthesis of nemorosone.5 Therefore, we decided to attempt the strategy on 
molecule 310; our plan was to epoxidize the enone 310 to 344, and then, regiospecifically, 
to open up the epoxide ring in 344 with any less bulky nucleophile. After the ring was 
opened, the alcohol 345 could then be oxidized to diketone 346.  
 
Scheme 3.16.9. C4 oxidation: epoxidation and nucleophilic ring opening 
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Unfortunately, the nucleophilic epoxidation with H2O2 in the THF and 10% KOH 
mixture did not touch the double bond of the enone 310, and we recovered 310.174 
3.16.4 Conjugate addition–oxidation 
We knew that thiols added to enones in a 1,4-fashion. Therefore, we thought of 
adding thiophenol at the C4 carbon in 310 (Scheme 3.16.10). Our idea was simple; if we 
could add PhS– to C4 of 310, we could close the ring, remove the PhS– by oxidizing the 
sulfur, and subsequently, install OH group at the C4. Accordingly, we attempted to add 
thiophenol to enone 310. Not surprisingly, the reaction did not go as per our hope, and we 
recovered the starting material 310.  
 
Scheme 3.16.10. Addition of sulfur nucleophile to bicyclic enone 
3.17 New plan for C4 oxidation 
“In solving a problem of this sort, the grand thing is to be able to reason backwards.” 
— Sir Arthur Conan Doyle, A Study in Scarlet.  
The problem of oxidation of C4 in 310, demanded further deliberation. We 
reexamined the crystal structure of 310. Its analysis revealed that the gem-dimethyl groups 
at the C6 hindered any approach of nucleophile or electrophile from the endo face of the 
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conjugated double bond. The exo face was still accessible to any approach of Nu–or 
electrophile, but, as the reaction proceeded, the endo H at C4 was forced into an eclipsing 
position with one of the gem-dimethyl groups, which rendered any reaction virtually 
impossible (Scheme 3.17.1). Henceforth, we realized that late stage oxidation of the C4 in 
310 would not be a viable option, and we needed to think an alternative.  
 
Scheme 3.17.1. Rationale for the failure of the oxidation at C4 in 310 
We decided to alter the route, keeping the alkynylation-aldol approach intact. We 
thought if the C4 carbon were in the right oxidation state before the aldol condensation, we 
could complete the synthesis. This idea led us to a new, revised synthetic scheme. 
3.18 The revised plan for oxidation of C4 
The C4 in 310 was stereochemically and electronically very resistant to change its 
hybridization from sp2 to sp3, as we learned from a series of failed reactions. Therefore, we 
envisioned developing a route where the C4 was already in a correct oxidation state before 
we thought about an aldol reaction to construct the bicyclo[3.3.1]nonane. However, the 
question remained: at what stage of the synthesis and on which molecule we could perform 
the oxidation?  
With this plan in mind, we realized that if we could add a heteroatom to the -
carbon atom of ,-unsaturated alkynal 332, then the -carbon atom would be in the 
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correct oxidation state, and after that we could carry out the aldol condensation (Scheme 
3.18.1). Settling with the substrate for the crucial oxidation, we were now in search of a 
nucleophile that could add to alkynal 332 in a Michael addition fashion.  
Thiols have shown such property of adding to a α, β–unsaturated aldehyde.175, 176 
Thiophenol is a known to add to β carbon of an alkynal. My predecessor had added a PhS 
group to the β-carbon of ,-unsaturated alkynal 332, but he obtained the E-alkynal 352, 
which could not undergo aldol condensation.  
 
Scheme 3.18.1. Addition of PhSH to 332 
The formation of E-alkenal 352 from the reaction of thiophenol and alkynal 332 
was disappointing. Therefore, we searched for an alternative to thiophenol. Ley showed 
that 1,2 and 1,3-propanedithiols are nucleophilic towards alkynals and alkynoates, giving 
a mixture of E and Z isomers (Scheme 3.18.2).177 We thought we could apply his 
methodology on our substrate 332. Our plan was to affect a Michael addition on 332 to 
give the aldehyde 354. However, we knew that we would get a Z-alkenal, but, after second 
Michael addition, there would not be any issue of E or Z. Therefore, we hoped to get 354A 
to avoid any façade of E or Z- geometry. 
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Scheme 3.18.2. Strategy for C4 oxidation via propanedithiol reaction 
 
Scheme 3.18.3. Addition of 1,2 or 1,3-dithiol to alkynal 
With these thoughts in mind, we combined alkynal 332 with 1.1 equivalents of 1,3-
propanedithiol in a 1:3 MeOH and THF mixture in the presence of NaOMe (Scheme 
3.18.3). We did not see any sign of product formation, 354 or 354A in the NMR spectrum 
of the crude material isolated from the reaction mixture. Instead, it appeared that 
propanedithiol reacted with the aldehyde carbon of 332, rather than the β-carbon, and, after 
the hydrolysis, we lost the aldehyde group. We attempted various bases to generate thiolate 
in situ to add to the -carbon of 332, but all the trials were unfruitful, leading only to the 
deformylation of 332 (Scheme 3.18.4).  
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Scheme 3.18.4. Proposed mechanism for the deformylation of 332 
Small, soft nucleophiles like N3 also add to α,β–unsaturated carbonyl compounds 
in 1,4-fashion (Scheme 3.18.5). Therefore, we envisioned adding N3 to the β-position of 
alkynal 332, converting it to 355, which could undergo a base-catalyzed aldol reaction, 
followed by a DMP oxidation, to 356. Using Staüdinger reaction condition, 356 could be 
reduced to enamine, and after the hydrolysis of enamine, we could get 310a. The literature 
suggested that Me3SiN3 and tetramethylguanidine hydrochloride would produce 
tetramethylguanidine azide that could undergo the addition reaction with 332.178  
 
Scheme 3.18.5. Azidation and oxidation strategy for C4 oxidation 
Accordingly, we performed the reaction with 332 as the substrate. Unfortunately, 
we did not see any 1,4-addition; instead, we observed loss of the CHO group after the 
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reaction (Scheme 3.18.5). The result was surprising; we rationalized it with a mechanism 
similar to the one shown in Scheme 3.18.4.  
3.18.1 Hydrosilylation and C–H activation  
Our next idea was to try to use a C–H activation reaction to functionalize the -
carbon of the bicyclic enone, using a nitrogen heterocycle tethered through a Si atom to the 
-carbon (Scheme 3.18.6). This approach required that we hydrosilylate alkynal 332 with 
a silane containing a heterocycle, and that the hydrosilylation of 332 would proceed with 
syn stereochemistry and would direct the silyl group selectively to the -carbon and the H 
to the -carbon.  
 
Scheme 3.18.6. Hydrosilylation–C–H activation route for C4 oxidation  
Hydrosilylation of an internal alkyne is not new to organic chemists.179, 180 Over the 
last two decades several research groups have been investigating on this topic.181, 182 There 
are some advantages of the hydrosilylation; it can reduce a triple bond to an E- or Z-alkene, 
depending on the choice of catalysts. Later, the silicon-containing group could be removed 
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from the substrate via a Tamao–Fleming reaction to carry out further downstream 
modifications, or one can perform Hiyama coupling on silanes.  
The biggest challenge of the hydrosilylation is to control the regio- and 
stereochemistry of the addition. Our substrate was unsymmetrical alkyne 332. An 
unsymmetrical internal alkyne can be hydrosilylated to give four isomers (, , E, and Z). 
Happily, we had already discovered conditions for the hydrosilylation of 332 that gave syn 
addition across the triple bond and regioselectively placed the silyl group on the -carbon 
and the H on the -carbon.183  
After the hydrosilylation, we expected that Z–silylated alkenal 357 would undergo 
the aldol condensation followed by oxidation to 358 (Scheme 3.18.6). We hypothesized if 
we used 2-pyridyldimethylsilane as a hydrosilylating agent, we could utilize the pyridyl 
group as a directing group to promote C–H activation at C4 of 358 to give 359. Then the 
pyridyl silane group could be removed by hydrolysis, and, hopefully, would provide 310.  
With this idea, we set out to hydrosilylate alkynal 332 with 2-
pyridyldimethylsilane. Following Ferreira’s method, the hydrosilylation of 332 with PtCl2 
and PySiHMe2 for more than 24 hours, did not produce 357;179 instead, we recovered 332 
(Scheme 3.18.7). We also attempted to implement Itami’s184 and Hosoya’s182 reaction 
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condition separately on 332 (Scheme 3.18.7), but we did not observe hydrosilylation; 
instead, we recovered starting material.  
 
Scheme 3.18.7. Attempts to hydrosilylate 332 with 2-pyridylsilane 
3.19 Co-promoted hydrosilylation 
Co-promoted hydrosilylation has been used to reduce an α,β-unsaturated alkynal.185 
In 2003, in an effort to develop a model to synthesize nemorosone, Dr. Grossman resorted 
to a Co2(CO)8-catalyzed hydrosilylation to reduce an alkynal stereoselectively to Z-
alkenal.5 Jayasekara implemented the methodology successfully to synthesize a 
bicyclo[3.3.1]nonane, 310 (Scheme 3.19.1). We decided to see if the same reaction would 
work with 2-pyridyldimethylsilane.53  
 
Scheme 3.19.1. Co-promoted hydrosilylation of alkynal 332 with HSiEt3 
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Following the protocol set by Jayasekara, we attempted to reproduce the result with 
2-(dimethylsilyl)pyridine. To our disappointment, we did not obtain 361 (Scheme 
3.19.2).184, 186, 187 An attempt at hydrosilylation with (4-methoxyphenyl)dimethylsilane was 
equally unsuccessful.  
 
Scheme 3.19.2. Co-promoted hydrosilylation with 2-pyridyldimethyl silane 
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Experimental 
General: All the reactions were done under N2 atmosphere unless otherwise mentioned. 
THF, Et2O, toluene, and benzene were dried over Na/benzophenone. CH2Cl2 was dried 
over CaH2. Anhydrous MeOH was purchased from Sigma.1,3-Cyclohexanedione, 2.5 (M) 
n-BuLi, 1.8 (M) MeLi, trimethylsilyldiazomethane, 3 (M) MeMgBr, and PdCl2 were 
purchased from Acros organic, and were used without any purification. Allyl alcohol and 
allyl bromide were distilled before use. Ethyl cyanoformate was synthesized in the lab 
using Weber-Childs protocol.150 The reactions were monitored by aluminum backed TLC, 
and GC. Iodine, KMnO4, and p-anisaldehyde were used as TLC stains where required. 
CDCl3 and C6D6 were used as NMR solvents. NMR spectra were obtained on a 400 MHz 
Varian instrument. All the chemical shifts were reported in δ ppm with respect to SiMe4.  
 
3-(propan-2-yloxy)cyclohex-2-en-1-one (316): A 250 mL three-necked round-bottomed 
flask equipped with a dean stack apparatus was charged with of 1,3-cyclohexanedione 
(7.50 g, 66.3 mmol) and PTSA·H2O (631 mg, 3.31 mmol). Isopropyl alcohol (10 mL, 165 
mmol) and benzene (30 mL) were added to the reaction mixture. The resulting light orange 
solution was refluxed for 4 h. GCMS was monitored to confirm the completion of the 
reaction. The reaction mixture was cooled to room temperature and the organic solvents 
were evaporated to red oil. The red oil was dissolved into Et2O (100 mL) and then the 
organic solvent was extracted with Na2CO3 (2×20 mL), NaHCO3 (2 20 mL), and H2O (20 
mL). The organic layer was finally washed with brine (20 mL). It was dried over anhydrous 
magnesium sulfate. Finally, the organic solvent was evaporated to red hued yellow oil (9.52 
O
O
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g, 60.0 mmol, yield 93%). 1H NMR (CDCl3): δ 5.30 (s, 1H), 4.41 (sep, 6.4 Hz, 1H), 2.25 
(m, 4H), 2.0 (dd, 13 Hz, 6.5 Hz, 2H), 1.26 (d, 6.4 Hz, 6H). 13C NMR (CDCl3): δ 199.9, 
176.9, 102.9, 70.8, 36.6, 29.5, 21.4, 21.1. IR (neat): 2978, 1649, 1379, 1379 1222 cm-1. 
 
6-(2-propen-1-yloxy)3-(propan-2-yloxy)cyclohex-2-en-1-one (317): n-BuLi in hexane ( 
2.50 M, 85.5 mL, 213 mmol) was added to a solution of distilled diisopropylamine (23.8 
g, 235 mmol) in anhydrous THF (350 mL) under nitrogen at –5 °C. The reaction was stirred 
for 1 h. The reaction mixture temperature was taken down to –78 °C. In a separate round-
bottomed flask, 316 (30.0 g, 200 mmol) was dissolved into dry THF (30 mL) and then 
added into the previous solution at –78 °C evenly over a period of 10 min. After the 
addition, the reaction mixture was stirred at –78 °C for 1 h. Allyl bromide (25.8 g, 213 
mmol) was dissolved into anhydrous THF (10 mL), and added slowly to the cooled 
solution. Thereafter, the reaction flask was removed from the dry ice acetone bath, and was 
allowed to reach at room temperature, and then the reaction mixture was stirred for 3½ h 
at room temperature. Saturated solution of NH4Cl (300 mL) was added to the reaction. The 
organic layer was separated, and the aqueous layer was extracted with Et2O (4×100 mL). 
The combined organic solvent was washed with H2O (2×100 mL) and brine (100 mL), and 
finally was dried over anhydrous MgSO4. The organic solvent was evaporated under 
reduced pressure to a light red oil. (34.1 g, 180 mmol, 93%). 1H NMR (CDCl3): δ 5.80 (m, 
1H), δ5.25 (s, 1H), 5.0 (m, 2H), 4.41(sep, 6.2 Hz, 1H), 2.64 (m, 1H), 2.37 (m, 1H), 2.12 
(m, 1H), 2.03 (m, 1H), 1.76 (m, 1H), 1.29 (d+m, 5.3 Hz, 6H). 13C(CDCl3): δ 200.6, 140.2, 
120, 100, 70, 42, 28, 26, 20, 12. IR (neat): 3050, 2985, 1741, 1447, 1374 cm-1; m/z= 194. 
O
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3-Methyl-4-(2-propen-1-yloxy)cyclohex-2-en-1-one (315): Compound 317 (6.0 g, 40.0 
mmol) was added to an oven dried Schlenk round-bottomed flask and then dry THF ( 100 
mL) was added. The solution was cooled to –5 °C under N2. 1.6 M MeLi (1.60 M, 37. 5 
mL, 60.0 mmol) was added to the cooled solution and it then was stirred at RT for half an 
hour through GCMS monitoring. Once the starting material vanished, the reaction mixture 
was cooled to 0 °C, and 1 M HCl (60 mL) was added slowly (warning: vigorous 
exotherm). The ice bath was removed, and the reaction mixture was stirred for 1 h again at 
RT. The reaction progress was monitored by GCMS. Next, the reaction mixture was poured 
into a separatory funnel, and the aqueous layer extracted with Et2O (2 ×50 mL). The 
combined organic layer was washed with water (2 × 50 mL) and then with brine (1 × 50 
mL). The organic solvent was dried over MgSO4, and evaporated to pale yellow liquid. 
The reaction yielded 315 (4.33 g, 30.0 mmol, yield 94%) after column chromatography 
(eluent: petroleum ether: ethyl acetate 5:5). 1H NMR (CDCl3): δ 5.80-5.60 (s+m, 2H), 5.20-
5.00 (m, 2H), 2.50-2.40 (m, 2H), 2.37 (m, 2H), 2.05-1.84 (m+s, 5H). 13C NMR (CDCl3): δ 
199.3, 164.9, 135.9, 127.0, 117.3, 39.1, 35.6, 33.7, 26.2, 22.9. IR (neat): 3074, 2928, 1669, 
1329, 1251 cm-1. 
 
Ethyl 2,2-dimethyl-6-oxo-3-(2-propen-1-yloxy)cyclohexane-1-carboxylate (318): 
O
O O
OEt
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Oven dried CuI (5.25 g, 25.8 mmol) and dry Et2O (60 mL) were added to an oven-dried 
three-necked flask fitted with a mechanical stirrer and N2 inlet. The suspension was cooled 
to –5 °C. To this cooled suspension, 1.60 M MeLi (33.0 mL, 51.6 mmol) was slowly added. 
Soon, the suspension turned into a lime yellow solution, which was stirred for 10 min at –
5 °C. Afterwards, enone 315 (2.00 g, 12.9 mmol) was dissolved into dry Et2O (10 mL), 
and was slowly added into the yellow solution over a period of 10 min. After the addition, 
the reaction mixture was stirred for 1 h at –5 °C. HMPA (10 mL, 55.8 mmol) was added 
and the reaction mixture was stirred vigorously, and the reaction temperature was taken 
down slowly to –70 °C by dry ice-methanol bath. 10 min later, ethyl cyanoformate (6.25 
g, 51.6 mmol) was dissolved into Et2O (10 mL) and added slowly to the previous solution 
at –70 °C. After the addition, the reaction mixture was allowed to reach room temperature 
within 1 h. Then, a 1:1 NH4OH and saturated solution of NH4Cl (100 mL) mixture was 
added to the reaction mixture and stirred for 30 min. The crude solution was passed through 
a celite pad to get rid of the fine copper precipitates. The organic phase was separated, and 
the aqueous layer was extracted with Et2O (3×50 mL). The combined organic layers were 
washed with H2O, brine, and dried over MgSO4. The organic solvent was evaporated to a 
pale-yellow liquid that was purified with 10% ethyl acetate in petroleum ether to a colorless 
oil 318 (3.05 g, 10.0 mmol 76.0%) as a mixture of diastereomers. 1H NMR (CDCl3): δ 5.80 
(m, 2H), 5.10 (m, 4H), 4.21 (q, 7.3 Hz, 2H), 3.01 (s, 1H), 2.90 (ddd, 19.3 Hz, 12.1 Hz, 7.1 
Hz, 1H), 2.44 (m, 1H), 2.29 (ddd, 15.5 Hz, 9.6 Hz, 6.6 Hz, 1H), 2.00 (m, 1H), 1.90 (ddd, 
12 Hz, 10 Hz, 8.2 Hz, 1H), 1.79 (m, 1H), 1.66 (ddd, 14 Hz, 9.0 Hz, 5.8 Hz, 1H), 1.53 (m, 
1H), 1.30 (t, 7.3 Hz, 3H), 1.13 (s, 3H), 0.99 (s, 3H). 13C NMR (CDCl3): δ 206.1, 169.0, 
137.7, 116.7, 68.8, 60.7, 46.7, 45.9, 41.2, 40.9, 38.9, 34.4, 27.6, 21.9, 14.3. IR (neat): 3423, 
2978, 2360, 1712, 1640, 1370, 1228, 1165 cm-1 
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Ethyl 6,6-dimethyl-5-(prop-2-en-1-yl)-2-(2-propen-1-yloxy)cyclohex-1-ene-1-
carboxylate (324): NaH (1.26 g, 31.5 mmol), which was washed with petroleum ether 
(3×5 mL), was added to a 250 mL round-bottomed flask and then dry THF ( 25 mL) was 
poured into the flask. The suspension was cooled to 0 °C and keto-ester 318 (6.00 g, 25.2 
mmol) was dissolved into anhydrous THF (25 mL), and added into the suspension for over 
5 min via an addition funnel. After the addition, the suspension was stirred for 1 h at room 
temperature. Allyl bromide (3.65 g, 30.2 mmol) was dissolved into anhydrous THF (4 mL) 
and added into the suspension. After this, the suspension was refluxed for 36 h at 60 °C. 
The reaction mixture was cooled to 0 °C. H2O (20 mL) was added followed by extraction 
with Et2O (3× 40 mL). The combined organic layers were washed with H2O (2 20 mL), 
brine (20 mL), and dried over MgSO4. Finally, the organic solvent was evaporated to a 
thick yellow liquid, and the thick liquid was purified by column chromatography (eluent: 
10 % EtOAc in petroleum ether) to yield a viscous liquid 324 (5.35 g, 20.0 mmol, yield 
76%). 1H NMR (CDCl3): δ 5.92 (m, 1H), 5.80 (m, 1H), 5.3 (dd 3.1 Hz, 1.7 Hz, 1H), 5.18 
(dd, 3.2 Hz, 1.6 Hz, 1H), 5.06 (m, 2H), 4.27 (m, 4H), 2.36 (m, 1H), 2.19 (m, 2H), 1.86 (m, 
1H), 1.74 (m, 1H), 1.48 (m, 1H), 1.3 (t, 7.66 Hz, 3H), 1.10 (s, 3H), 1.02 (s, 3H). 13C NMR 
(CDCl3):  170.3, 152.4, 138.7, 134.7, 122.2, 117.0, 116.5, 115.9, 68.7, 60.4, 43.4, 36.1, 
34.0, 27.1, 24.0, 22.4, 22.4, 14.4. IR (neat): 3077, 2972, 2935, 2862, 1714, 1667 cm-1.  
O O
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Ethyl (1R,3S)-2,2-dimethyl-6-oxo-1,3-bis(2-propen-1-yl)cyclohexane-1-carboxylate 
(314): O-allyl vinyl ether 324 (5.80 g, 20.8 mmol) was dissolved into anhydrous toluene 
(62 mL) and was heated to 150 °C for 8 hours in a sealed tube. After 8 h, the toluene was 
evaporated to a red oil and the residue was purified through a column using 5% ethyl 
acetate in petroleum ether. The reaction furnished required diastereomer 314 (4.40 g, 20.0 
mmol, yield 75.0%). 1H NMR (CDCl3): δ 5.80 (m, 2H), 5.08 (m, 4H), 4.21 (q, 7.3 Hz, 2H), 
2.74 (m, 2H), 2.44 (m, 1H), 2.29 (ddd, 15.5 Hz, 9.6 Hz, 6.6 Hz, 1H), 2.08 (m, 1H), 1.90 
(ddd, 13 Hz, 11 Hz, 8.3 Hz, 1H), 1.79 (m, 1H), 1.66 (ddd, 14 Hz, 9.0 Hz, 5.8 Hz, 1H), 1.30 
(t, 7.24 Hz, 3H), 1.13 (s, 3H), 0.99 (s, 3H). 13C NMR (CDCl3): δ 205.5, 170.6, 164.3, 137.8, 
134.9, 117.0, 115.8, 67.6, 60.2, 45.0, 43.18, 42.4, 37.4, 35.3, 33.5, 24.7, 21.7, 13.6. IR 
(neat): 3076, 2973, 2360, 1712, 1640, 1442, 1371 cm-1. 
 
Ethyl (1R, 5R)-2-methoxy-6,6-dimethyl-1,5-bis(2-propen-1-yl)cyclohex-2-ene-1-
carboxylate (325): Anhydrous CH(OMe)3 (2.04 mL, 22.7 mmol) and MeOH (1.50 mL, 
0.10 mL/mmol) were mixed in a separate round-bottomed flask. Ethyl carboxylate 314 
(3.85 g, 15.1 mmol) was added into the previous solution. The reaction was cooled in an 
ice bath. After that, conc. H2SO4 (40.0 L, 0.07 mmol) was added, and the reaction mixture 
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was stirred for 36 h at room temperature. GCMS was checked after 36 hours, and then the 
reaction mixture was concentrated. The crude mass was dissolved into of Et2O (30 mL). 
The organic layer was washed with a saturated solution of NaHCO3 (2×20 mL), H2O (10 
mL), and brine. The organic solvent was dried over anhydrous MgSO4. After rotary 
evaporation and column chromatography by 5% ethyl acetate in petroleum ether, the 
reaction yielded methyl enol ester 325 (3.70 g, 12.0 mmol, yield 87%). 1H NMR (CDCl3): 
δ 5.80 (m, 2H), 5.0 (m, 2H), 4.88 (dd, 7.84 Hz, 2.04 Hz, 1H), 4.78 (dd, 6.1 Hz, 2.0 Hz, 
1H), 4.22 (m, 2H), 3.41 (s, 3H), 2.81 (m, 1H), 2.54 (dd, 14 Hz, 9.3 Hz, 1H), 2.3 (m, 1H), 
2.14 (ddd, 16 Hz, 6.0 Hz, 4.06 Hz, 1H), 1.78 (m, 3H), 1.24 (t, 7.0 Hz, 3H), 1.05 (s, 3H), 
0.78 (s, 3H); 13C NMR (CDCl3): δ 173.1, 154.3, 138.2, 137.0, 115.5, 114.6, 95.7, 60.0, 
59.2 54.0, 38.8, 38.0, 34.1, 26.6, 22.3, 19.8, 14.2. IR (neat): 3073, 2974, 2946, 2834, 1722, 
1671 cm-1. 
 
 [(1S,5R)-2-methoxy-6,6-dimethyl-1,5-bis(2-propen-1-yl)cyclohex-2-en-1-
yl]methanol (326): Ethyl enol ester 325 (3.94 g, 14.1 mmol) was dissolved in dry Et2O 
(150 mL) and cooled to 0 °C. LiAlH4 (927 mg, 22.5 mmol) was added to the cold solution 
of enol ester 325 at 0 °C, and stirred for 3½ h at RT. H2O (1 mL) and 1 M NaOH (1 mL) 
were added to the reaction mixture. A few minutes later, H2O (3 mL) was added to it. 
Diethyl ether (100 mL) was added to the slurry and stirred under nitrogen for 20 min at 
room temperature. The organic solvent was decanted carefully, dried over anhydrous 
MgSO4, and evaporated to a thick white liquid (3.02 g, 10.0 mmol, 86%). 1H NMR 
MeO
OH
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(CDCl3): δ 5.90 (m, 2H), 5.04 (m, 4H), 4.77 (dd, 5.37 Hz, 2.31 Hz, 1H), 3.81 (dd, 11 Hz, 
6.5 Hz, 1H), 3.71 (dd, 11 Hz 8.1 Hz, 1H), 3.48 (s, 3H), 2.54 (dd, 8.0 Hz, 6.1 Hz, 1H), 2.32 
(m, 2H), 2.18 (dt, 11 Hz, 5.3 Hz, 1H), 1.89 (m, 3H), 0.98 (s, 3H), 0.82 (s, 3H). 13CNMR 
(CDCl3): δ 157.1, 138.4, 137.9, 115.3, 114.7, 95.5, 65.8, 65.2, 53.8, 49.5, 38.9,38.1, 34.2, 
26,9, 21.8, 17.6, 15.2. IR (neat): 3435, 3073, 2969, 2934, 2832, 1672 cm-1. 
 
 (4R, 6R)-6-ethynyl-5,5-dimethyl-4,6-bis(2-propen-1-yl)-1-(2-propene-1-
yloxy)cyclohex-1-ene (329): Allyl alcohol (5 mL, 0.07 mmol), CSA·H2O (14.3 mg, 0.06 
mmol) and benzene (15 mL) were added in a 50 mL round-bottomed flask, fitted with dean 
stack apparatus, and the reaction mixture was heated to reflux for an hour. The solution 
was allowed to reach room temperature and then alkyne 328 (300 mg, 1.22 mmol), 
dissolved in anhydrous benzene (5 mL), was added to the previous solution. The reaction 
mixture was refluxed for 2½ h. The reaction mixture was cooled to room temperature and 
the organic layer was diluted with 20 mL of Et2O. The organic solvent was extracted with 
Na2CO3 (2× 10 mL), NaHCO3 (2  10 mL) and brine. The organic layer was dried over 
anhydrous MgSO4 and was evaporated to dryness. The residue was eluted with 5% ethyl 
acetate in petroleum ether to furnish O-allyl-alkyne 329 (276 mg, 0.01 mmol, yield 78%). 
1H NMR (CDCl3): δ 6.03 (m, 1H), 5.98 (m, 1H), 5.8 (m, 1H), 5.38 (ddd, 17 Hz, 3.7 Hz, 
2.1 Hz, 1H), 5.18 (ddd, 10 Hz, 3.4 Hz, 1.8 Hz, 1H), 5.04 (m, 4H), 4.58 (dd,  5.1 Hz, 2.8 
Hz, 1H), 4.26 (ddt, 13 Hz, 5.4 Hz, 1.8 Hz, 1H), 4.08 (ddt,  13 Hz, 5.4 Hz, 1.8 Hz, 1H), 2.56 
(ddt, 13.4 Hz, 6.8 Hz, 2.02 Hz, 1H), 2.44 (dd, 13, 7.8 Hz, 1H), 2.34 (dd, 9.3 Hz, 5.5 Hz, 
O
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1H), 2.22 (s, 1H), 2.19 (dt, 9.8 Hz, 5.0 Hz, 1H), 1.78 (m, 2H), 1.68 (m, 1H), 1.42 (s, 3H), 
1.0 (s, 3H). 13C NMR (CDCl3): δ 153.3, 138.0, 136.9, 133.6, 128.3, 116.0, 115.6, 114.6, 
94.3, 85.4, 71.7, 67.5, 49.8, 42.8, 39.4, 36.9, 35.1, 29.6, 27.1, 23.1, 19.1. IR (neat): 3075, 
2955, 2923, 2855, 2150, 1639 cm-1 
 
 (3aR, 6R, 7aR)-7a-hydroxy-5,5-dimethyl-2,3a,6-tris(2-propen-1-yl)-octahydro-1H-
inden-1-one (343): Mg powder (30.0 mg, 1.27 mmol) was added in an oven dried round-
bottomed Schlenk flask. Enone 310 (19.0 mg, 0.06 mmol) was dissolved into anhydrous 
MeOH (3.00 mL) in a separate round-bottomed flask, and then was added to the Schlenk 
flask. The reaction mixture was refluxed for 3 h, and then the reaction mixture was cooled 
to room temperature. The reaction mixture was treated with 1 M HCl (2 mL). The reaction 
mass was extracted with Et2O (3×5 mL) and then, H2O (1×10 mL). The combined organic 
layer was dried over anhydrous MgSO4. The organic solvent was evaporated under reduced 
pressure, and the residue was chromatographed (eluent 7:3 petroleum ether: EtOAc) to 
afford 343 (8.35 mg, 0.04 mmol, yield 51%). 1H NMR (CDCl3): δ 5.8-5.6 (m, 3H), 5.0 (m, 
6H), 3.6 (s, 1H), 2.80-2.40 (m, 8H), 1.10 (s, 3H), 1.00 (s, 3H). 13C NMR (CDCl3): δ 219.7, 
139.3, 136.7, 136.0, 117.7, 116.2, 115.6, 83.6, 50.1, 47.5, 37.4, 35.2, 33.2, 32.4, 31.2, 28.5, 
23.9, 23.5, 23.3. 
  
HOO
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Conclusion 
7-epi-Clusianone is an important molecule because of its broad range of biological 
activity, namely, vasorelaxant, antimalarial, cytotoxic. These properties have inspired us 
to devise a scheme for a total synthesis of the molecule and, later, propose a general scheme 
for other endo or exo PPAPs. We have not succeeded in finishing the synthesis; however, 
we have a couple of feats in this project that has offered more satisfaction than conceiving 
a solution.  
We developed a robust method of a 1,4-addition followed by an acylation even on 
a large scale (Scheme 3.7.1). Establishing a method for synthesis of methyl enol ether from 
a β-keto ester without transesterification is worth mentioning here (Scheme 3.8.1). 
We established a robust method for constructing a bicyclo [3.3.1] nonane using 
alkynylation followed by aldol approach. The strategy has viability with a board substrate 
scope including silanes, although the yield was not impressive.  
We observed an interesting rearrangement of a carbon skeleton into another when 
we tried to reduce a α, β-bond in bicyclic enone (310) to a saturated ketone. As far as 
our knowledge goes, it was a first of its kind of reaction, where a bicyclo [3.3.1] nonane 
rearranged to a bicyclo [4.3.0] nonane (Scheme 3.16.6). Currently, we are writing the 
manuscripts to publish the result.  
Finally, we have realized that the oxidation of C4 carbon has been a bottleneck for the 
overall scheme of the total synthesis. The gem-dimethyl at C6 has been at the root of the 
problem. Therefore, we need to devise a scheme where C4 is in the correct oxidation 
state before we think about the constructing the quaternary center at C6. 
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Appendix 
 
 
Figure 3.19.1 H NMR of 343 
HOO
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Figure 3.19.2. C NMR of 343 
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Table 3.2.  Crystal data and structure refinement for 343. 
Empirical formula        C20H30O2 
Formula weight        302.44 
Temperature         90.0(2) K 
Wavelength         1.54178 Å 
Crystal system, space group     Triclinic, P -1 
Unit cell dimensions 
a          6.6628(2) Å 
α              78.1350(11)° 
b          11.2157(3) Å 
β              76.4840(12)° 
c          12.1836(3) Å 
γ              84.0060(12)° 
Volume         864.81(4) Å3 
Z, Calculated density       2, 1.161 
Mg/m3 
Absorption coefficient       0.561 mm−1 
F(000)
 332 
Crystal size (mm)      0.200 x 0.080 x 0.025 
Θ range for data collection (°)    3.799 to 68.211 
Limiting indices        -3 ≤ h ≤ 8 
•          13 ≤ k ≤ 13 
          14 ≤ l ≤ 14 
Reflections collected / unique     11768 / 3080 
[Rint = 0.0351] 
Completeness to        Θ = 67.679 98.4% 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission        0.956 and 0.871 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters        3080 / 0 / 201 
Goodness-of-fit on F2 1.077 
Final R indices [I > 2σ(I)] R1 = 0.0371, wR2 = 0.0953 
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R i ndices (all dat a) R1 = 0. 0411, wR2 = 0. 0981 
Exti nction coeffici ent 0. 0023(5) 
Lar gest diff. peak and hole 0. 261 and -0. 198 e· Å−3 
Table 3.3. Atomic coordinates (x 104) and equivalent isotropic 
displacement parameters (A2 x 103) for 343. 
U (eq) is defined as one third of the trace of the orthogonalized 
Uij tensor. 
x                  y                z               U(eq) 
 
O(1)         4505(1)       8253(1)       6162(1)       18(1) 
O(2)         7748(1)       9497(1)       4492(1)       20(1) 
C(1)         6948(2)       8677(1)       7236(1)       16(1) 
C(2)         8119(2)       8604(1)       5187(1)       16(1) 
C(3)        10161(2)       7883(1)       5159(1)       19(1) 
C(4)         9690(2)       6708(1)       6052(1)       18(1) 
C(5)         7297(2)       6674(1)       6453(1)       16(1) 
C(6)         6579(2)       5959(1)       7722(1)       18(1) 
C(7)         6811(2)       6679(1)       8655(1)       19(1) 
C(8)         5901(2)       7989(1)       8409(1)       18(1) 
C(9)         6586(2)       8060(1)       6270(1)       15(1) 
C(10)        6213(2)      10037(1)       7088(1)       19(1) 
C(11)        7165(2)      10695(1)       7776(1)       21(1) 
C(12)        6134(2)      11200(1)       8641(1)       29(1) 
C(13)        6468(2)       6063(1)       5620(1)       20(1) 
C(14)        7365(2)       6441(1)       4357(1)       21(1) 
C(15)        6303(2)       7001(1)       3597(1)       29(1) 
C(16)        8970(2)       6664(1)       8922(1)       22(1) 
C(17)        8843(2)       7106(1)      10019(1)       27(1) 
C(18)        9681(2)       8083(2)      10105(2)       35(1) 
C(19)        7754(2)       4702(1)       7900(1)       23(1) 
C(20)        4263(2)       5722(1)       7965(1)       23(1) 
— — 
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Table 3.5 Anisotropic displacement parameters (A2 x 103) for 343. The 
anisotropic displacement factor exponent takes the form: 
2 Π2 [h2 a*2 U11 + ... + 2 h k a* b* U12] 
          U11      U22      U33      U23       U13    U12 
 
O(1)     14(1)    15(1)     24(1)    -1(1)    -7(1)   0(1) 
O(2)     26(1)    14(1)     18(1)    -1(1)    -6(1)   -1(1) 
C(1)     16(1)    16(1)     17(1)    -2(1)    -5(1)   -1(1) 
C(2)     20(1)    14(1)     17(1)    -5(1)    -6(1)   -3(1) 
C(3)     17(1)    18(1)     20(1)    -2(1)    -2(1)   -2(1) 
C(4)     17(1)    16(1)     19(1)    -2(1)    -3(1)   1(1) 
C(5)     17(1)    14(1)     18(1)    -1(1)    -4(1)   0(1) 
C(6)     18(1)    16(1)     20(1)     1(1)    -3(1)   -1(1) 
C(7)     17(1)    20(1)     16(1)     1(1)    -2(1)   0(1) 
C(8)     17(1)    20(1)     16(1)    -2(1)    -3(1)   1(1) 
C(9)     12(1)    15(1)     17(1)    -2(1)    -5(1)   -1(1) 
C(10)    22(1)    17(1)     18(1)    -3(1)    -5(1)   0(1) 
C(11)    23(1)    18(1)     23(1)    -3(1)    -7(1)   -2(1) 
C(12)    31(1)    31(1)     28(1)   -12(1)   -11(1)   1(1) 
C(13)    22(1)    14(1)     22(1)    -3(1)    -6(1)   -2(1) 
C(14)    26(1)    16(1)     24(1)    -7(1)    -4(1)   -2(1) 
C(15)    40(1)    24(1)     25(1)    -5(1)   -10(1)   -4(1) 
C(16)    21(1)    23(1)     21(1)    -1(1)    -7(1)   3(1) 
C(17)    25(1)    34(1)     23(1)    -2(1)    -9(1)   0(1) 
C(18)    27(1)    45(1)     37(1)   -13(1)   -10(1)   -2(1) 
C(19)    26(1)    17(1)     24(1)     2(1)    -4(1)   0(1) 
C(20)    20(1)    21(1)     24(1)     2(1)    -2(1)   -6(1) 
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Table 3.6 Hydrogen coordinates (x 104) and isotropic displacement              
parameters (Å2 x 103) for 343. 
                                   x             y             z         U (eq) 
 
H(1O)        4254          8996          5910          27 
H(1A)        8469          8621          7199          20 
H(3A)       11164          8348          5360          22 
H(3B)       10742          7692          4385          22 
H(4A)       10316          6704          6715          22 
H(4B)       10268          5986          5708          22 
H(7A)        5906          6281          9388          23 
H(8A)        4404          7976          8442          22 
H(8B)        6060          8423          9010          22 
H(10A)       6589         10421          6265          23 
H(10B)       4688         10112          7339          23 
H(11A)       8623         10750          7571          25 
H(12A)       4675         11164          8871          34 
H(12B)       6850         11602          9035          34 
H(13A)       6719          5168          5831          23 
H(13B)       4952          6237          5751          23 
H(14A)       8800          6262          4089          25 
H(15A)       4864          7194          3834          35 
H(15B)       6975          7212          2811          35 
H(16A)       9608          5822          8986          27 
H(16B)       9865          7190          8281          27 
H(17A)       8095          6642         10708          33 
H(18A)      10442          8573          9437          42 
H(18B)       9527          8300         10836          42 
H(19A)       7282          4277          8693          35 
H(19B)       9240          4811          7750          35 
H(19C)       7487          4219          7370          35 
H(20A)       3827          5277          8754          34 
H(20B)       4039          5234          7427          34 
H(20C)       3453          6502          7867          34 
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Table 3.7 Torsion angles [°] for 343. 
O(2)-C(2)-C(3)-C(4)                       -167.61(12) 
C(9)-C(2)-C(3)-C(4)                         14.64(13) 
C(2)-C(3)-C(4)-C(5)                          8.84(13) 
C(3)-C(4)-C(5)-C(13)                        87.13(12) 
C(3)-C(4)-C(5)-C(9)                        -27.83(12) 
C(3)-C(4)-C(5)-C(6)                       -151.28(10) 
C(4)-C(5)-C(6)-C(19)                       -49.88(14) 
C(13)-C(5)-C(6)-C(19)                       71.43(13) 
C(9)-C(5)-C(6)-C(19)                      -166.34(10) 
C(4)-C(5)-C(6)-C(20)                      -167.72(10) 
C(13)-C(5)-C(6)-C(20)                      -46.40(13) 
C(9)-C(5)-C(6)-C(20)                        75.83(13) 
C(4)-C(5)-C(6)-C(7)                         73.93(13) 
C(13)-C(5)-C(6)-C(7)                      -164.76(10) 
C(9)-C(5)-C(6)-C(7)                        -42.53(14) 
C(19)-C(6)-C(7)-C(8)                       172.69(10) 
C(20)-C(6)-C(7)-C(8)                       -72.53(12) 
C(5)-C(6)-C(7)-C(8)                         48.07(13) 
C(19)-C(6)-C(7)-C(16)                       44.05(15) 
C(20)-C(6)-C(7)-C(16)                      158.83(11) 
C(5)-C(6)-C(7)-C(16)                       -80.58(13) 
C(10)-C(1)-C(8)-C(7)                      -171.99(10) 
C(9)-C(1)-C(8)-C(7)                         62.80(13) 
C(16)-C(7)-C(8)-C(1)                        73.64(13) 
C(6)-C(7)-C(8)-C(1)                        -59.11(13) 
O(2)-C(2)-C(9)-O(1)                         29.15(16) 
C(3)-C(2)-C(9)-O(1)                       -153.06(10) 
O(2)-C(2)-C(9)-C(1)                        -92.45(13) 
C(3)-C(2)-C(9)-C(1)                         85.34(11) 
O(2)-C(2)-C(9)-C(5)                        150.17(11) 
C(3)-C(2)-C(9)-C(5)                        -32.04(12) 
C(8)-C(1)-C(9)-O(1)                         70.94(12) 
C(10)-C(1)-C(9)-O(1)                       -53.00(13) 
C(8)-C(1)-C(9)-C(2)                       -165.96(9) 
C(10)-C(1)-C(9)-C(2)                        70.10(12) 
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C(8)-C(1)-C(9)-C(5)                        -54.73(13) 
C(10)-C(1)-C(9)-C(5)                      -178.67(10) 
C(4)-C(5)-C(9)-O(1)                        157.78(10) 
C(13)-C(5)-C(9)-O(1)                        42.81(13) 
C(6)-C(5)-C(9)-O(1)                        -79.70(12) 
C(4)-C(5)-C(9)-C(2)                         35.70(11) 
C(13)-C(5)-C(9)-C(2)                       -79.27(11) 
C(6)-C(5)-C(9)-C(2)                        158.22(10) 
C(4)-C(5)-C(9)-C(1)                        -76.97(12) 
C(13)-C(5)-C(9)-C(1)                       168.06(10) 
C(6)-C(5)-C(9)-C(1)                         45.55(13) 
C(8)-C(1)-C(10)-C(11)                       74.57(13) 
C(9)-C(1)-C(10)-C(11)                     -161.74(10) 
C(1)-C(10)-C(11)-C(12)                    -115.65(15) 
C(4)-C(5)-C(13)-C(14)                      -43.30(14) 
C(9)-C(5)-C(13)-C(14)                       67.33(13) 
C(6)-C(5)-C(13)-C(14)                     -167.14(10) 
C(5)-C(13)-C(14)-C(15)                    -116.66(15) 
C(8)-C(7)-C(16)-C(17)                       65.85(14) 
C(6)-C(7)-C(16)-C(17)                     -165.35(11) 
C(7)-C(16)-C(17)-C(18)                    -117.10(16) 
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Table 3.8.  Hydrogen bonds for 343 [Å and °] 
D-H...A              d (D-H)   d(H...A)  d(D...A)    <(DHA) 
O(1)-H(1O)...O(2)#1    0.84      2.09    2.8635(12)  152.6 
Symmetry transformations used to generate equivalent atoms: 
#1 -x+1, -y+2, -z+1 
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Table 3.9. Crystal data and structure refinement for 329B. 
Identification code 329B 
Empirical formula C18 H24 O3 
Formula weight 288.37 
Temperature 90.0(2) K 
Wavelength 1.54178 Å  
Crystal system, space group Orthorhombic, P2(1)2(1)2(1) 
Unit cell dimensions 
a 7.6532(3) Å 
α 90 ° 
b 13.3427(6) Å 
β 90 ° 
c 15.7225(7) Å 
γ 90 ° 
Volume 1605.49(12) A3 
Z, Calculated density 4, 1.193 Mg/m3 
Absorption coefficient 0.634F (000) 624(mm−1) 
Crystal size  0.270 x 0.250 x 0.200 mm 
Θ range for data collection 4.346 to 68.064 ° 
Limiting indices -9<=h<=3 -15<=k<=15 
 18<=l<=18 
Reflections collected / unique 20802 / 2912 
[R (int) = 0.0439] 
Completeness to Θ = 67.679 99.9 % 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.929 and 0.721 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2912 / 0 / 193 
Goodness-of-fit on F2 1.089 
Final R indices [I>2σ(I)] R1 = 0.0324, wR2 = 0.0908 
R indices (all data)  R1 = 0.0334, wR2 = 0.0916 
Absolute structure parameter 0.43(6) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.167 and -0.128 (e. Å-3) 
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Table 3.10 Atomic coordinates (x 104) and equivalent 
isotropic displacement parameters (A2 x 103) for 329B. 
U (eq) is defined as one third of the trace of the 
orthogonalized 
Uij tensor.  
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               x             y              z          U(eq) 
 
O(1)         6612(2)       5826(1)       7472(1)       39(1) 
O(2)          -73(2)       5426(1)       8711(1)       37(1) 
O(3)         2182(2)       4376(1)       8919(1)       40(1) 
C(1)         6668(2)       6724(1)       7565(1)       30(1) 
C(2)         8269(3)       7337(2)       7369(1)       33(1) 
C(3)         8743(2)       8063(2)       8086(1)       31(1) 
C(4)         7176(2)       8694(1)       8367(1)       26(1) 
C(5)         5613(2)       8029(1)       8648(1)       26(1) 
C(6)         5065(2)       7323(1)       7883(1)       27(1) 
C(7)         4305(3)       7929(2)       7115(1)       30(1) 
C(8)         3807(3)       7298(2)       6366(1)       38(1) 
C(9)         4447(3)       7414(2)       5595(1)       46(1) 
C(10)        7698(2)       9465(2)       9049(1)       31(1) 
C(11)        9236(3)      10095(2)       8799(1)       32(1) 
C(12)       10543(3)      10316(2)       9295(2)       40(1) 
C(13)        6106(3)       7366(2)       9408(1)       31(1) 
C(14)        4050(2)       8688(2)       8903(1)       30(1) 
C(15)        3738(2)       6602(1)       8171(1)       30(1) 
C(16)        2700(3)       5998(2)       8415(1)       32(1) 
C(17)        1615(3)       5177(2)       8708(1)       30(1) 
C(18)       -1241(3)       4617(2)       8955(2)       40(1) 
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Table 3.12.  Anisotropic displacement parameters (A2 x 103) 
for 329B. 
The anisotropic displacement factor exponent takes the form: 
• 2 Π2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
          U11        U22        U33        U23        U13        U12 
 
O(1)     40(1)      28(1)      49(1)      -6(1)       1(1)       1(1) 
O(2)     29(1)      36(1)      47(1)       5(1)       2(1)      -4(1) 
O(3)     38(1)      33(1)      48(1)       2(1)       5(1)      -2(1) 
C(1)     31(1)      29(1)      30(1)      -2(1)      -2(1)       1(1) 
C(2)     29(1)      31(1)      39(1)      -4(1)       4(1)       3(1) 
C(3)     25(1)      32(1)      37(1)      -2(1)       2(1)      -1(1) 
C(4)     24(1)      26(1)      27(1)       1(1)       0(1)       0(1) 
C(5)     25(1)      27(1)      27(1)       2(1)       0(1)       1(1) 
C(6)     25(1)      27(1)      29(1)       1(1)       0(1)      -1(1) 
C(7)     28(1)      32(1)      31(1)       3(1)      -3(1)       1(1) 
C(8)     38(1)      37(1)      38(1)       2(1)      -8(1)      -5(1) 
C(9)     56(1)      47(1)      36(1)      -4(1)      -6(1)      -1(1) 
C(10)    30(1)      30(1)      32(1)      -2(1)      -1(1)      -1(1) 
C(11)    33(1)      29(1)      33(1)       0(1)      -1(1)      -2(1) 
C(12)    36(1)      40(1)      45(1)       4(1)      -6(1)      -7(1) 
C(13)    32(1)      31(1)      31(1)       6(1)      -3(1)      -3(1) 
C(14)    28(1)      31(1)      32(1)       0(1)       3(1)       1(1) 
C(15)    29(1)      31(1)      28(1)       0(1)      -3(1)      -1(1) 
C(16)    31(1)      33(1)      31(1)      -1(1)      -2(1)      -4(1) 
C(17)    32(1)      31(1)      27(1)      -5(1)       1(1)      -6(1) 
C(18)    32(1)      41(1)      47(1)       1(1)       4(1)     -11(1) 
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Table 5.  Hydrogen coordinates (x 104) and isotropic 
displacement parameters (A2 x 103) for 329B. 
            x             y             z           U(eq) 
H(2A)        8065          7723          6840          40 
H(2B)        9267          6880          7267          40 
H(3A)        9187          7678          8579          37 
H(3B)        9689          8514          7890          37 
H(4A)        6782          9082          7858          31 
H(7A)        3261          8302          7310          36 
H(7B)        5185          8428          6931          36 
H(8A)        2975          6780          6453          45 
H(9A)        5282          7924          5486          55 
H(9B)        4073          6986          5147          55 
H(10A)       6688          9909          9163          37 
H(10B)       7977          9107          9583          37 
H(11A)       9258         10354          8236          38 
H(12A)      10568         10072          9862          48 
H(12B)      11472         10721          9089          48 
H(13A)       6525          7788          9875          47 
H(13B)       7030          6898          9239          47 
H(13C)       5077          6988          9595          47 
H(14A)       4247          8964          9472          46 
H(14B)       2983          8282          8905          46 
H(14C)       3923          9237          8494          46 
H(18A)      -2447          4801          8815          60 
H(18B)      -1144          4498          9569          60 
H(18C)       -920          4006          8647          60 
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Table 3.13. Torsion angles [°] for 329B. 
O(1)-C(1)-C(2)-C(3)                                -131.8(2) 
C(6)-C(1)-C(2)-C(3)                                  49.3(2) 
C(1)-C(2)-C(3)-C(4)                                 -50.6(2) 
C(2)-C(3)-C(4)-C(10)                               -176.47(16) 
C(2)-C(3)-C(4)-C(5)                                  56.5(2) 
C(3)-C(4)-C(5)-C(13)                                 61.1(2) 
C(10)-C(4)-C(5)-C(13)                               -65.34(19) 
C(3)-C(4)-C(5)-C(14)                               -178.50(16) 
C(10)-C(4)-C(5)-C(14)                                55.1(2) 
C(3)-C(4)-C(5)-C(6)                                 -58.25(19) 
C(10)-C(4)-C(5)-C(6)                                175.33(15) 
O(1)-C(1)-C(6)-C(15)                                 10.0(3) 
C(2)-C(1)-C(6)-C(15)                               -171.04(16) 
O(1)-C(1)-C(6)-C(7)                                -107.4(2) 
C(2)-C(1)-C(6)-C(7)                                  71.5(2) 
O(1)-C(1)-C(6)-C(5)                                 129.8(2) 
C(2)-C(1)-C(6)-C(5)                                 -51.3(2) 
C(13)-C(5)-C(6)-C(15)                                51.8(2) 
C(14)-C(5)-C(6)-C(15)                               -66.29(19) 
C(4)-C(5)-C(6)-C(15)                                172.88(15) 
C(13)-C(5)-C(6)-C(1)                                -67.01(19) 
C(14)-C(5)-C(6)-C(1)                                174.95(15) 
C(4)-C(5)-C(6)-C(1)                                  54.11(19) 
C(13)-C(5)-C(6)-C(7)                                172.52(16) 
C(14)-C(5)-C(6)-C(7)                                 54.5(2) 
C(4)-C(5)-C(6)-C(7)                                 -66.35(19) 
C(15)-C(6)-C(7)-C(8)                                -60.0(2) 
C(1)-C(6)-C(7)-C(8)                                  57.1(2) 
C(5)-C(6)-C(7)-C(8)                                 178.55(17) 
C(6)-C(7)-C(8)-C(9)                                -122.2(2) 
C(3)-C(4)-C(10)-C(11)                                51.9(2) 
C(5)-C(4)-C(10)-C(11)                               178.48(15) 
C(4)-C(10)-C(11)-C(12)                             -135.9(2) 
C(18)-O(2)-C(17)-O(3)                                -3.1(3) 
C(18)-O(2)-C(17)-C(16)                              176.89(16) 
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